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Background: Assistive technology and telecare have been promoted to manage the risks associated
with independent living for people with dementia, but there is limited evidence of their effectiveness.
Objectives: This trial aimed to establish whether or not assistive technology and telecare assessments
and interventions extend the time that people with dementia can continue to live independently at
home and whether or not they are cost-effective. Caregiver burden, the quality of life of caregivers
and of people with dementia and whether or not assistive technology and telecare reduce safety risks
were also investigated.
Design: This was a pragmatic, randomised controlled trial. Blinding was not undertaken as it was not
feasible to do so. All consenting participants were included in an intention-to-treat analysis.
Setting: This trial was set in 12 councils in England with adult social services responsibilities.
Participants: Participants were people with dementia living in the community who had an identified
need that might benefit from assistive technology and telecare.
Interventions: Participants were randomly assigned to receive either assistive technology and telecare
recommended by a health or social care professional to meet their assessed needs (a full assistive
technology and telecare package) or a pendant alarm, non-monitored smoke and carbon monoxide
detectors and a key safe (a basic assistive technology and telecare package).
Main outcome measures: The primary outcomes were time to admission to care and cost-effectiveness.
Secondary outcomes assessed caregivers using the 10-item Center for Epidemiological Studies Depression
Scale, the State–Trait Anxiety Inventory 6-item scale and the Zarit Burden Interview.
Results: Of 495 participants, 248 were randomised to receive full assistive technology and telecare and
247 received the limited control. Comparing the assistive technology and telecare group with the control
group, the hazard ratio for institutionalisation was 0.76 (95% confidence interval 0.58 to 1.01; p = 0.054).
After adjusting for an imbalance in the baseline activities of daily living score between trial arms, the
hazard ratio was 0.84 (95% confidence interval 0.63 to 1.12; p= 0.20). At 104 weeks, there were no
significant differences between groups in health and social care resource use costs (intervention group –
control group difference: mean –£909, 95% confidence interval –£5336 to £3345) or in societal costs
(intervention group – control group difference: mean –£3545; 95% confidence interval –£13,914 to
£6581). At 104 weeks, based on quality-adjusted life-years derived from the participant-rated EuroQol-5
Dimensions questionnaire, the intervention group had 0.105 (95% confidence interval –0.204 to –0.007)
fewer quality-adjusted life-years than the control group. The number of quality-adjusted life-years derived
from the proxy-rated EuroQol-5 Dimensions questionnaire did not differ between groups. Caregiver
outcomes did not differ between groups over 24 weeks.
Limitations: Compliance with the assigned trial arm was variable, as was the quality of assistive
technology and telecare needs assessments. Attrition from assessments led to data loss additional to
that attributable to care home admission and censoring events.
Conclusions: A full package of assistive technology and telecare did not increase the length of time
that participants with dementia remained in the community, and nor did it decrease caregiver burden,
depression or anxiety, relative to a basic package of assistive technology and telecare. Use of the full
assistive technology and telecare package did not increase participants’ health and social care or
societal costs. Quality-adjusted life-years based on participants’ EuroQol-5 Dimensions questionnaire
responses were reduced in the intervention group compared with the control group; groups did not
differ in the number of quality-adjusted life-years based on the proxy-rated EuroQol-5 Dimensions
questionnaire.
Future work: Future work could examine whether or not improved assessment that is more
personalised to an individual is beneficial.
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Trial registration: Current Controlled Trials ISRCTN86537017.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 19. See the NIHR Journals Library website for further project information.
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Many people with dementia living at home are recommended assistive technology and telecareto help them remain living safely and independently in the community. These devices are
meant to assist and support activities such as taking medication or cooking, or to raise an alert when
there is an issue, such as a fire; however, there is currently little evidence to support such claims.
This trial investigated whether or not assistive technology and telecare could delay people moving
into residential care and keep them any safer than alternatives, and whether or not they were
cost-effective.
We recruited 495 people with dementia and their unpaid caregivers, who were randomly assigned
to receive either a package of assistive technology and telecare recommended by a health or social
care professional or alternative support involving only basic assistive technology and telecare.
We monitored the residential status, the use of health-care services and the health and well-being
of participants with dementia and their caregivers over a 2-year period. Researchers also spent time
with participants to see how they were living with the technology.
The trial found no difference in the time that people with dementia with full assistive technology
and telecare remained at home, nor any reduction in the number of safety incidents, compared with
the participants who received basic assistive technology and telecare only. Full assistive technology
and telecare did not increase health and social care costs. It did not improve the well-being of people
with dementia or that of their caregivers. People with dementia who had full assistive technology
and telecare rated their quality of life poorer than those with basic assistive technology and telecare
did, but their caregivers rated their quality of life as about the same as caregivers of people with basic
assistive technology and telecare. The technology sometimes averted crises but also disrupted people’s
everyday lives.
These results suggest that assistive technology and telecare for people with dementia provided in
real-world conditions may not be as beneficial as previously claimed. The way that assistive technology
and telecare services are organised bears further investigation to see how these services could
be improved.
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.





There are approximately 850,000 people with dementia in the UK, most of whom will require
accommodation in nursing or residential care homes when their illness has progressed to the point at
which they can no longer live safely and independently in their own homes. The financial cost of caring
for people with dementia is considerable, as are the social and psychological costs to unpaid caregivers,
who are usually family. Caregiver breakdown is a common reason for the unplanned admission of older
people to permanent nursing or residential care. Assistive technology and telecare offer a relatively
new means of delivering care and support to people with social care needs by helping to manage the
risks facing people with dementia who wish to remain living independently at home. Despite growing
implementation of assistive technology and telecare, the evidence to support their use is limited, with
many studies having poor methodology or contradictory results. This trial was designed to answer
questions about the efficacy and cost-effectiveness of assistive technology and telecare, with particular
relevance for those who commission and provide care for people with dementia.
Objectives
The Assistive Technology and Telecare to maintain Independent Living At home for people with
dementia (ATTILA) trial aimed to test the following hypotheses that:
l the application of assistive technology and telecare will significantly extend the time that people
with dementia can continue to live independently and safely in their own homes
l assistive technology and telecare interventions are cost-effective in the management of risk and in
maintaining independence among people with dementia living in their own homes
l the provision of assistive technology and telecare interventions to people with dementia living at
home will significantly reduce the number of incidents involving serious risks to safety and
independent living, particularly those involving acute admissions to hospital
l assistive technology and telecare interventions will reduce burden and stress in family and other
unpaid caregivers and increase quality of life for people with dementia.
Method
The ATTILA trial was a pragmatic randomised controlled trial comparing the outcomes of people with
dementia who received assistive technology and telecare with the outcomes of people who received
equivalent traditional community services but not assistive technology and telecare.
Participants were adults with suspected or diagnosed dementia living in the community who had been
recommended assistive technology and telecare to help manage challenges at home caused by their
dementia-related cognitive decline. Inclusion criteria were any dementia diagnosis or evidence of
memory difficulties or possible dementia, a professionally assessed need for assistive technology and
telecare from a health or social care professional, living in the community and living in a dwelling
suitable for the installation of assistive technology and telecare. Exclusion criteria were already
receiving an assistive technology and telecare intervention (excluding a non-linked smoke detector
or carbon monoxide detector, a key safe or a pendant alarm) or having been previously provided
assistive technology and telecare but not using it; being unlikely to comply with follow-up, for example
owing to an unstable medical or psychiatric condition; participating in another clinical trial involving an
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intervention for dementia; having an urgent need for a care package owing to immediate and severe
risks to self or others; the absence of an appropriate unpaid caregiver; and living in accommodation
unsuitable for the provision of assistive technology and telecare.
All aspects of the intervention (assistive technology and telecare assessment, funding, choice of devices,
or ordering and installation of devices) were determined by staff from participating local authorities or
telecare providers. Each participant underwent an assessment with the assistive technology and telecare
provider to determine the level of need and what services were required. The intervention involved the
installation of simple, battery-operated, standalone technologies and/or telecare (a range of devices and
sensors that communicate and relay messages to an external call centre where an appropriate response
is arranged). The installation and selection of the technology to be deployed was the responsibility of
the local authorities involved. Those in the control arm were limited to a pendant alarm, non-monitored
smoke and carbon monoxide detectors and a key safe, as recommended by the health or social care
professional assessing their needs. Both arms could use additional support services, such as paid care,
meals on wheels and attendance at day centres.
Participants were followed up for a minimum of 2 years or until they either moved into residential care
or died. Over these 2 years, participants had five follow-up assessments, if they were still living in the
community. After this time, they were invited to have a telephone assessment every 6 months until the
end of the trial, for a maximum of 3 years or until the point of care home admission or death.
There were two co-primary outcomes to establish whether or not assistive technology and interventions
(1) can extend the time that people with dementia can continue to live independently and safely in the
community and (2) are cost-effective in the management of risk and in maintaining independence in
people with dementia living in their own homes. Secondary outcomes were as follows:
l to establish whether or not these technologies can –
¢ significantly reduce the number of incidents involving serious risks to safety and independent
living, including acute admissions to hospital
¢ reduce stress in family and other unpaid caregivers
¢ increase quality of life for those with dementia and their caregivers
l to collect qualitative and quantitative data from people living with dementia and their formal and
unpaid caregivers about their experiences of using these technologies.
All participants were included in an intention-to-treat analysis.
Results
Out of 495 participants, 248 were randomised to receive the full assistive technology and telecare
package and 247 were randomised to the limited control package. We sought to describe the assistive
technology and telecare intervention using the Template for Intervention Description and Replication
(TIDieR) framework. We found a poor fit between the assistive technology and telecare needs and
the assessment recommendations (τ = 0.242; p < 0.000) and a moderate fit between the assistive
technology and telecare recommendations and the installations (τ = –0.470; p < 0.000). Furthermore,
62% of devices were installed for assistive technology and telecare needs that had not been identified
in the assessment process, and 53% of devices recommended as a result of assessment were not
installed by week 24. Median survival outside a care home was 127 weeks in the assistive technology
and telecare group and 128 weeks in the control group (hazard ratio for institutionalisation over
3 years 0.76, 95% confidence interval 0.58 to 1.01; p = 0.054). After adjusting for an imbalance in
baseline activities of daily living scores between trial arms, the hazard ratio was 0.84 (95% confidence
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interval 0.63 to 1.12; p = 0.20). At 104 weeks, there were no significant differences between groups
in health and social care resource use costs (intervention group – control group difference: mean
–£909, 95% confidence interval –£5336 to £3345) or societal costs (intervention group – control
group difference: mean –£3545, 95% confidence interval –£13,914 to £6581). At 104 weeks, based
on quality-adjusted life-years derived from the participant-rated EuroQol-5 Dimensions questionnaire,
the intervention group had 0.105 (95% confidence interval –0.204 to –0.007) fewer quality-adjusted
life-years than the control group. The number of quality-adjusted life-years derived from the
proxy-rated EuroQol-5 Dimensions questionnaire did not differ between groups.
Carer outcomes did not differ between groups over 24 weeks. Ethnographic research examining the
way in which participants with dementia and carers were living with the technology found that
technological mediation through assistive technology and telecare could replace, displace and disrupt
co-located, face-to-face interactions.
Conclusions
A full package of assistive technology and telecare did not result in a significant increase to the length
of time a person with dementia could remain living in the community, nor did it achieve decreases in
caregiver burden, depression or anxiety. Use of the full assistive technology and telecare package did
not increase participants’ health and social care or societal costs. Quality-adjusted life-years based
on participants’ EuroQol-5 Dimensions questionnaire responses were reduced in the intervention,
compared with the control group; the groups did not differ in the number of quality-adjusted life-years
based on the proxy-rated EuroQol-5 Dimensions questionnaire. Work is needed to understand the
impacts of assistive technology and telecare service configurations across public, voluntary and private
sectors. Designers and service provider organisations should work with caregivers and people with
dementia and their advocates to co-produce suitable technological interventions.
Future work
Future work could examine whether or not improved assessment that is more personalised to each
individual is beneficial.
Trial registration
This trial is registered as ISRCTN86537017.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 19.
See the NIHR Journals Library website for further project information.
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.




Parts of this report are reproduced with permission from Leroi et al.1 This article is publishedunder license to BioMed Central Ltd. This is an open access article distributed under the terms
of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Parts of this report are reproduced with permission from Howard et al.2 This is an Open Access article
distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt and build upon this work, for non-commercial use,
provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/. The text
below includes minor additions and formatting changes to the original text.
Scientific background
There are approximately 850,000 people with dementia in the UK3,4 and an estimated 700,000 people
who provide unpaid care for them. Many of these people with dementia will require accommodation in
nursing or residential care homes when their illness has progressed to the point at which they can no
longer live safely and independently in their own homes. It has been estimated that, over the next two
decades, the number of people aged ≥ 85 years will increase by two-thirds.5 Over half of all users of
adult social care services are aged ≥ 65 years,6 and a steep rise in the numbers of people living with
dementia is expected over the next few decades. The financial cost of caring for people with dementia
is considerable,3 as is the social and psychological cost to unpaid caregivers (generally a relative or
friend, subsequently referred to as ‘caregivers’). Caregiver breakdown is a common reason for the
unplanned admission of older people (many of whom will have dementia) to permanent nursing or
residential care.7
Living Well with Dementia, the theme of the 2009 National Dementia Strategy for England,8 involves
helping people with dementia to retain their independence while living in their own homes, and to
maintain their quality of their life. People living with dementia who move from their own homes
into institutional care often experience a loss of independence and quality of life. To minimise this
possibility, the NHS and councils with adult social services responsibilities (CASSRs) in England aim
to support people with dementia to live safely in their own homes for as long as possible.
Assistive technology and telecare (ATT) offer relatively new means of delivering care and support to
people with social care needs by helping to manage the risks facing older people with dementia who
wish to remain living independently at home. It is claimed that sensors (e.g. to detect falls, floods or
the presence of gas from an unlit appliance in someone’s home), passive monitoring that uses sensors
placed in a home environment to detect movement, and alerting devices to relay information from
the person’s home to a remote site such as a call centre support the independence of people with
social care needs,9,10 reduce the burden on caregivers11–15 and save money for CASSRs.16 By addressing
risks associated with independent living for people with dementia, it is claimed that ATT help reduce
the need for community care, prevent unnecessary hospital admissions and delay or prevent admission
to residential or nursing care.12,17–19 The evidence to support such claims is limited, and based largely
on qualitative evidence or uncontrolled quantitative studies.20,21 There is, therefore, an urgent need
to provide evidence to inform decisions about whether or not to provide ATT in the homes of people
with dementia.
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The first use of electronic ATT in the UK, in the 1990s, was to provide support for people with
dementia and their caregivers.17,22–25 Within a decade, interest in ATT has developed from a fringe
interest for a handful of enthusiasts to a multimillion-pound industry commanding government support,
a Department of Health and Social Care (DHSC) strategy26 and, increasingly, the use of ATT in CASSR
settings as a mainstream service (see Woolham et al.25). However, as interest in ATT has increased,
the specific focus on its application for those living with dementia has diminished.13 The performance
indicators that followed the Preventative Technology Grant (given to CASSRs in 2008 by the DHSC26)
were intended to promote the widest possible use of telecare. The DHSC did not, however, offer a
clear indication of what this grant was supposed to ‘prevent’. Although Woolham12 has drawn attention
to the cost-effectiveness of telecare for people with dementia by closely matching ATT with assessed
need, thereby preventing the need for more expensive forms of care, Poole27 has argued that CASSRs
should see ATT as a long-term investment, deploying it at an early stage without expecting immediate
savings. This has contributed to a situation in which CASSRs have implemented ATT across several
different care groups without always referring to the needs of the specific groups, such as people with
dementia. The current economic situation, and a significant reduction in government CASSR funding,
has led to increasing numbers of CASSRs developing an interest in ATT. Some have developed local
strategies to use it, whereas others already have well-developed ATT services that can be deployed
alongside, or instead of, non-institutional forms of support, often known as ‘community care’ in the UK.
Despite growing ATT use, the evidence to support its use is limited. The Whole System Demonstrator
(WSD) study was funded by the DHSC in 2008 to investigate the impact and effectiveness of ATT in
England.28–35 However, individuals with dementia were not specifically included. This, together with the
relative dearth of dementia-specific studies relating ATT, means that a significant gap in the evidence
remains. Although there are relatively large numbers of qualitative studies, audits and service evaluations,
there are few studies with sufficient rigour and appropriate design to offer any degree of generalisability21
or agreement about how ‘success’ can be measured.36 One study25 has suggested that, when used
appropriately, ATT are highly cost-effective, but limitations in design and methodology constrain the
generalisability of this study’s findings. A Cochrane review in 201737 found no research evaluating
assistive technology for people via a randomised controlled trial (RCT), with the exception of this
Assistive Technology and Telecare to maintain Independent Living At home for people with dementia
(ATTILA) trial, which was in progress at the time of publication of the Cochrane review.37 Evidence
from a well-designed trial such as ATTILA is clearly needed to guide future policy direction.
The DHSC’s ‘Building Telecare’ strategy in 200513 provided generic advice to CASSRs. As part of this
strategy, a Preventative Technology Grant, which CASSRs were required to spend on developing local
ATT services, was made available. England’s 2009 National Dementia Strategy8 recommended a
‘watching brief’ for emerging evidence of the impact of telecare, stating:
However, with respect to more recent innovations, this is not an area where the strategy is able at this time to
make specific recommendations. Instead, central, regional and local teams should keep in touch with initiatives
in the areas of housing and telecare and make appropriate commissioning decisions as data become available,
for example from the Department’s large-scale field trials of telecare and assistive technology.
Reproduced from DHSC.8 © Crown copyright 2009. Contains public sector
information licensed under the Open Government Licence v3.0
Aims and objectives of the trial
The ATTILA trial was designed to answer questions about the efficacy and cost-effectiveness of ATT,
with relevance for those who commission and provide care for people with dementia.
INTRODUCTION
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The aims of the ATTILA trial were to test the following hypotheses:
l that the application of ATT will significantly extend the time that people with dementia can continue
to live independently and safely in their own homes
l that ATT interventions are cost-effective in the management of risk and maintenance of
independence for people with dementia living in their own homes
l that provision of ATT interventions to people with dementia living at home will significantly reduce
the number of incidents involving serious risks to safety and independent living, particularly those
involving acute admissions to hospital
l that ATT interventions will reduce burden and stress in family and other caregivers and increase
quality of life for people with dementia.
These hypotheses were tested by the following primary and secondary objectives:
l Primary objective – to establish whether or not ATT assessments and interventions extend the time
that people with dementia can continue to live independently in their own homes and whether or
not this is cost-effective.
l Secondary objectives –
¢ to establish whether or not these technologies can significantly reduce the number of incidents
involving serious risks to safety and independent living, including acute admissions to hospital
¢ to reduce burden and stress in family and other caregivers, and increase quality of life for
people with dementia and their caregivers
¢ to collect qualitative and quantitative data from people living with dementia, their paid and
unpaid caregivers, and members of the NHS and CASSR teams about their experience of using
these technologies.
Structure of the report
In Chapter 2, we provide a summary of the trial methods. In the chapters that follow, we set out the
methods and results of the research, beginning with work carried out to describe the intervention (see
Chapter 3). In subsequent chapters, we report on participant outcomes, cost-effectiveness, caregiver
outcomes and ethnographic research with participants and caregivers. In Chapter 8, we summarise the
findings, reflect on the strengths and weaknesses of the research and make recommendations for
future research and practice.
Deviations from the protocol
We did not conduct one proposed cost-effectiveness analysis. It was proposed that an analysis of the
change in EuroQol-5 Dimensions, five-level version (EQ-5D-5L), score over 2 years would take into
account the costs of permanent care home and hospital stays of those admitted to care homes over
that period. This analysis was not conducted because no outcomes and costs data were collected from
caregivers when participants were permanently admitted to care during the 2-year follow-up.
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The ATTILA trial was a pragmatic RCT comparing outcomes for people with dementia who received a full
ATT package with the outcomes for people with dementia who received equivalent community services
but ATTwere limited to a pendant alarm, non-monitored smoke and carbon monoxide detectors, and
key safes. Assistive technology is defined as ‘any item, piece of equipment, product or system, whether
acquired commercially, off the shelf, modified or customised, that is used to increase, maintain, or
improve functional capabilities of individuals with cognitive, physical or communication difficulties’.22
Telecare can include many different interventions, including those aimed at delivering care and
monitoring remotely.38 For the purposes of this trial, these devices had to be provided to support
challenges related to memory problems and recommended by a health or social care professional.
The primary objectives of the trial were to establish whether or not:
l ATT assessments and interventions can extend the time that people with dementia can continue to
live independently and safely in the community
l ATT interventions are cost-effective in the management of risk and maintenance of independence in
people with dementia living in their own homes.
The secondary objectives were to:
l establish whether or not these technologies can significantly reduce the number of incidents
involving serious risks to safety and independent living, including acute admissions to hospital;
reduce stress in family and other caregivers; and increase quality of life for those with dementia
and their caregivers
l collect qualitative and quantitative data from people living with dementia and their formal
caregivers about their experience of using these technologies.
Trial design
The ATTILA trial was a multicentre, pragmatic RCT, conducted over 260 weeks, that took place
in the homes of people living with dementia who were eligible to receive a package of care. The
trial compared outcomes in two groups of participants randomised to one of the two trial arms:
(1) receiving an assessment of needs followed by the installation of appropriate ATT devices and
response services to be deployed by the CASSR or NHS (a full ATT package) or (2) receiving an
assessment of needs followed by the installation of an ATT package restricted to smoke and carbon
monoxide detectors, a key safe and a pendant alarm if indicated, also arranged by the CASSR (a basic
ATT package). The co-primary outcomes were time to institutionalisation and cost-effectiveness of
the intervention.
The trial was not funded to source, assess for, or deploy ATT. Our approach was to work alongside
CASSRs who were charged by the Department of Health and Social Care with responsibility for
establishing and developing local ATT services.
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Site identification and recruitment
Recruitment of local authority Adult Social Care Department (ASCD) sites to the trial was opportunistic
because of anticipated difficulties in securing permissions. Sites known to have well-established telecare
services were identified, as well as those located in geographical areas close to the place of employment
of research team members. This also meant that participating ASCDs were geographically widely spread
across England, and that all types of local authority were represented. Telephone contact was usually first
made with a telecare manager in identified sites. In most cases, this person referred our request to the
departmental senior management team or to the director. In some sites, repeated visits were needed to
discuss the request. Several ASCDs declined to take part in the main trial, either because they did not feel
that they had the resources to do so or because of lack of fit between the trial aims and the strategic
priorities of the service.
Participants
Participants were people with any dementia diagnosis, or suspected dementia, who were living in the
community and were from one or more of three constituencies:
1. people who sought help or support from local authority social care services in the areas that had
agreed to support the trial (Barnsley, Blackburn, Blackpool, Cambridgeshire, Croydon, Lambeth,
Lancashire, Nottingham, Norfolk, Oxfordshire, Southwark and Suffolk) and who met local ASCD
eligibility criteria for their support
2. people who were supported by the services of the NHS and were referred to an ASCD and met
local ASCD eligibility criteria
3. people who were recruited from the caseload of NHS services for older adults and referred to local
social services and met local ASCD eligibility criteria.
Those referred from the NHS usually had to meet eligibility criteria for social care because this often
determined if ATT could be provided.
Most participants (n = 431, 87.1%) did have a dementia diagnosis, but some of those referred by
LAs had not yet had a formal diagnosis. In these cases, clinical judgement was used by the research
worker and health or social care staff involved to decide whether or not the cause of the potential
participant’s memory impairment was dementia. If necessary, the research worker could discuss further
with the local principal investigator.
Screening for eligibility and the preliminary information visit
All trial procedures, including the initial visit and consent visit, took place in participants’ homes.
At the first appointment, participants were assessed for eligibility based on the following inclusion
and exclusion criteria.
Inclusion criteria
l Had any dementia diagnosis, evidence of memory difficulties or possible dementia.
l Had a professionally assessed need for ATT from a health or social care professional.
l Was resident in a community.
l Lived in a dwelling suitable for the installation of ATT.
METHODS
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Exclusion criteria
l Had already received an ATT intervention (excluding non-linked smoke detector or carbon
monoxide detector, key safe or pendant alarm) or ATT had been previously provided but was
not used.
l Was unlikely to comply with follow-up, for example owing to an unstable medical or
psychiatric condition.
l Was participating in another clinical trial involving an intervention for dementia.
l Had an urgent need for a care package owing to immediate and severe risks to self or others.
l Did not have a suitable caregiver.
l Was living in accommodation unsuitable for the provision of ATT.
Selection and recruitment
There were several routes for participant recruitment. Most participants were referred from local
authority social services, but other referring services included not-for-profit organisations providing
ATT; charitable organisations such as Age UK and the Alzheimer’s Society; and NHS mental health,
community care and primary care services. Those referred from the NHS had to meet eligibility criteria
for social care provision.
After assessing eligibility of new referrals for both social care support and the ATTILA trial, participating
services asked if a potential participant’s contact details could be made available to a named individual
in the local research team. Once identified, the research worker contacted this person and arranged to
visit them and a caregiver who knew them well. Those meeting the eligibility criteria had the possible
benefits and risks of participation in the trial explained to them. Following this, the participant was
given a general outline of three possible options: (1) taking part in the ATTILA trial with the intervention
(i.e. ATT package or regular support package without ATT) decided by randomisation, (2) declining to
participate in the ATTILA trial and (3) taking more time to consider their decision about whether or
not to participate. Those who were interested in taking part in the trial were provided with participant
and caregiver information leaflets to find out more about the trial before deciding whether or not to
participate. After a full explanation of the intervention options and the manner of treatment allocation,
all suitable participants were invited to take part in the randomised component of the trial. If urgent
provision of support services was required, then consent was sought at that visit so that they could
be immediately randomised. Otherwise, information about the trial could be left with the prospective
participant and, if they required more time to consider participation, the researcher would return at a
later date to take consent and subsequently randomise the participant. Consent was also obtained
from the caregiver using the caregiver consent form in the trial folder. If a participant lacked capacity,
a professional or personal consultee was involved to ensure that participation in the trial was in the
person’s best interests (according to guidelines established in the Mental Capacity Act 2005: Code of
Practice39). When appropriate, data-sharing agreements were agreed with the CASSRs and health services
concerned to ensure that the transfer of personal data from the local authority to the research team was
lawful. If consent was not given, the participant was not included and any personal data were removed
from research team records and destroyed. Reasons why those who were potentially eligible did not
consent to take part were recorded on a screening log in the ATTILA trial folder. After randomisation,
assessment for ATT and provision of ATT services (within limits set by randomisation) were left entirely
up to the local authority or health service operational teams concerned.
Outcome measures
The co-primary trial outcomes were (1) time to institutionalisation and (2) the cost-effectiveness of the
ATT intervention. Table 1 shows the schedule of all assessment points and the measures used at each.
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
7


































ATT needs assessment at home ✗
Capacity assessment ✗ ✗ (prior to consent) ✗ ✗ ✗ ✗ ✗
Informed consent ✗
Randomisation data ✗
Inform local authority of randomisation outcome ✗
Install intervention (ATT or alternatives)a ✗
SMMSE ✗
BADLS ✗ ✗
EQ-5D-5L ✗ ✗ ✗ ✗ ✗
EQ-5D-5L Proxy (carer) ✗ ✗ ✗ ✗ ✗
STAI-6 (carer) ✗ ✗ ✗ ✗ ✗
CES-D-10 (carer) ✗ ✗ ✗ ✗ ✗
ZBI (carer) ✗ ✗ ✗ ✗ ✗
SUTAQ (carer) ✗ ✗ ✗ ✗
CSRI (carer) ✗ ✗ ✗ ✗ ✗
Follow-up form ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
ATT checklist ✗ ✗ ✗ ✗ ✗
Adverse events ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
BADLS, Bristol Activities of Daily Living Scale; CES-D-10, 10-item Center for Epidemiological Studies Depression Scale; CSRI, Client Service Receipt Inventory; SMMSE, Standardised
Mini-Mental State Examination; STAI-6, State–Trait Anxiety Inventory-6 items; SUTAQ, Service User Technology Acceptability Questionnaire; ZBI, Zarit Burden Interview.





























Time in days from randomisation to institutionalisation
This was defined as permanent transition of a participant from living in their own home to living in a
nursing or residential care home or to admission to an acute care facility that results in permanent
placement in a residential care or nursing home. Caregivers were asked to report the date of this
transition; if necessary, health or social care results would also be consulted. Analyses were by
intention to treat, with all randomised participants included in the comparison and analysed according
to their randomised allocation, including those who discontinued the trial. The primary outcome of time
to institutionalisation was compared between intervention and control arms using survival analysis
methods. Kaplan–Meier survival curves were created for graphical representation of the time to event
comparisons (see Figures 4, 5 and 7). Statistical significance was determined by the log-rank test.
Analyses included all events, even those occurring after 2 years. Participants who died, withdrew from
follow-up or were lost to follow-up were censored at the date of withdrawal from the trial.
Cost-effectiveness
Economic evaluation methods (see Chapter 5) included cost-effectiveness and cost–utility analyses.
The evaluation considered three outcomes: days to institutionalisation, change in the EuroQol-5
Dimensions (EQ-5D) index40,41 and quality-adjusted life-years (QALYs). Cost-effectiveness analyses
were conducted from two perspectives: (1) health and social care and (2) societal. Costs were
calculated by attaching nationally applicable unit cost measures to health and social service use.42,43
These data focused on ATT, health-care and other service use patterns and caregiver inputs, and were
collected at baseline and at 12, 24, 52 and 104 weeks for each participant using a modified version of
the Client Service Receipt Inventory (CSRI).44 Data on caregiver time and task inputs came from the
CSRI and were valued using (and comparing, in sensitivity analyses) replacement wage and opportunity
cost approaches. ATT intervention costs were calculated drawing on sources including key informant
interviews about the production of ATT in ATTILA trial sites, and from price data drawn from procurement
contract databases of the Northern Housing Consortium (NHC). Difference-in-difference analyses of
EQ-5D change, with non-parametric bootstrapping, were performed; institutionalisation-free days and
QALY outcome analyses employed a combination of population-averaged generalised gamma and survival
models with non-parametric bootstrapping. Incremental cost-effectiveness ratios were computed and
cost-effectiveness acceptability curves (CEACs) were plotted over a range of values of willingness
to pay (WTP) for each outcome.
Secondary efficacy parameters
Caregiver burden
We measured both burden associated with caregiving and levels of psychological distress among the
principal caregivers of participants at baseline and at 12, 24, 52 and 104 weeks. The 22-item short
version of the Zarit Burden Interview (ZBI) questions caregivers about their experiences in terms of
emotional, physical and social strains or difficulties that result from their role as a caregiver. Items
include topics such as feeling that one’s own health has suffered, feeling that caregiving has affected
relationships with family and friends and how burdened one feels. Caregivers respond by indicating
how often they experience each item and responses are scored on a five-point scale ranging from
‘never’ to ‘frequently’. Higher burden is indicated by a higher score and the combined 12 items have
high reliability (alpha = 0.86).45 We also assessed psychological distress with the 10-item Center for
Epidemiological Studies Depression Scale (CES-D-10) and the State–Trait Anxiety Inventory (STAI).
Number and severity of serious adverse events
Serious adverse events (SAEs) were recorded and reported. Researchers systematically enquired
about changes in participants’ health, any compromises of participant safety or changes in living
circumstances between assessments. Safety was assessed by the researcher at the 12-, 24-, 52- and
104-week assessments, and then at the 130-, 156-, 182-, 208-, 234- and 260-week telephone calls to
participants’ caregivers. The adverse event (AE) reporting arrangements that apply to investigational
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medicinal products were not applicable, or appropriate, for the ATTILA trial. The focus was to capture
as complete information as possible on compromises of participant safety that might have been
preventable by the use of ATT. An adapted version of the AE reporting scheme was therefore used in
the ATTILA trial.
A SAE was any compromise of participant safety that:
l resulted in death
l was life-threatening
l necessitated hospitalisation or prolongation of existing hospitalisation
l resulted in persistent or significant disability or incapacity
l necessitated the intervention of emergency services
l resulted in admission to permanent residential care.
Assessment of preventability
The potential preventability of a SAE by the use of ATT was also assessed and categorised by the local
researcher and principal investigator into one of the following five categories:
1. Not preventable with assistive technology – the event or its consequences would have been the
same with or without ATT.
2. Unlikely to be preventable – the event or its consequences were unlikely to be altered by ATT.
3. Possibly preventable – it is possible that the event or its consequences might have been prevented
or mitigated by ATT.
4. Likely to be preventable – it is reasonable to believe that the event or its consequences might have
been prevented or mitigated by use of ATT.
5. Definitely preventable – the event or its consequences would have been prevented or mitigated
by ATT.
In the analysis, ‘possibly’, ‘likely’ and ‘definitely’ preventable categories were considered as preventable.
Throughout the trial, the local ASCD retained responsibility for the ATT and any other support
provided, and retained full case responsibility. The trial team had a duty of care to report relevant
issues if the ASCD involved were not already aware and would signpost when necessary, but it did not
provide equipment, care or support to trial participants.
Quantitative and qualitative data
Data on the acceptability, applicability and reliability of ATT intervention packages were collected using
the Service User Technology Acceptability Questionnaire. This questionnaire was validated using data
from the WSD project.46 We anticipated that unpaid caregivers’ experiences would provide examples of
ways that their lives, well-being and caregiver roles had been enhanced and/or undermined by the use
of these technologies. Longitudinal qualitative data were collected through an embedded ethnographic
study with a subset of the ATTILA trial participants to observe how people with dementia and their
caregivers actually used (or chose not to use) ATT in their everyday routines and built environments.
This methodology allowed for the team to investigate changes in participants’ technologically enabled
care practices over time, as the care needs of people with dementia became more acute.
Sample size
The two primary outcome measures were time to transition to institutional care and cost-effectiveness.
It was anticipated that 50% of participants with a Bristol Activities of Daily Living Scale (BADLS)47 score
of ≥ 15 would transition to institutional care after 24 months, based on observed institutionalisation
rates in participants from the AD2000 (Alzheimer’s disease) cohort.48 A reduction in the estimated
24-month transition to care home rate by 30% (i.e. 50% institutionalised at 2 years reduced to 35%)
METHODS
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would require the involvement of 500 participants, allowing for 10% attrition due to death while still
community resident. This equated to an average of 55 days more of independent home life for each
participant who received ATT. The trial would therefore be powered to detect a mean institutionalisation
delay of just under 8 weeks. Expert opinion suggests that 8 weeks is close to the minimum clinically
important difference in delaying institutionalisation.
Trial interventions
As the trial design was pragmatic, all aspects of the intervention (ATT assessment, funding, choice of
devices, or ordering and installation of devices) were determined by staff from participating LAs or
telecare providers. We worked alongside these teams, which have been charged by the Department of
Health and Social Care with responsibility for establishing and developing local ATT services. The trial
was not funded to source, assess for or deploy ATT.
Each participant underwent an assessment with the ATT provider to determine the level of need and
what services that they required. The intervention involved the installation of simple, battery-operated,
standalone technologies and/or telecare (a range of devices and sensors that communicate and relay
messages to an external call centre where an appropriate response is arranged). The installation and
selection of the technology to be deployed was the responsibility of the LAs involved. Those in the
control arm were limited to a pendant alarm, non-monitored smoke and carbon monoxide detectors,
and a key safe, as recommended by the health or social care professional assessing their needs. Both
arms could use additional support services, such as paid care, meals on wheels and day centres.
Randomisation
Participants were randomised in a one-to-one ratio, using telephone-based randomisation and a
computerised data entry portal provided by the Oxford Clinical Trial Service Unit. Treatment allocation
was via a minimised randomisation procedure stratified by the following variables to reduce the risk of
chance imbalances between arms. This information was obtained by the local trial team following
consent and during the screening process. Variables were as follows:
l sex
l age (< 65, 65–80 or > 80 years)
l risk of wandering or leaving the home inappropriately (low, moderate or high risk)
l safety risk in the home (low, moderate or high risk)
l level of caregiver support available (live-in caregiver, caregiver visits at least once daily or caregiver
visits less often than daily).
This stratification procedure was reviewed by the Trial Steering Committee after the first
100 randomisations.
Blinding
Blinding was not undertaken for participants or trial staff collecting data as it was not practicable or
ethical to conceal allocation of ATT. The staff who entered the data were unaware of which arm a
participant had been allocated to.
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Patient and public involvement
The Alzheimer’s Society was involved in devising the research question and in the production of the
trial materials. Two service user representatives sat on the Trial Steering Committee.
Ethics approval
The trial was conducted and designed in compliance with the principles of the Declaration of Helsinki49
and the International Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use – Good Clinical Practice (ICH-GCP).50 All researchers working on the
trial received training in ICH-GCP guidelines. The integrated form for both site-specific information and
research and development approval at all participating NHS sites was approved prior to recruitment
at each site. Annual progress and safety reports and a final report at conclusion of the trial were
submitted to the Multicentre Research Ethics Committee and the Health Technology Assessment
programme within the timelines agreed.
The trial was approved by the NHS Health Research Authority National Research Ethics Committee
(reference number 12/LO/186) and is registered with the International Standard Randomised
Controlled Trial Number registry (ISRCTN86537017).
Sponsorship
The trial was sponsored by South London and Maudsley NHS Foundation Trust.
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Chapter 3 Describing the intervention
Parts of this chapter are reproduced with permission from Forsyth et al.51 Reprinted from Alzheimers &Dementia, 5, Forsyth K, Henderson C, Davis L, Singh Roy A, Dunk B, Curnow E, et al., Assessment of
need and practice for assistive technology and telecare for people with dementia – The ATTILA (Assistive
Technology and Telecare to maintain Independent Living At home for people with dementia) trial,
420–30, 2019, with permission from Elsevier.
Introduction
A detailed exploration of the intervention under investigation is needed to give insight into the fidelity
of the intervention and to allow for replication.52 The aim, therefore, was to provide an overview of
routine ATT practice and the systems in place to deliver ATT for people with dementia.
Method
We adhered to the Template for Intervention Description and Replication (TIDieR)53 checklist in
describing the components of the ATTILA trial intervention, in terms of what happened; who was
involved; how, where and when the intervention happened; how much ATT was provided; and whether
or not it was tailored to participants.
Assistive technology and telecare delivery systems
To describe the delivery systems for ATT deployment, interviews were conducted by staff with key
informants from local authority operational/commissioning teams and telecare monitoring centre
managers in the seven sites from which the majority of trial participants were recruited (n = 484).
Invitations were sent to 21 potential key informants, resulting in 14 interviews covering six sites (no key
informants were available for interview in one site) between June and September 2016. Interviews were
not recorded but written notes were taken; interviewees were also asked for supporting documentation
that might help in understanding the policies and procedures in relation to ATT deployment. Data were
also collected on ATT assessment and delivery processes via pro formas completed by local researchers
in 2015 and via a follow-up desk-based search in 2017. Data were examined using NVivo version 11
qualitative data analysis software (QSR International, Warrington, UK). Data were first structured into
five production stages within a framework analysis:54 assessment, equipment procurement/ordering,
installation, call monitoring, and response to sensor activations. To identify commonalities in local
systems for delivering ATT to trial participants, we took an approach based on value network role
analysis.55,56 Production inputs and processes observed in each site were mapped onto value network
frameworks.
Assistive technology and telecare
The ATT intervention was defined for the purposes of the ATTILA trial as a two-stage process:
1. an ATT assessment, with subsequent ATT recommendation(s)
2. the installation of ATT devices alongside monitoring services, as appropriate.
Framework analysis
We assumed that social services departments in each ATTILA trial site had distilled local and national
guidelines on best practice in ATT assessment when constructing local assessment templates. To
establish a practice standard for ATT assessments in the ATTILA trial sites, ATT assessment templates
and guidance were sourced from each site between August 2013 and August 2016. Sites were asked
to resend documentation if there were changes during the lifetime of the trial; as a result, two sets of
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new documentation were submitted. Framework analysis54 to identify common assessment themes
across sites was applied to this documentation, using the Model of Human Occupation Screening
Tool (MOHOST).57 The MOHOST is designed to detail people’s values, insight, interests, routines,
communication, cognitive and physical skills, and physical and social environment to gain a detailed
picture of an individual’s life. The resultant ATT assessment standard consisted of a set of 14 ATT
assessment areas (Table 2). A 4-point scale was developed for each assessment area in the ATT
assessment standard, where 4 = no risk when doing daily activity, 3 =mostly risk free when doing daily
activity, 2 = some risk when doing daily activity and 1 = significant multiple risks when doing daily
activity. Specific definitions were developed for rating each assessment area (see Appendix 2). ATT
needs were identified when an assessment area received a rating of 1 (significant multiple risks when
doing daily activity) or 2 (some risk when doing daily activity).
TABLE 2 The ATT assessment standard: current practicea across sites
Key themesb ATTILA trial site exemplar questionsc
Motivation
l The person’s motivation drives their choice to
carry out or not carry out daily activity. They may
not have insight into their ability to carry out
daily activities safely or are motivated to do
things that are of importance but not safe to do
1. Insight
l Does the person’s lack of insight into their difficulties
put them at risk? For example, no insight into their lack
of ability to safely do an everyday activity (may appear
overconfident), lack confidence to do activities that may
carry risks, lack insight to activate ATT if required, not able
to be involved in ATT process
2. Values
l Does what is important to the person put them at risk?
For example, the person’s skills do not match what they
think is really important to do; nothing is important to
them, leading to passivity; support is not acceptable to
them as they feel that it is important to be independent;
not willing to explore options, that is they do not want
‘ugly’ equipment as they are house proud
Routines
l Maintaining particular routines and
responsibilities for activities of daily living are
pivotal aspects of life. These routines and
activities provide meaning and structure to how
people spend their time
3. Wandering/disorientation
l Does the person’s routine put them at risk? For example,
wandering, disturbance in day/night activity levels,
getting up at night and become disoriented, kitchen
routines not effective, periods of restlessness, periods
of agitation/aggression
4. Daily activity
l Does the person’s responsibility for their daily activity put
them at risk? For example, cannot manage medication,
cannot safely do their cooking or make a hot drink/snack,
cannot safely bathe/dress
Communication skills
l These skills enable people to describe their needs
and to respond to the messages of others
5. Conversation
l Does the person’s ability to have a conversation put them
at risk? For example, confabulation, unable to communicate
their needs, unable to use a telephone or lifeline unit
without becoming disoriented in conversation
6. Express needs
l Does the person’s ability to express their needs put them
at risk? For example, a speech impairment, an inability to
express their needs, incomplete sentence structure, mute,
speak another language only
DESCRIBING THE INTERVENTION
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TABLE 2 The ATT assessment standard: current practicea across sites (continued )
Key themesb ATTILA trial site exemplar questionsc
Cognitive skills
l Impaired cognitive skill of a person can impact
on their daily activities and on how ATT might
be used to reduce risks and facilitate their
engagement in meaningful activities
7. Memory
l Does memory and having an understanding of how to do
things put them at risk? For example, needing prompting,
forgetting to take medication, forgetting to close doors/
turn off taps, no awareness of how to use appliances, no
awareness of how to respond to alarms
8. Problem solving
l Does the ability to problem solve put the person at risk?
For example, unable to anticipate and adapt to difficulties
that arise and makes inappropriate decisions
Physical skills
l People use physical skills to move themselves or
objects while doing everyday things. This includes
posture, mobility, strength and effort
9. Mobility
l Does the person’s mobility put them at risk? For example,
poor posture and instability/poor balance when walking
indoors; unsafe using stairs; unsafe walking outdoors; walks
with a shuffle, putting them at risk of falls; very mobile
(alongside disorientation)
10. Grip/dexterity
l Does the person’s grip/dexterity put them at risk? For
example, drops hot liquids/burn risk, cannot effectively use
domestic appliances because of poor grip, cannot operate
ATT because of poor grip and lack of strength
Physical environment
l Each physical environment offers a different
combination of opportunities and resources,
demands and constraints
11. Space
l Does the person’s physical space put them at risks?
For example, blocked access, rugs, cables, bolts/chains,
poor state of repair, poor lighting, negotiating stairs,
accessing rooms
12. Resources
l Does the person’s physical resources put them at risk? For
example, appliances are in disrepair and are a fire risk, that
is electric fire, cookers; no smoke alarms; excessively hot
water/risk of scalding; only bath available, which is not safe
for the person to use; no night light when needed
Social environment
l The social environment consists of the people in
the life of the person with dementia, for example
caregivers, neighbours, home helps, friends,
family. Daily activities are completed in particular
ways that have been defined by society norms
13. Social support
l Does the person’s social support put them at risk? For
example, no family support; caregiver’s needs not being
met, no caregiver currently available when needed to
prompt, provide emergency access or respond to an alert;
no acceptance of a non-familiar person, no one to
maintain ATT
14. The way an activity is completed
l Does the way the person completes the activity put them
at risk? For example, unsafely using an overhead gas grill
instead of a toaster, unsafely (lack of light) going to the
toilet at night, unsafely having a night-time bath when
tired, using stairs repeatedly in the day when physically
not able, not wearing shoes/coat outdoors in wet weather
a As defined in the ATT assessment documentation across sites.
b Output from the framework analysis using the MOHOST.
c Each question was criterion-referenced and rated on a 4-point rating scale.
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Fidelity of assistive technology and telecare assessment to assessment standard
Locally completed ATT assessments for each participant were reviewed against the ATT assessment
standard to assess whether or not locally completed ATT assessments across ATTILA trial sites addressed
the ATT assessment areas identified by the templates. Fidelity to this standard was determined by two trial
practitioners with experience in dementia care and ATT assessment, who independently classified the
content of each locally completed ATT assessment against the ATT assessment standard and assigned risk
ratings. They then reviewed ratings together and resolved discrepancies.
Assistive technology and telecare taxonomy/checklist
There is no recognised taxonomy of ATT for people with dementia; therefore, a taxonomy was
developed in collaboration with Trent Dementia Services Development Centre and the ‘atdementia’
initiative (www.atdementia.org.uk; accessed 13 July 2018), an independent online ATT resource. This
taxonomy was then developed into two identical technology checklist forms (one for recommended
ATT and one for installed ATT), which covered the following ATT functions: (1) reminder or prompting
devices, (2) devices to support safety, (3) safer walking technologies, (4) communication devices,
(5) devices that support meaningful use of leisure time and (6) monitoring and response information.
The form also recorded data about which type of assessor had assessed for ATT (ATT assessor, health
or social care professional, other), the method of assessment (in person, at home; in person, not at
home; telephone assessment; using case notes; other), whether or not ATT were monitored (yes/no)
and who would respond to ATT alerts (direct to responder or via a call centre). Two trial practitioners
with experience in dementia care and ATT assessment collaboratively classified each device recommended
in the locally completed ATT needs assessment using the technology checklist (for recommended ATT).
Assistive technology and telecare installations
Assistive technology and telecare checklist
Local trial researchers used the technology checklist (for installed ATT) during home visits at weeks 12,
24, 52 and 104.
Statistical analysis
Categorical data were summarised in percentages and numbers of observations. Correlations between
count variables were tested using non-parametric methods (Kendall rank correlation coefficient, τ). The
Kruskal–Wallis test was used to assess if there were statistically significant differences between multiple
groups for outcomes. Freidman’s test was used to determine the significance of change over time in
the count variables. In the case of categorical variables, differences between observed and expected
frequencies were tested using Pearson’s chi-squared test for independence, or, alternatively, Fisher’s
exact test, when the assumption of minimum expected cell count in contingency tables was not met.58
Standardised Mini-Mental State Examination (SMMSE) scores were categorised into stages of dementia59
for the purposes of analysis (30 = no dementia, 26–29 = questionable dementia, 21–25=mild dementia,
11–20=moderate dementia and 0–10 = severe dementia). Effective tailoring of the intervention was
described through the strength of the correlation60 between ATT needs and ATT recommendations at
baseline and between ATT recommendations and ATT installation by 24 weeks. We also compared the
ATT that were recommended in the needs assessment with subsequent installations for each participant




A total of 495 participants were randomised to the ATTILA trial (intervention group, n = 248; control
group, n = 247). Of these, 451 had a documented needs assessment. A total of 209 intervention group
participants had documented ATT installations.
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Assessment
Of the 451 documented ATT needs assessments available, 413 contained an ATT recommendation.
Of the 248 participants recruited to the intervention arm, data from 209 participants were available
for analysis of ATT installations.
In total, 60% of assessment responses identified an ATT need, with 4.4 ATT needs (range 0–12)
identified per participant (Tables 3 and 4). The mean number of ATT needs identified varied, ranging
from two to six per site (p < 0.001). The areas of concern most frequently identified as triggering the
need for ATT were daily activities (93%), memory (89%) and problem-solving (83%). Health and social
care professionals identified more ATT needs than ATT assessors (p = 0.047). More ATT needs were
identified through in-person, at-home assessments than through telephone assessment methods
(p < 0.001). There was no significant difference between ATT needs in men and women (p = 0.337).
The number of ATT needs identified for each participant differed depending on the risk of wandering
(p = 0.005): a medium risk of wandering was associated with more ATT needs than a low risk of
wandering (p = 0.016). ATT needs varied by category of SMMSE score (p < 0.001): participants with
severe dementia had more ATT needs than those with mild (p < 0.001), those with moderate
(p = 0.002) or those with questionable dementia (p < 0.001).
Fidelity of assessment
The local ATT assessment fidelity with the ATT assessment standard was 52% (7.2 assessment areas
were addressed per assessment) (see Tables 3 and 4). Of 451 ATT assessments reviewed, 99 (22%)
addressed 0–2 areas of assessment. There was higher fidelity to assessment areas relating to ‘mobility’
(74%), ‘social support’ (72%), ‘daily activity’ (71%) and ‘memory’ (71%). Fidelity varied across sites: the
mean number of assessment areas addressed ranged from two to 13 per site (p < 0.001), with public
TABLE 3 Fidelity with ATT assessment standard and identified ATT needs, by assessment areas
Site ATT assessment areas/standard
Fidelity with ATT
assessments standard
ATT needs (i.e. responses
rated as ‘at risk’)
n/N % n/N %
1. Insight 241/451 53 151/241 63
2. Values 245/451 54 100/245 41
3. Wandering/disorientation 284/451 63 219/284 77
4. Daily activity 321/451 71 298/321 93
5. Conversation 226/451 50 100/226 44
6. Express needs 175/451 39 24/175 14
7. Memory 320/451 71 284/320 89
8. Problem-solving 218/451 48 181/218 83
9. Mobility 335/451 74 224/335 67
10. Grip/dexterity 147/451 33 18/147 12
11. Space 140/451 31 47/140 34
12. Resources 128/451 28 26/128 20
13. Social support 325/451 72 183/325 56
14. The way the activity is completed 162/451 36 118/162 73
Total responses 3267/6314 52 1973/3267 60
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TABLE 4 Fidelity with ATT assessment standard and identified ATT needs, by participant and assessment characteristics
Characteristic
Fidelity with ATT assessments standard Number of ATT needs
Median Mean % Median Mean %
Participant characteristic
Gender
Female 8 7.67 62 4 4.46 60
Male 5 6.65 38 3 4.25 40
p = 0.027 p = 0.337
Risk of wandering
Low 7 6.93 70 4 4.10 68
Medium 9 8.37 23 5 5.04 23
High 6 7.24 7 4 5.24 9
p = 0.038 p = 0.005
SMMSE score of 18 points
Questionable dementia (26–29) 7 7.22 13 3 3.38 10
Mild dementia (21–25) 7 6.6 27 4 3.9 27
Moderate dementia (11–20) 7 7.38 45 4 4.27 44
Severe dementia (0–10) 8.5 7.96 15 5.5 5.79 19
p = 0.309 p < 0.000
Assessment characteristic
Assessors
Health and social care
professionals
8 7.85 68 4 4.66 67
ATT assessor 5.5 6.51 29 3 3.86 29
p = 0.051 p = 0.028
Assessment method
In person, at home 10 9.14 85 5 5.06 82
In person, not at home 5 6.43 8 3 3.38 8
Telephone 2 3.42 6 2 2.71 9
Case notes 3 3.33 1 2.5 3 1
p < 0.000 p < 0.000
Service structure
Public telecare provider 7 7.59 73 4 4.41 70
Not-for-profit telecare provider 6 6.41 25 4 4.31 28
p = 0.026 p = 1.00
Mean fidelity with ATT assessment
standard per participant: 7.2 assessment
areas addressed (range 0–13)
Mean number of responses per
participant rated as an ATT need:
4.4 ATT needs (range 0–12)
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telecare providers addressing more assessment areas than not-for-profit telecare providers (p = 0.026).
Health and social care professionals addressed more assessment areas than ATT assessors (p = 0.046).
Fidelity varied across assessment methods (p < 0.001), with the in-person, at-home assessment method
addressing more assessment areas than in-person, not-at-home (p = 0.003), telephone (p < 0.001) and
case notes assessment methods (p = 0.003). Women had more assessment areas addressed than men
(p = 0.027). More assessment areas were addressed for participants at medium risk of wandering than
for participants at low risk of wandering (p = 0.028).
Assistive technology and telecare delivery system
Value networks
Networks delivering services (offering value) to participants in ATTILA trial sites were classified into
two types (Figures 1 and 2). First were ‘public telecare provider networks’ (n = 4), for which two assessor
roles were identified: the ATT assessor and the authorised (or trusted) assessor (health or social care
professional). ATT assessors were employed by public agencies (NHS or CASSRs); their primary role was
to assess for a full range of ATT devices [‘networked’ (monitored by a telecare call centre or caregiver)
or ‘standalone’]. Authorised assessors could offer first-generation telecare (pendant-only systems) or
straightforward ATT (e.g. adding on an additional sensor or providing a memo minder), depending on
their level of experience and local permissions; they performed ATT assessment as a secondary role.
In these networks, most or all of the ATT infrastructure for procurement, installation, stock control and
maintenance of ATT devices fell to units in the CASSR. The second type of networks were ‘not-for-profit
provider networks’ (n = 3). Three assessor roles were identified across these ‘not-for-profit telecare
networks’. Telecare assessors working for not-for-profit telecare providers assessed for AT that was
networked to providers’ call-monitoring centres. Assessment for standalone assistive technology fell
to assessors in the CASSR. A ‘social care ATT assessor’ role was also identified; these assessors could
assess for ATT (networked or standalone) and work with a choice of suppliers to procure and arrange
the installation of ATT devices. Private companies offered combinations of procurement and stock
control, installation, and maintenance services to the not-for-profit telecare providers.
Assistive technology and telecare recommendations
A documented ATT recommendation was given for 413 participants, with 1090 ATT devices recommended
at baseline [mean three devices (range 1–14 devices)]. For 57% (n = 235) of participants, just one or two
ATT devices were recommended. The correlation between the ATT needs and the ATT recommendations
identified in local ATT assessments was weak (τ = 0.242; p < 0.001). Most recommendations were for
safety-related devices (59%, 644/1090), followed by reminder/prompting devices (25%, 269/1090).
ATT devices required monitoring in 62% (673/1090) of recommendations, and 67% (353/526) of
monitored devices with an identified responder required a formal (call centre) response.
Assistive technology and telecare installations
Frequency of assistive technology and telecare categories
By 24 weeks, a mean of 3.5 devices had been recommended for participants in the intervention arm.
Of the ATT devices recommended, 53% (306/572) were not installed.
Relationship of assistive technology and telecare installations to assistive
technology and telecare recommendations
A total of 62% (438/704) of the ATT devices that were installed had not been recommended in the needs
assessment (Table 5). There was a moderate negative correlation between number of recommendations
and number of installations per participant per ATT category (τ = –0.470; both p < 0.001).
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
19
































































































































































































































































































































































































































































































TABLE 5 Recommended ATT devices matched to ATT devices installed at 24 weeks (intervention arm only)
ATT technology
checklist













Pendant alarm 44/572 (8) 22/44 (50) 22/44 (50) 89/704 (13) 67/89 (75)
Non-monitored smoke
detector
0/572 (0) 0 (0) 0 (0) 68/704 (10) 68/68 (100)
Non-monitored carbon
monoxide detector
1/572 (0) 0/1 (0) 1 (100) 36/704 (5) 36/36 (100)
Key safe 18/572 (3) 9/18 (50) 9/18 (50) 89/704 (13) 80/89 (90)
Activity monitors
assessment only
8/572 (1) 4/8 (50) 4/8 (50) 5/704 (1) 1/5 (20)
Other devices 1/572 (0) 0/1 (0) 1/1 (100) 6/704 (1) 6/6 (100)
Intervention group technology
Reminder or prompting devices
Date and time reminders 31/572 (5) 13/31 (42) 18/31 (58) 46/704 (7) 33/46 (72)
Item-locator devices 9/572 (2) 8/9 (89) 1/9 (11) 11/704 (2) 3/11 (27)
Medication reminders/
dispensers
56/572 (10) 25/56 (45) 31/56 (55) 33/704 (5) 8/33 (24)
Voice recorders and
memo minders
46/572 (8) 27/46 (59) 19/46 (41) 38/704 (5) 11/38 (29)
Other reminder/
prompting devices
1/572 (0) 0/1 (0) 1/1 (100) 6/704 (1) 6/6 (100)
Devices to promote safety
Activity monitors –
ongoing monitoring
5/572 (1) 1/5 (20) 4/5 (80) 6/704 (1) 5/6 (83)
Fall detectors 75/572 (13) 31/75 (41) 44/75 (59) 53/704 (8) 22/53 (42)
Continence management
devices
1/572 (0) 1/1 (100) 0/1 (0) 1/704 (0) 0/1 (0)




14/572 (2) 9/14 (64) 5/14 (36) 11/704 (2) 2/11 (18)
Gas detectors 21/572 (4) 8/21 (38) 13/21 (62) 19/704 (3) 11/19 (58)
Monitored carbon
monoxide detectors
25/572 (4) 8/25 (32) 17/25 (68) 22/704 (3) 14/22 (64)
Monitored smoke
detectors
59/572 (10) 39/59 (66) 20/59 (34) 47/704 (7) 8/47 (17)
Monitored extreme
temperature sensors
26/572 (5) 18/26 (42) 15/26 (58) 19/704 (3) 8/19 (42)
Lighting devices 2/572 (0) 1/2 (50) 1/2 (50) 8/704 (1) 7/8 (88)
Other safety and security
devices
15/572 (3) 2/15 (13) 13/15 (87) 9/704 (1) 7/9 (78)
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Week 12–104, assistive technology and telecare devices installed
(intervention arm only)
From week 12 to week 104, 888 ATT devices were installed for 209 participants in the intervention
arm, which is a mean of 4.2 devices per participant (range 1–15 devices). Of the devices installed for
intervention participants (Table 6), 42% (374/888) involved the types of technology provided to control
arm participants (e.g. non-monitored smoke detectors). Installations decreased over time (p = 0.031),
with 79% (704/888) of ATT installed by week 24. Intervention participants’ ATT devices were most
frequently installed for safety reasons (38%) or for reminder/prompting (18%). ATT assessors were
most frequently identified as having assessed for the installed devices (32%), followed by health and
social care professionals (20%), but 40% of assessors’ backgrounds were unknown. A total of 41% of
installations followed an in-person home visit (41%), but in 42% of cases participants could not report
the method of assessment. Nearly half (47%) of the ATT devices installed required monitoring; 38%
of monitored devices were networked to a call centre (so that any alerts would receive an initial
response from paid services).
TABLE 5 Recommended ATT devices matched to ATT devices installed at 24 weeks (intervention arm only) (continued )
ATT technology
checklist













To locate the user 43/572 (8) 20/43 (47) 23/43 (53) 28/704 (4) 8/28 (29)
To alert the responder to
movement
59/572 (10) 25/59 (42) 34/59 (58) 37/704 (5) 12/37 (32)
Communication devices
Intercoms 2/572 (0) 0/2 (0) 2/2 (100) 1/704 (0) 1/1 (100)
Telephones 3/572 (1) 0/3 (0) 3/3 (100) 7/704 (1) 7/7 (100)
Communication aids 0/572 (0) 0/0 (0) 0/0 (0) 1/704 (0) 1/1 (100)
Other communication
devices
1/572 (0) 0/1 (0) 1/1 (100) 0/704 (0) 0/0 (0)
Devices that support meaningful use of leisure time








0/572 (0) 0/0 (0) 0/0 (0) 0 (0) 0 (0)
Electronic games 0/5572 (0) 0/0 (0) 0/0 (0) 1/551 (0) 1/1 (100)
Other devices 1/572 (0) 0/1 (0) 1/1 (100) 2/551 (0) 2/2 (100)
Total 572 266/572 (47) 306/572 (53) 704 438/704 (62)
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TABLE 6 The ATT installations, 12–104 weeks (intervention arm only)
Week, n (%)
Total (weeks 12–104),
n (%)12 24 52 104
Control group technology installed
Basic ATT 235 (41) 58 (47) 45 (52) 36 (37) 374 (42)
Intervention technology installed
Reminder/prompting 116 (20) 18 (15) 9 (10) 17 (18) 160 (18)
Safety 220 (38) 45 (36) 30 (35) 43 (44) 338 (38)
Communication 8 (1) 1 (0) 2 (2) 1 (1) 12 (2)
Support leisure time 1 (0) 2 (2) 1 (1) 0 (0) 4 (0)
Any other devices 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total installed 580 (100) 124 (100) 87 (100) 97 (100) 888 (100)
Assessor
Health or social care professional 126 (22) 20(16) 13 (15) 17 (18) 176 (20)
ATT assessor 152 (26) 58 (47) 23 (26) 45 (46) 278 (32)
Other 68 (12) 0 (0) 3 (4) 4 (4) 75 (8)
Unknown 234 (40) 46 (37) 48 (55) 31 (32) 359 (40)
Total installed 580 (100) 124 (100) 87 (100) 97 (100) 888 (100)
Assessment method
In person, at home 216 (37) 70 (57) 30 (34) 55 (57) 371 (41)
In person, not at home 7 (1) 3 (2) 1 (1) 4 (4) 15 (2)
Telephone 50 (9) 4 (3) 1 (1) 4 (4) 59 (7)
Using case notes 7 (1) 0 (0) 0 (0) 2 (2) 9 (1)
Other 56 (10) 1 (1) 2 (2) 0 (0) 59 (7)
Unknown 244 (42) 46 (37) 53 (61) 32 (33) 375 (42)
Total installed 580 (100) 124 (100) 87 (100) 97 (100) 888 (100)
Monitoring
Yes 292 (51) 56 (45) 32 (37) 42 (43) 422 (47)
No 147 (25) 45 (36) 25 (29) 40 (41) 257 (29)
Unknown 141 (24) 23 (19) 30 (34) 15 (16) 209 (24)
Total installed 580 (100) 124 (100) 87 (100) 97 (100) 888 (100)
Response
Formal services 104 (36) 29 (52) 15 (47) 14 (33) 1622 (38)
Informal services 79 (27) 11 (20) 8 (25) 16 (38) 1142 (27)
Mixed services 106 (36) 14 (25) 8 (25) 12 (29) 1402 (33)
Unknown 3 (1) 2 (3) 1 (3) 0 (0) 62 (2)
Total installed 292 (100) 56 (100) 32 (100) 42 (100) 422 (100)
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Summary
The findings are the first to describe assistive technology for people with dementia. The components
of the ATTILA trial intervention have been described, in terms of what happened, who was involved,
how, where and when the intervention happened, how many devices was provided and whether or
not the intervention was tailored to participants. Value networks operating in ATTILA trial sites were
characterised as either public or not-for-profit telecare provider network types. The ATTILA trial
intervention is summarised in Table 7, using the TIDieR format.
TABLE 7 Current ATT practice with people with dementia, using the TIDieR format
TIDieR format Current ATT practice for people with dementia
When?
When did assessments, recommendation and
installations happen?
Baseline (week 0): assessment and recommendations
Weeks 12, 24, 52 and 104: assessment and installation
What?
What areas of assessment, in local ATT assessments,
had higher fidelity to the ATT assessment standard?
Daily activity, memory, mobility and social support
What areas of assessment more frequently triggered
the need for ATT?
Daily activities, memory and problem-solving
What ATT devices were recommended more
frequently in local ATT assessments?
Devices for safety issues and to remind/prompt with
monitoring/formal response
What ATT devices were installed more frequently? Devices for safety issues and to remind/prompt with
monitoring/formal response and control arm devices
(e.g. non-monitored smoke detectors)
How much?
How much of the ATT assessment was completed? 52% of the ATT assessment areas were completed
7.2 ATT assessment areas were addressed, on average
(range 0–13)
How many ATT needs were present? 4.4 ATT needs, on average (range 0–12 needs)
How many ATT recommendations were identified? 3 ATT devices, on average (range 1–14 devices)
57% of participants had one or two ATT devices
recommended
How many installations were conducted? 4.2 ATT devices were installed, on average
(range 1–15 devices) (including control arm devices)
79% were installed by week 24, with a reduction in
installation over time
How much monitoring and response happened? 47% of installed ATT devices required monitoring,
of which 38% required a formal response
Who?
Who were the participants? > 80 years of age, female, widowed, white British,
not living alone and had moderate dementia
continued
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TABLE 7 Current ATT practice with people with dementia, using the TIDieR format (continued )
TIDieR format Current ATT practice for people with dementia
Who were the assessors of the installed devices? Baseline:
l 57% – health and social care professionals
l 33% – ATT assessors
l 10% – not known
Weeks 12–104:
l 32% – ATT assessors
l 20% – health and social care professionals
l 40% – not known
l 8% – other
Where?
Where did the ATT assessment take place? 41% of assessments were in-person, at home
Where did the installations take place? Participant’s homes
Tailoring
Were the devices tailored to the participants? There was an expectation that ATT installations would
be tailored to participants by the baseline ATT
assessment; however, there was weak to moderate
tailoring between (1) baseline ATT needs and ATT
recommendations (τ = 0.242; p < 0.000) and (2) ATT
recommendations and the ATT installed (τ = –0.470;
p < 0.000); 62% of devices were installed for ATT needs
that had not been identified in the assessment process,
and 53% of the devices recommended as a result of
assessment were not installed by week 24
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Chapter 4 Primary outcome results
Recruitment
Eleven sites in England were opened for recruitment to the ATTILA trial. The first participant was
randomised on 14 August 2013; recruitment ended on 26 October 2016. The ATTILA trial randomised
over a period of 38 months, with an average recruitment rate of 13 participants per month. Yearly
recruitment per site is shown in Table 8.
A total of 1411 people were assessed for trial eligibility; of these, 495 were randomised across the
11 sites: 248 were randomised to receive ATT and 247 were randomised to the control arm. The
Consolidated Standards of Reporting Trials flow diagram of participants through the ATTILA trial is
shown in Figure 3, and Table 9 shows the participant status at the end of the trial.
Those people who declined to consent did so because they wanted ATT (n = 53), because they did not
want ATT (n = 83) or because they did not want to participate in research (n = 162). Other reasons for
being excluded were, primarily, that the researcher was unable to contact the potential participant
(n = 131) or because participation was deemed inappropriate (n = 48).
During the follow-up of the ATTILA trial, in total, 200 participants were admitted to care, 89 participants
died, 42 withdrew from further follow-up and 18 were lost to follow-up. This resulted in 146 participants
finishing the trial living independently in the community: 85 in the intervention arm and 61 in the control
arm. Relatively few participants (3.6%) were lost to follow-up, as, once randomised, every effort was made
to follow up participants throughout the trial to obtain all follow-up forms and outcome assessments.
Of the 18 lost to follow-up, 10 were in the intervention arm and eight were in the control arm.
TABLE 8 Yearly recruitment per site
Site
Year (number of participants recruited)
Total number of
participants recruited2013 2014 2015 2016
Croydon 4 21 13 10 48
Lambeth 5 13 28 17 63
Southwark 3 21 21 26 71
Cambridge 2 49 37 51 139
Oxford 0 18 8 4 30
Suffolk 3 23 24 11 61
Lancashire 1 14 35 22 72
Blackpool 0 1 3 0 4
Nottingham 0 2 0 0 2
Barnsley 0 0 0 3 3
Blackburn 0 0 2 0 2
Yearly total 18 162 171 144 495
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                                Excluded
                                 (n = 916)
• Not meeting inclusion criteria, n = 408
• Declined to participate, n = 298
• Other reasons, n = 210
Randomised







                           Community resident
                                         (n = 235)
• Admitted to care, n = 9
• Died, n = 1
• No longer wished to participate, n = 3
Week 12
                                     Analysed
                                     (n = 248)
• Admitted to care, n = 93
• Died, n = 41
• No longer wished to participate, n = 19
• Lost to follow-up, n = 10
Analysis
                           Community resident
                                         (n = 182)
• Admitted to care, n = 25
• Died, n = 6
• No longer wished to participate, n = 8
• Lost to follow-up, n = 2
Week 52
                           Community resident          
                                         (n = 123)
• Admitted to care, n = 34
• Died, n = 19
• No longer wished to participate, n = 1
• Lost to follow-up, n = 5
Week 104
                           Community resident
                                         (n = 223)
• Admitted to care, n = 7
• Died, n = 2
• No longer wished to participate, n = 2
• Lost to follow-up, n = 1
Week 24
                           Community resident
                                         (n = 85)
• Admitted to care, n = 18
• Died, n = 13
• No longer wished to participate, n = 5
• Lost to follow-up, n = 2
                           Community resident
                                         (n = 225)
• Admitted to care, n = 10
• Died, n = 3
• No longer wished to participate, n = 8
• Lost to follow-up, n = 1
                                     Analysed
                                      (n = 247)
• Admitted to care, n = 107
• Died, n = 48
• No longer wished to participate, n = 23
• Lost to follow-up, n = 8
                           Community resident
                                         (n = 162)
• Admitted to care, n = 27
• Died, n = 9
• No longer wished to participate, n = 3
                           Community resident
                                         (n = 107)
• Admitted to care, n = 28
• Died, n = 22
• No longer wished to participate, n = 3
• Lost to follow-up, n = 2
                           Community resident
                                         (n = 201)
• Admitted to care, n = 10
• Died, n = 8
• No longer wished to participate, n = 3
• Lost to follow-up, n = 3
                           Community resident
                                         (n = 61)
• Admitted to care, n = 32
• Died, n = 6
• No longer wished to participate, n = 6
• Lost to follow-up, n = 2
End of study
FIGURE 3 The Consolidated Standards of Reporting Trials flow diagram.
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Once a participant was admitted to care, the follow-up was terminated and no outcome assessments were
collected. Table 10 displays a comparison of the key participant characteristics of the 495 participants
randomised.
All characteristics appear to be reasonably well balanced across the two randomised arms. The average
age was 80.9 years, 59% (290/495) were female and 48% (240/495) had a live-in caregiver. The majority
of participants, 72% (358/495), were classified as being at low risk of wandering or leaving their home
inappropriately. Half of the participants (249/495) were deemed to have low safety risks identified
within the home. The average SMMSE score was 18.7 points in the intervention arm and 16.9 points
in the control arm, so participants in the intervention arm had a slightly higher baseline SMMSE score
than those in the control arm. The average BADLS score was 19.5 in the intervention arm and 20.4 in
the control arm. The missingness of these data was similar between the two arms.
TABLE 9 Participant status at the end of the ATTILA trial
Status
Trial arm, n (%)
Total (N= 495), n (%)Intervention (N= 248) Control (N= 247)
Admitted to care 93 (37.5) 107 (43.3) 200 (40.4)
Death while a community resident 41 (16.5) 48 (19.4) 89 (18.0)
Withdrew from further follow-up 19 (7.7) 23 (9.3) 42 (8.5)
Lost to follow-up (unable to contact) 10 (4.0) 8 (3.2) 18 (3.6)
Finished trial living in the community 85 (34.3) 61 (24.8) 146 (29.5)
TABLE 10 Participant baseline characteristics
Characteristic
Trial arm
Intervention (N= 248) Control (N= 247)
Age (years)
< 65, n (%) 11 (4) 4 (2)
65–80, n (%) 89 (36) 93 (38)
> 80, n (%) 148 (60) 150 (61)
Mean (SD) 81.0 (8.2) 80.8 (7.4)
Gender, n (%)
Male 102 (41) 103 (42)
Female 146 (59) 144 (58)
Risk of wandering/leaving home inappropriately, n (%)
Low 178 (72) 180 (73)
Medium 52 (21) 48 (19)
High 18 (7) 19 (8)
Safety risks within home identified, n (%)
Low 125 (50) 124 (50)
Medium 104 (42) 101 (41)
High 19 (8) 22 (9)
continued
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The primary analysis of admission to care was defined as a permanent transition from living in a
participant’s own home to living in nursing or residential care, or admission to an acute care facility
that resulted in permanent placement. The end point was compared between the intervention and
control arms using survival analysis. Kaplan–Meier curves are for graphical representation of time to
an event. Statistical significance was determined through log-rank test. The primary analysis was
conducted according to intention to treat, and participants who have died, withdrawn from follow-up
or who were lost to follow-up were censored at the date of withdrawal. The time to admission to care,
split by randomised arm, is shown in Figure 4.
The intervention and control arms showed a similar pattern of time to admission to care over the
3-year period plotted. Comparing the ATT arm with the control arm, the hazard ratio is 0.76
[95% confidence interval (CI) 0.58 to 1.01; p = 0.054]. This unadjusted analysis showed a borderline
significant difference in slowing the time to admission to care with ATT use when compared with the
control. At 2 years, the admission to care rate for the ATT arm was 65.6% (95% CI 58.8% to 71.5%),
compared with 63.4% (95% CI 56.3% to 69.7%) for the control arm.
The rates of admission to care can be affected by participants’ functional ability. This was measured
using the BADLS. BADLS scores range from 0–60, with higher scores indicating greater impairment.
Figure 5 shows the time to admission to care split by BADLS scores 0–4, 5–14, 15–29 and 30–60.
TABLE 10 Participant baseline characteristics (continued )
Characteristic
Trial arm
Intervention (N= 248) Control (N= 247)
Level of caregiver support, n (%)
Live in 119 (48) 121 (49)
Once daily 60 (24) 61 (25)
Less than once daily 69 (28) 65 (26)
SMMSE scorea
0–9, n (%) 23 (10) 34 (15)
10–19, n (%) 79 (36) 96 (43)
20–25, n (%) 87 (39) 74 (33)
26–30, n (%) 32 (14) 19 (9)
Mean (SD) 18.7 (6.6) 16.9 (6.9)
BADLS scoreb
0–4, n (%) 17 (7) 10 (4)
5–14, n (%) 72 (31) 64 (28)
15–29, n (%) 95 (41) 102 (45)
30–60, n (%) 46 (20) 49 (22)
Mean (SD) 19.5 (11.3) 20.4 (10.9)
a Scores range from 0 to 30; higher scores indicate better cognitive function.
b Scores range from 0 to 60; higher scores indicate greater impairment.
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There was a highly significant difference in the time to admission to care when comparing baseline
BADLS scores. Participants with a higher baseline BADLS score were more likely to be admitted to
care (p < 0.0001). Baseline BADLS scores are presented in Table 10 and shows an imbalance in baseline
scores. More participants in the intervention arm than in the control arm had a lower baseline BADLS
score. As Figure 5 showed that participants with a higher baseline BADLS score are more likely to be
admitted to care; this difference at baseline was adjusted for in the primary analysis. A forest plot split
by baseline BADLS score is shown in Figure 6.
When adjusting for baseline BADLS scores, there is no significant difference in the time to admission
to care between those in the intervention group and those in the control group (hazard ratio 0.84,
95% CI 0.63 to 1.12; p = 0.20).
The reasons for admission to care are usually multifactorial. To determine whether or not ATT might have
helped prevent admissions to care, the reasons given for institutionalisation have been categorised as
having any mention of safety, then any mention of wandering and then falls, with others classified as
inability to perform activities of daily living (ADL), behaviour, other medical condition, deterioration
(unspecified), caregiver health, other and unknown. This can give only an approximate classification, given
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FIGURE 4 Kaplan–Meier survival curve: time to admission to care by randomised arm, unadjusted analysis.
0–4 (n = 27)
5–14 (n = 136)
15–29 (n = 197)
































FIGURE 5 Kaplan–Meier survival curve: time to admission to care by baseline BADLS score.
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The most common reason for admission to care is the inability to perform ADL. Institutionalisation for
safety concerns, which might have been expected to be reduced by ATT, is actually more common in
the intervention group (12 vs. 4 participants; p = 0.043). By contrast, the risk of wandering, which
might, again, be mitigated by appropriate ATT, was reduced in the intervention group (5 vs. 13
participants; p = 0.054). There was also a significant reduction in the number of participants moving
into residential care because of the inability to perform ADL (14 vs. 29 participants; p = 0.016). A total







Test for heterogeneity between subgroups: χ23 = 4.0; p = 0.3; NS
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FIGURE 6 Forest plot: admission to care by randomised arm, adjusted for baseline BADLS score. NS, not significant;
O/E, observed over expected; Var., variance.
TABLE 11 Reasons for admission to care categorised
Categorised reason
Trial arm (number of participants)
Total number of
participants (N= 495) p-valueaIntervention (N= 248) Control (N= 247)
Safety concern 12 4 16 0.043
Wandering 5 13 18 0.054
Falls 13 13 26 0.990
Loss of ADL 14 29 43 0.016
Behaviour 8 10 18 0.630
Other medical condition 7 6 13 0.790
Deterioration (unspecified) 14 11 25 0.540
Caregiver health 9 3 12 0.081
Other 6 8 14 0.580
Unknown 5 10 15 0.190
Any cause 93 107 200
a p-value from Mantel–Haenszel test (ignoring time to event).
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Subgroup analysis
To investigate whether or not ATT use varied by baseline characteristics, we did subgroup analyses of
admission to care in the ATT group compared with admission to care in the control group by gender,
age, risk of wandering from home and safety risk within the home (Figure 7). As there were no significant
differences seen, there is no indication of any benefit from ATT use in any of these subgroups.
Deaths while in the community
Eighty-nine participants died while in the community. Figure 8 is the Kaplan–Meier graph of time to
death while community resident and Table 12 shows the categorised reasons for cause of death. In the
Kaplan–Meier analysis, participants who had been admitted to care, withdrawn from follow-up or lost
to follow-up were censored at the date of withdrawal.
There were no significant differences seen overall (p = 0.14) or in the grouped categories for cause of
death (see Figure 8 and Table 12).
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FIGURE 7 Subgroup analyses of admission to care for the ATT group vs. the control group, by baseline characteristics.
O/E, observed over expected; Var., variance.
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Serious adverse events
Serious adverse events have been grouped into broad categories and are summarised in Tables 13
and 14. The categories were decided on by members of the ATTILA trial team with clinical expertise
and were categorised separately by two members of the team, then assessed for consistency. Any
differences were discussed, and input sought from a clinical expert in the team. Raters were unaware
of treatment allocation of the participants involved. Table 13 presents the counts of SAEs recorded and
Table 14 presents the number of participants reporting the SAEs, as participants can report multiple
SAEs. Similarly to the reasons for admissions to care, SAEs could be multifactorial. The categories are
any mention of safety concerns, wandering, falls, dementia progression, behaviour, other medical
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FIGURE 8 Kaplan–Meier survival curve: time to death while community resident, by randomised arm.
TABLE 12 Causes of death categorised
Cause of death
Trial arm (number of participants)
Total number of
participants (N= 495) p-valueaIntervention (N= 248) Control (N= 247)
Health/dementia deterioration 8 4 12 0.25
Pneumonia/respiratory failure 4 10 14 0.10
Heart attack/heart failure 3 8 11 0.13
Stroke 7 5 12 0.56
Cancer 7 4 11 0.36
Infection 6 4 10 0.53
Other 2 4 6 0.41
Unknown 4 9 13 0.16
Total 41 48 89
a p-value from Mantel–Haenszel test (ignoring time to event).
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Participants reported multiple SAEs. Overall, 1135 SAEs were reported from 396 participants. The
most common SAE was ‘other medical condition’, which was reported by 216 participants. The second
most-reported SAE was related to falls (369 falls were reported by 174 participants). Figure 9 plots the
number of participants experiencing each SAE type, ordered by hierarchy of classification, with a test
of significance between intervention and control participants.
TABLE 13 Counts of categorised SAEs
Categorised SAE
SAE count (n)
Intervention arm Control arm Total
Safety concerns 15 5 20
Wandering 36 71 107
Falls 182 187 369
Dementia progression 37 46 83
Behaviour 5 21 26
Other medical condition 214 220 434
Caregiver related 11 10 21
Environmental/accident 14 21 35
Health deterioration 6 3 9
Other 2 1 6
Unknown 10 18 28
Total count of SAEs 532 603 1135
TABLE 14 Number of participants reporting categorised SAEs
Categorised SAE
Number of participants
p-valueIntervention arm Control arm Total
Safety concerns 13 5 18 0.06
Wandering 25 36 61 0.13
Falls 86 88 174 0.83
Dementia progression 37 43 80 0.45
Behaviour 5 16 21 0.01
Other medical condition 107 109 216 0.83
Caregiver related 11 10 21 0.83
Environmental/accident 13 15 28 0.69
Health deterioration 5 2 7 0.26
Other 2 1 3 0.57
Unknown 10 16 26 0.22
Total 195 201 396 0.45
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
35
Figure 9 shows that there was a significant reduction in the number of participants experiencing
behavioural-related SAEs in the intervention group, compared with the control group (p = 0.01).
More participants in the intervention group than in the control group reported SAEs related to safety
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FIGURE 9 Forest plot of the incidence of SAEs. p-values fromMantel–Haenszel tests (ignoring time to event). OR, odds ratio.
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Chapter 5 Economic evaluation
The economic evaluation addressed the question ‘are ATT interventions cost-effective in themanagement of risk and maintenance of independence in people with dementia living in their
own homes?’.
Methods
The economic evaluation included cost-effectiveness and cost–utility analyses.
Outcomes
The economic evaluation examined three outcomes for participants with dementia:
1. the incremental cost of community-based support per institutional day avoided
(days to institutionalisation)
2. the incremental cost of change in the EQ-5D-5L index over 24, 52 and 104 weeks
3. the incremental cost per QALY over 24, 52 and 104 weeks.
Participant-rated and proxy-rated utilities were calculated from the EQ-5D-5L, valued by ‘crosswalking’
EQ-5D-5L health-state profiles to the UK value set for EuroQol-5 Dimensions, three-level version,61,62
as currently recommended by the National Institute for Health and Care Excellence (NICE).63
Perspective
Analyses were conducted from a health and social care perspective (cost to the NHS and to CASSRs)
and from a societal perspective (costs to the participant and caregiver). We assumed service costs
(e.g. of community, primary and hospital health care) were borne by public payers, except in the case
of home adaptations and ADL equipment, for which only items reported to have been paid for by the
NHS or council were included. Societal costs included lost production, costs of providing unpaid care
and out-of-pocket payments for home adaptations and ADL equipment and travel costs (restricted to
dementia-related treatment and day care).
Time horizon
The participant- and caregiver-reported EQ-5D-5L and the caregiver-reported CSRI were administered
alongside other measures at each assessment point (see Table 1). The CSRI covered service receipt
over the previous 3 months. An annual discount rate of 3.5%64 was applied to costs and days in the
community in the second year, as the time horizon was 2 years.
Costs
The analysis considered comprehensive costs of care and support to the person with dementia.
Health-care, social care and societal costs (excluding direct costs of the ATT intervention) were
calculated by drawing on data from the CSRI. Direct costs of the ATT intervention were calculated
from the ATT technology checklist and from interview data (see Intervention costs, Valuing assessment
time and Valuing the assistive technology and telecare package). Costs of health and social care service
use were calculated from service use data by applying the relevant published unit costs.42,43 Caregiver
inputs were valued by taking an opportunity-costs approach in the main analyses, following methods
described in Wimo et al.,65 by valuing the lost working time of working caregivers at the national
average wage66 and lost leisure time of non-working caregivers at 35% of that figure. In the case of
care from others (e.g. other relatives), caregivers were assumed to be working and their time was
valued at national average wage. A replacement-costs valuation (using the hourly cost of a domiciliary
care worker) was applied in a sensitivity analysis.43,67 Unit costs used in valuing resource use are
reported in Appendix 3.
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The costs of individual services were first aggregated to category level (hospital; primary and community
health; mental health; overnight respite; community, social and day care; equipment and adaptations;
mental health medications; telecare intervention; and caregiver), and then to health and social care and
societal totals. Costs at category level were calculated so that if > 2% of component costs in the category
were not available, the total of the category was considered missing. Total costs across categories were
considered missing if any category of cost was missing.
The CSRI data did not cover the entirety of the 2-year follow-up, as caregivers were always asked to
report service use over the previous 3 months. The costs of the intervening periods were estimated by
carrying forward cost categories of the previous period to the interval between the 24-week point and
the retrospectively recalled 3-month period ending at week 52, and then between week 52 and the
retrospectively recalled 3-month period ending at week 104. The carrying-forward process for the
9-month interval in year 2 created three additional intervals running up to the 3 months prior to
the 104-week assessment point. The one exception in the process of carrying forward costs was for
hospital admissions and emergency department visits: data drawn from SAE reporting were used to
estimate these costs. Therefore, the costs of routinely used services were assumed to be constant over
the intervening periods, but emergency department and hospital admissions reflected the observed use
in those periods. The costs were not carried forward to intervals when the person had been admitted
to care, died, was lost to follow-up or no longer wished to participate.
Intervention costs
Proposed methods of costing the ATT intervention are described in detail in Appendix 1. We planned to
describe the production of the full ATT package and to assess the feasibility of collecting data from
sites to calculate the costs of the ATT intervention. Data on the delivery system for ATT were collected
from local researchers via pro formas and from key informants via interviews with local authority
operational/middle managers in adult services, local authority commissioners of telecare and managers
in telecare provider organisations. Interviews in seven sites took place in 2016 (only sites with more
than five participants were approached). We had planned to request data on ATT equipment from
providers, but it proved difficult to draw up the necessary data-sharing agreements covering electronic
data extraction in every site. The scope and level of detail of information on total costs and unit costs
of ATT gathered to date varied considerably between sites, depending on the size of the local authority
and the complexity of the local ATT market. Information from this process was used to describe, in
some detail, the local actors involved in delivering ATT and the process of ATT production in each site.
Based on these descriptions, the production of ATT across all sites involves the following components:
assessment, procurement/purchasing, installation, call-handling (monitoring) and response. The data
collected were not consistent enough to enable calculation of the costs of ATT for use in the economic
evaluation. Instead, the costs of the ATT production process were built up from several sources; some
components will reflect costs at a more granular level of detail than others, as described in Valuing
assessment time and Valuing the assistive technology and telecare package.
Valuing assessment time
The time taken to carry out ATT assessments could vary substantially depending on the level of need
and the specific devices required. Feedback from pro formas and interviews yielded a range of
estimates of assessment time. The assumption based on information from interviews was that an ATT
assessment took 1 hour.
The personnel conducting assessments varied depending on the site and the nature of the ATT need.
Data from the ATT technology checklist were available: the checklist distinguishes between health and
social care assessors and specialist ATT assessors, but researchers were not always able to determine
an assessor’s qualifications. There was considerable variation in assessment personnel, depending on
the local area and the sector of the assessor’s employer (see Chapter 3). The assumption made in
costing assessor time was that health and social care assessors were non-specialist NHS professionals
paid at (NHS) Agenda for Change band 5 and that specialist ATT assessors were specialist community
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occupational therapists paid at (NHS) Agenda for Change band 6.43 Assessor costs (including on-costs,
overheads and capital costs; see Appendix 3) were calculated from the relevant costs per working hour
given in the Unit Costs of Health and Social Care 2017.43
When the assessor type was unknown, the proportions of health and social care assessors and
specialist ATT assessors (disregarding other/unknown assessor types) conducting assessments at
the needs assessment point (see Tables 3 and 4 and Appendix 3) were used to calculate a weighted
hourly rate. Only the pre-baseline ATT needs assessment was costed into the package, in line with
the protocol’s definition of the intervention. ATT device data were taken from the ATT checklist data.
All device types noted by the researchers at each time point were considered to be relevant costs.
Valuing the assistive technology and telecare package
Data to estimate ATT package costs were taken from several sources. Data from the NHC68 were
obtained to enable valuation of components of the ATT production process. The NHC offers
consortium procurement services to the UK public sector organisations that make up its membership.
Members include local authorities, not-for-profit providers, housing associations and industry partners.
Each consortium procurement framework remains in place for 4 years, recording contract prices paid
by members for any service or product covered by the framework to supply partners in relevant
industries. Two consortium frameworks that were relevant to ATT products and services were in
operation during the trial period. The Assisted Living framework, and the Technology Enabled Care
Services (TECS) framework that superseded it, covered telecare products and related installation and
services. The TECS framework covered a broader range of ATT devices than the Assisted Living
framework (not only telecare, but also telemedicine and telehealth). The TECS framework covered
services such as installation and maintenance of devices, call monitoring and mobile response. The
NHC supplied data from consortium framework databases on actual contract prices paid during
contracts that had expired by 2017. Data were available from Assisted Living framework contracts
in place in 2015 and from TECS contracts in place in 2016. The frameworks covered key elements of
ATT provision relevant to purchasers in local authorities and not-for-profit agencies. The activities
covered by the contracts corresponded well with three ATT production stages (as previously outlined):
installation, call-handling/monitoring and response. A per-person annual cost of the installation,
maintenance, call-monitoring and mobile response elements of ATT was calculated from contract prices
derived from NHC framework data (see Appendix 3).
Assistive technology and telecare devices
The Consortium provided information on 2016 device prices from the TECS framework suppliers’
catalogue. Prices for some categories of devices were available as mean and median prices across that
category, weighted (by volume) and including NHC discounts available to members. In other cases, only
the lowest and highest prices per item were available, and it was not possible to calculate a weighted
mean. In such cases, the lowest and highest costs were summarised by category and the mid-point of
the range between these was used. Device costs were annuitised over 5 years at a discount rate of
3.5%. Data on the types of ATT devices installed at each assessment point (see Chapter 3) were taken
from the ATT checklist; valuation of these devices was drawn from information obtained from the NHC
price data, as described in the preceding section.
Missing data
A sizeable number of participants and caregivers declined to complete at least one of the follow-up
assessments while continuing to participate in status checks. Missingness in the CSRI data available
from people who had participated in complete assessments was very low for most variables (typically
around 1%). Data on certain variables were missing at baseline because of subsequent version changes
in the ATT and CSRI measures. The first version of the CSRI (subsequently revised in September 2014)
did not include questions on caregivers’ time spent providing care (for this reason, 8% of baseline data
on this variable were missing) and thus missing for reasons unrelated to participants’ health status.
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Missing data reduction strategies were employed in certain cases. When ADL equipment/adaptations
provider data were missing (fewer than 10 instances), the provider was assumed to be the local
authority. For medication costs, if the dates of first use were missing, when there was information on
first use and ongoing use of particular medications, dosages, units and frequencies, these dates were
assigned to preceding and succeeding periods when the same medication, unit dosage and frequency
were reported, as long as the dates preceded the assessment date. As a further step, the average
duration over which medications were taken in contiguous periods from baseline to 24 weeks
(per medication, per participant) was calculated from available duration data and applied to missing
durations over these periods. The average duration of medications taken in these periods was 84 days,
and < 5% had durations of ≤ 36 days, indicating long-term use. For the remaining missing durations,
it was assumed that the medication had been taken over the whole of the prior period. For future
evaluations, the medication question could be improved by asking whether or not the participant had
been taking the medication for > 3 months, rather than asking the date of first use. No assumptions
could reasonably be made on caregiver time spent providing care when this was missing because of
version changes.
Compared with the expected number of responses (given the number of assessments administered),
approximately 10% of EQ-5D participant-reported index scores were missing at baseline. At 12 weeks,
13% of intervention participants’ and 20% of control participants’ responses were missing; at 24 weeks,
15% of intervention and 21% of control group participants’ responses were missing; at 52 weeks, 25%
intervention and 31% of control group participants’ responses were missing. At 104 weeks, 22% of
intervention and 34% of control group participants’ responses were missing. The proportion of missing
responses did not differ between groups at the 5% level on chi-squared tests at any time point. Of
expected responses (given the number of assessments administered), proxy-completed EQ-5D index
scores featured lower levels of missingness than seen in the participant-reported measure (baseline
missingness: 9% intervention, 12% control; missingness at 12 weeks: 10% intervention, 9% control;
missingness at 24 weeks: 8% intervention, 8% control; missingness at 52 weeks: 5% intervention,
9% control; and missingness at 104 weeks: 4% intervention, 7% control).
When EQ-5D index scores were missing, index score values were interpolated between adjacent time
points. Compared with the expected number of responses (given the number of assessments administered)
for the EQ-5D participant-reported index scores, after interpolation, at 12 weeks, 7% of the intervention
and 14% of control group participants’ responses were missing; at 24 weeks, 12% of the intervention and
15% of control group participants’ responses were missing; and at 52 weeks, 20% of intervention and
25% of control group participants’ responses were missing. Of expected responses (given the number of
assessments administered) for the proxy-completed EQ-5D index scores, after interpolation, at 12 weeks,
6% of intervention and 5% of control group participants’ responses were missing; at 24 weeks, 3% of the
intervention and 6% of control group participants’ responses were missing; and at 52 weeks, 4% of the
intervention and 7% of control group participants’ responses were missing.
Apart from these measures, missing costs and outcome data were not imputed. Data required for the
cost-effectiveness analyses were ‘missing’ for several reasons. When the trial end point of care home
admission was met, no further assessments were administered. Some participants died, there was loss
to trial follow-up and some dyads decided to cease participation in the trial completely. Some dyads
did not complete assessments (no measures were administered), although the dyad continued to
participate in the trial status checks; this could have been for several reasons, including disagreement
with allocation, burden of assessments and delays in assessments being completed. Missingness was
handled in different ways, depending on the analysis. The difference-in-difference analyses were
estimated by maximum likelihood (see Analyses). Cases were excluded from the analyses when the
dyad had participated in no assessments over the trial and when the baseline BADLS score was
missing (there were no missing data in other baseline covariates, which were stratifying variables used
in the randomisation procedure). The analyses of institutionalisation-free days and QALYs employed
models to explicitly manage data-censoring due to withdrawal, loss to follow-up and death.
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Analyses
Descriptive analyses were produced for service and other resource use items available at each time
point, presented in terms of the proportions of each treatment group using the service and the mean
use of the service in each group. Group means and standard errors (SEs) were calculated for categories
and totals of costs and for outcomes at each time point, as were mean differences and SEs of the
difference between groups.
For the outcome days in the community until admission to a care home, the number of days was
estimated in a survival analysis accelerated failure time model using the Weibull distribution, adjusting
for baseline BADLS score. A further step was involved in the QALY outcome: to quality-adjust the days
lived in the community, taking a population (or group-based) approach to produce a quality-adjusted
survival curve, using the EQ-5D index scores at each assessment point to estimate the average utility
per treatment group.69,70 Costs were partitioned and estimated in a generalised gamma accelerated
failure time model with a square root link; the probability of not being censored in each time interval
was estimated by accelerated failure time models (generalised gamma model at 104 weeks and a
Weibull model at 52 and 104 weeks, as the generalised gamma model did not converge), generating
inverse probability weights for costs at each interval.70–72 Cost regressions were adjusted for the
treatment allocation, BADLS score and stratifying variables. Cases without a baseline BADLS score
and cases for whom the dyad had never participated in assessments were excluded from the analyses.
Bias-corrected bootstrapped CIs of regression estimates of cost and outcome differences were
produced (25,000 resamples).
For the change in EQ-5D-5L index outcome, multilevel linear difference-in-difference models were
fitted to costs and EQ-5D index scores data. The models estimated the difference in the change in
scores from baseline to follow-up in the intervention group, less the difference in the change in scores
from baseline to follow-up in the control group (i.e. the difference between groups in the difference
between baseline and follow-up costs/outcomes in each group). Models were adjusted for stratifying
variables and the three-category BADLS variable for dependency (see Chapter 4). Multilevel mixed-
effects linear models were estimated by maximum likelihood, assuming that data were missing at
random on the response variable. In other words, missingness was assumed to be dependent on model
covariates or on previous or following responses, had they been observed, but not on the missing
responses.73,74 Cases at 52 and 104 weeks were considered available for analysis if baseline outcome/
cost data and at least two follow-up data points were available; at 24 weeks, cases were considered
available if baseline outcome/cost data and at least one follow-up data point were available. Bias-
corrected bootstrapped CIs of the model estimates of cost and outcome differences were obtained
(5000 resamples).
Cost-effectiveness analyses
Incremental cost-effectiveness ratios (ICERs) were calculated for each outcome. ICERs were calculated
separately for the difference in the EQ-5D outcome at the 24-, 52- and 104-week follow-ups, and for
QALY-adjusted institutionalisation-free days. The ICER was defined as the difference in mean costs
incurred by the intervention and control groups (ΔC), divided by the difference in mean outcome (ΔE)
between the treatment groups. The ATT intervention can be interpreted as representing value for
money if the ICER is below some threshold of WTP for a unit of additional effectiveness, λ:75
ΔC/ΔE< λ. (1)
A full package of ATT can be considered cost-effective if (1) the package is significantly more effective
and less expensive than a basic package of ATT or (2) ATT is significantly more effective and more
expensive, but the payer is willing to pay the additional cost (up to λ) to achieve the additional
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effectiveness or, possibly, (3) ATT is significantly less effective and less expensive, but the payer
considers the sacrifice of some effectiveness worth making because of the savings that could be
achieved. ATT can be considered, unambiguously, to be not cost-effective if it is both significantly less
effective and more expensive.
Incremental net monetary benefit75 can be expressed as a rearrangement of the decision rule in (1):
λ × ΔE –ΔE > 0. (2)
This is the monetary value of gains in outcomes associated with the treatment at a given WTP
threshold, net of (less) the additional cost of providing the treatment.76
Cost-effectiveness acceptability curves (CEACs) were produced when the intervention strategy was
more effective and costs were lower. Estimates of cost and outcome differences were obtained by
non-parametric bootstrapping of regression estimates, producing 25,000 replicates in the case of the
institutionalisation-free days and QALY outcomes and 5000 replicates in the case of the change in
EQ-5D index outcome. The proportion of replicates for which the net monetary benefit was positive
was graphed over a series of WTP values from £0 to £50,000 to produce CEACs. The current NICE
WTP threshold for the adoption of new technologies is between £20,000 and £30,000 per QALY.77
A sensitivity analysis explored the impact on societal costs of valuing time spent by caregivers in
providing care to the person with dementia at replacement cost (the hourly cost of a home care
worker) at 104 weeks.
Results
Sample numbers
The flow of dyads who completed assessments is given in Figure 10. As can be seen, some dyads declined
to participate in full assessments involving the completion of participant-/proxy-/caregiver-reported
measures, but agreed to remain in the study and provide more limited information on community
residence and SAEs or AEs (by telephone follow-up). There were 412 dyads who participated in the
baseline and at least one follow-up assessment. A small number (intervention, n = 11; control, n = 14) did
not participate in an assessment at any point and 45 (intervention, n = 19; control, n = 26) participated
only at baseline. A substantial proportion of the 12-week follow-up assessments were not conducted:
20% in the intervention group and 17% in the control group. The numbers of dyads contributing data
to the cost-effectiveness analyses varied depending on the measures and the analysis; valid numbers
of observations associated with each measure are presented with the results of the analyses (see
Cost-effectiveness analyses). Demographic characteristics of the sample participating in full assessments
at baseline are given in Appendix 4.
Use of care and support services
Baseline
The participant use of community health and social care services at baseline was very high (see
Appendix 4): 69% of intervention and 65% of control participants had seen a general practitioner (GP)
in the previous 3 months. Practice nurses were seen by 38% of participants in both groups. Thirteen
per cent of intervention and 17% of control group participants had used emergency department
services. In terms of inpatient stays, 10% of intervention and 16% of control group participants had
had a spell in hospital prior to baseline; the mean number of inpatient days among control group
participants was twice that among intervention group participants [2.39 days (SD 0.57 days) vs.
1.24 days (SD 0.35 days), respectively]. In terms of outpatient attendances, 43% of intervention and
41% of control group participants had had at least one outpatient attendance. Use of community
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• Not meeting inclusion criteria, n = 408
• Declined to participate, n = 298
• Other reasons, n = 210Randomised







• Delayed, n = 3
• Missed, no reason given, n = 3
• Missed, scheduling issues, n = 1
• Status check call only, n = 12
Baseline
• Delayed, n = 3
• Missed, no reason given, n = 2
• Missed, scheduling issues, n = 2
• Status check call only, n = 16
• Admitted to care, n = 9
• Died, n = 1
• No longer wished to participate, n = 3
• Lost to follow-up, n = 0
Not completed or delayed (n = 47)
• Delayed, n = 18
• Missed, no reason given, n = 7
• Missed, scheduling issues, n = 8
• Status check call only, n = 14
Week 12
Week 52
• Admitted to care, n = 7
• Died, n = 2
• No longer wished to participate, n = 2
• Lost to follow-up, n = 1
Not completed or delayed (n = 45)
• Delayed, n = 7
• Missed, no reason given, n = 7
• Missed, scheduling issues, n = 8
• Status check call only, n = 23
Week 24
• Admitted to care, n = 10
• Died, n = 3
• No longer wished to participate, n = 8
• Lost to follow-up, n = 1
Not completed or delayed (n = 38)
• Delayed, n = 5
• Missed, no reason given, n = 6
• Missed, scheduling issues, n = 8
• Status check call only, n = 19
• Admitted to care, n = 10
• Died, n = 8
• No longer wished to participate, n = 3
• Lost to follow-up, n = 3
Not completed or delayed (n = 33)
• Delayed, n = 7
• Missed, no reason given, n = 4
• Missed, scheduling issues, n = 6
• Status check call only, n = 16
• Admitted to care, n = 25
• Died, n = 6
• No longer wished to participate, n = 8
• Lost to follow-up, n = 2
Not completed or delayed (n = 32)
• Delayed, n = 2
• Missed, no reason given, n = 1
• Missed, scheduling issues, n = 12
• Status check call only, n = 17
• Admitted to care, n = 27
• Died, n = 9
• No longer wished to participate, n = 3
• Lost to follow-up, n = 0
Not completed or delayed (n = 23)
• Delayed, n = 0
• Missed, no reason given, n = 3
• Missed, scheduling issues, n = 3
• Status check call only, n = 17
Week 104
• Admitted to care, n = 34
• Died, n = 19
• No longer wished to participate, n = 1
• Lost to follow-up, n = 5
Not completed or delayed (n = 27)
• Delayed, n = 3
• Missed, no reason given, n = 1
• Missed, scheduling issues, n = 12
• Status check call only, n = 11
• Admitted to care, n = 28
• Died, n = 22
• No longer wished to participate, n = 3
• Lost to follow-up, n = 2
Not completed or delayed (n = 17)
• Delayed, n = 0
• Missed, no reason given, n = 0
• Missed, scheduling issues, n = 9
• Status check call only, n = 8
Completion
across study
to week 104No assessments conducted or delayed (n = 11)
Baseline not conducted or delayed (n = 19)
Follow-up not conducted or delayed (n = 6)
Baseline assessment completed only (n = 19)
Baseline assessment and any one other follow-up
completed (n = 212)
Baseline assessment and any two other follow-ups
completed (n = 182)
Baseline assessment and any three other follow-ups
completed (n = 137)
Baseline assessment and all other follow-ups completed (n = 77)
No assessments conducted or delayed (n = 14)
Baseline not conducted or delayed (n = 23)
Follow-up not conducted or delayed (n = 2)
Baseline assessment completed only (n = 26)
Baseline assessment and any one other follow-up
completed (n = 200)
Baseline assessment and any two other follow-ups
completed (n = 170)
Baseline assessment and any three other follow-ups
completed (n = 129)





Not completed or delayed
(n = 19)
Completed assessment
 (n = 224)


































Number participating in assessment at any time point
(n = 237)
Number participating in assessment at any time point
(n = 233)
FIGURE 10 The ATTILA trial flow of dyads. Delayed: researcher noted that the assessment had been delayed enough
that the date of the assessment was closer to that of the next scheduled assessment than to that of the previous
assessment or randomisation screening visit.
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rehabilitation professionals, particularly occupational therapists, was noticeably higher at baseline than
at the other time points. This suggests that some initial ATT assessment-related visits were being
reported as being community rehabilitation-related visits or that involvement in the trial in some other
way stimulated referrals to these services. One-third of participants had seen a social worker or care
manager over the previous 3 months and 40% of participants received home care (an average of 57
and 60 visits were received among intervention and control group participants, respectively). Day
centre use was reported by approximately one-sixth of participants. Almost all caregivers reported
providing care to participants over the previous 3 months. A mean of 564 hours of unpaid care was
provided to participants in the intervention group, and a mean of 661 hours of unpaid care was
provided to participants in the control group.
In terms of ATT devices (of any type, including those defined as ‘basic’, and rounding to whole
numbers), intervention participants had three ATT devices whereas control participants had two
ATT devices.
Follow-up time points
Over the follow-up assessments, the proportion reporting GP visits declined slightly, then increased
to around baseline levels at 104 weeks (71% and 65% for the intervention and control groups,
respectively). Practice nurses were seen by 30% of both groups at 104 weeks. About one-sixth of
participants used emergency department services across all follow-ups. The numbers of home care
visits and the total duration (in hours) of visits rose steadily in each group over the follow-up period.
At 104 weeks, 49% of intervention participants and 56% of control participants remaining in the
community received home care; these users received very substantial numbers of visits (98 and
110 visits in the intervention and control groups, respectively), indicating the receipt of multiple visits
per day. Few received any other community social services, such as meals on wheels. Day centres
were used by between one-quarter and one-fifth of participants at the 52- and 104-week follow-ups.
As at baseline, most caregivers reported providing care to participants over the previous 3 months. At
104 weeks, caregivers had provided 656 hours of care to intervention group participants, and 777 hours
of care to control group participants, over the previous 3 months. Control group participants had
received somewhat more care hours than intervention group participants at all follow-ups.
In terms of ATT devices of any type, intervention group participants had three ATT devices at 12 and
24 weeks and four devices at 52 and 104 weeks; control group participants had two devices at 12 and
24 weeks and three devices at 52 and 104 weeks.
Outcomes
The mean EQ-5D participant-reported index scores (Table 15) were higher than the proxy-reported
scores at all time points. The mean participant-reported baseline and week 12 scores were similar
between groups, but at 24, 52 and 104 weeks, the mean scores for the intervention group were
significantly lower than the scores for the control group (p < 0.05 in each case). The mean scores of the
proxy-reported measures did not differ between groups.
Costs of care and support services
Baseline
Baseline costs (unadjusted for covariates) over the previous 3 months (Table 16) were similar between
the groups except for hospital costs, which were significantly higher for the control group (–£518,
95% CI –£1025 to –£12; p = 0.045). The costs of ATT were £85 (SE £2) and £75 (SE £2) for the
intervention and control groups, respectively. Average health and social care costs (including the
intervention) were £2276 for the intervention group and £3400 for the control group. Societal costs
were more than double those of health and social care in both arms.
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Baseline Expected = 229 Expected = 224
EQ-5D –
participant
208 0.748 (0.016) 199 0.774 (0.016) –0.026 (–0.070 to 0.018) 0.2452
EQ-5D –
proxy
208 0.539 (0.015) 197 0.526 (0.018) 0.014 (–0.032 to 0.060) 0.5616
Week 12 Expected = 189 Expected = 188
EQ-5D –
participant
175 0.734 (0.019) 161 0.767 (0.017) –0.033 (–0.084 to 0.018) 0.2031
EQ-5D –
proxy
178 0.551 (0.017) 178 0.512 (0.019) 0.039 (–0.011 to 0.088) 0.1248
Week 24 Expected = 178 Expected = 168
EQ-5D –
participant
157 0.731 (0.02) 143 0.785 (0.019) –0.054 (–0.108 to 0.001) 0.055
EQ-5D –
proxy
172 0.512 (0.019) 158 0.517 (0.019) –0.006 (–0.059 to 0.048) 0.8371
Week 52 Expected = 150 Expected = 139
EQ-5D –
participant
120 0.709 (0.023) 104 0.787 (0.02) –0.079 (–0.139 to –0.018) 0.0112
EQ-5D –
proxy
144 0.482 (0.023) 129 0.48 (0.022) 0.001 (–0.062 to 0.065) 0.9643
Week 104 Expected = 96 Expected = 90
EQ-5D –
participant
75 0.73 (0.03) 59 0.818 (0.026) –0.088 (–0.169 to –0.008) 0.0321
EQ-5D –
proxy
92 0.462 (0.029) 84 0.429 (0.029) 0.032 (–0.048 to 0.113) 0.4305
TABLE 16 Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total
health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week














Baseline Expected = 229 Expected = 224
Hospital 229 619 (130) 223 1138 (225) –518* (–1025 to –12)
Primary and
community health
229 253 (18) 223 227 (18) 26 (–25 to 77)
Community mental
health
227 62 (7) 223 51 (7) 11 (–8 to 30)
Respite residential/
nursing
228 35 (19) 223 83 (40) –48 (–135 to 39)
Community care 224 1433 (299) 220 1813 (405) –380 (–1367 to 608)
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TABLE 16 Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total
health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week
















229 153 (36) 223 127 (23) 27 (–58 to 111)
Equipment and
adaptationsa
218 4 (1) 203 6 (1) –2 (–5 to 2)
Medications 226 23 (5) 222 23 (5) –1 (–14 to 12)
Unpaid careb 217 5928 (488) 202 6553 (473) –625 (–1965 to 715)
Equipment and
adaptations – selfc
218 2 (1) 203 2 (1) 0 (–3 to 3)
Out of pocketd 219 8 (2) 202 4 (1) 3 (–0 to 7)
Health and social care 210 2231 (228) 201 3281 (521) –1050 (–2152 to 52)
Intervention 223 85 (2) 203 75 (2) 11*** (5 to 16)
Intervention + health
and social care
205 2276 (228) 189 3400 (550) –1124 (–2262 to 14)
Societale 208 8162 (540) 200 9836 (680) –1674 (–3374 to 26)
Intervention + societale 203 8262 (546) 188 9963 (715) –1701 (–3454 to 52)
Week 12 Expected = 189 Expected = 188
Hospital 189 467 (121) 186 623 (148) –156 (–532 to 220)
Primary and
community health
188 223 (21) 185 231 (23) –8 (–70 to 54)
Community mental
health
186 36 (8) 186 38 (8) –1 (–24 to 21)
Respite residential/
nursing
188 45 (26) 185 82 (31) –38 (–117 to 41)
Community care 188 1857 (377) 185 2060 (508) –203 (–1445 to 1038)
Day care 189 229 (45) 186 185 (39) 44 (–72 to 160)
Equipment and
adaptationsa
186 4 (1) 184 5 (2) –1 (–6 to 3)
Medications 189 34 (9) 186 26 (5) 8 (–12 to 28)
Unpaid careb 186 6214 (470) 183 6928 (547) –714 (–2129 to 702)
Equipment and
adaptations – selfc
186 2 (1) 184 4 (2) –2 (–6 to 2)
Out of pocketd 188 7 (2) 184 6 (2) 1 (–5 to 7)
Health and social care 182 2930 (416) 181 2986 (457) –57 (–1271 to 1158)
Intervention 188 61 (3) 166 39 (3) 21*** (13 to 29)
Intervention + health
and social care
181 2978 (418) 161 3005 (501) –27 (–1301 to 1247)
Societale 182 9202 (620) 180 10,010 (679) –807 (–2616 to 1001)
Intervention + societale 181 9283 (624) 160 10,017 (734) –734 (–2616 to 1148)
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TABLE 16 Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total
health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week














Week 24 Expected = 178 Expected = 168
Hospital 177 296 (73) 168 848 (274) –552* (–1098 to -7)
Primary and
community health
177 193 (20) 168 215 (31) –22 (–94 to 50)
Community mental
health
177 21 (4) 168 25 (5) –4 (–16 to 9)
Respite residential/
nursing
175 35 (21) 166 37 (26) –2 (–67 to 64)
Community care 176 2475 (537) 165 2005 (439) 469 (–906 to 1844)
Day care 177 230 (48) 167 181 (36) 49 (–70 to 168)
Equipment and
adaptationsa
176 7 (2) 168 5 (2) 1 (–4 to 7)
Medications 177 26 (5) 168 22 (5) 3 (–10 to 17)
Unpaid careb 175 6843 (575) 168 7352 (592) –510 (–2133 to 1113)
Equipment and
adaptations – selfc
176 3 (2) 168 1 (1) 2 (–1 to 6)
Out of pocketd 177 6 (2) 168 7 (3) –2 (–8 to 5)
Health and social care 173 3298 (560) 162 3289 (531) 9 (–1513 to 1532)
Intervention 176 55 (3) 157 43 (3) 13** (5 to 20)
Intervention + health
and social care
171 3382 (566) 151 3358 (554) 24 (–1542 to 1591)
Societale 172 9954 (769) 162 10637 (766) –683 (–2820 to 1454)
Intervention + societale 170 10,032 (778) 151 10,567 (797) –535 (–2731 to 1660)
Week 52 Expected = 150 Expected = 139
Hospital 148 470 (149) 137 786 (177) –316 (–769 to 137)
Primary and
community health
148 195 (18) 137 266 (32) –71 (–143 to 0)
Community mental
health
148 28 (18) 137 17 (5) 10 (–28 to 48)
Respite residential/
nursing
148 60 (37) 137 94 (45) –34 (–148 to 80)
Community care 148 3377 (747) 137 2206 (462) 1171 (–590 to 2933)
Day care 148 361 (72) 137 212 (44) 149 (–21 to 318)
Equipment and
adaptationsa
148 8 (2) 137 5 (2) 3 (–3 to 9)
Medications 147 25 (5) 137 22 (6) 2 (–13 to 17)
Unpaid careb 147 6851 (560) 136 9002 (793) –2151* (–4040 to –262)
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TABLE 16 Mean costs (SEs): health and social care services for participant, caregiver costs, out-of-pocket costs, total
health and social care and societal costs over the previous 3 months, at baseline and at the 12-, 24-, 52- and 104-week
















148 6 (2) 137 3 (2) 3 (–3 to 9)
Out of pocketd 147 6 (2) 136 7 (3) –2 (–8 to 5)
Health and social care 147 4510 (777) 137 3608 (523) 901 (–970 to 2773)
Intervention 146 64 (3) 129 50 (3) 15*** (6 to 23)
Intervention + health
and social care
143 4613 (797) 129 3615 (548) 998 (–947 to 2942)
Societale 146 11,442 (927) 136 12,629 (972) –1187 (–3830 to 1457)
Intervention + societale 143 11,492 (947) 128 12,526 (1010) –1033 (–3757 to 1690)
Week 104 Expected = 96 Expected = 90
Hospital 93 430 (186) 89 767 (202) –337 (–877 to 203)
Primary and
community health
93 227 (26) 89 283 (44) –56 (–155 to 43)
Community mental
health
93 4 (2) 89 10 (3) –6 (–14 to 2)
Respite residential/
nursing
93 3 (3) 89 69 (33) –66* (–130 to –3)
Community care 93 4537 (1264) 87 3062 (754) 1475 (–1478 to 4427)
Day care 93 365 (98) 89 285 (70) 80 (–159 to 319)
Equipment and
adaptationsa
93 9 (3) 89 3 (1) 7* (0 to 13)
Medications 93 21 (6) 89 18 (5) 4 (–11 to 19)
Unpaid careb 93 7308 (781) 89 7672 (753) –364 (–2508 to 1779)
Equipment and
adaptations – selfc
93 3 (2) 89 2 (1) 1 (–4 to 6)
Out of pocketd 93 6 (3) 89 9 (4) –3 (–12 to 6)
Health and social care 93 5693 (1300) 87 4599 (811) 1094 (–1978 to 4166)
Intervention 93 63 (4) 87 51 (4) 12* (2 to 23)
Intervention + health
and social care
92 5808 (1314) 84 4728 (838) 1080 (–2060 to 4220)
Societale 93 12,961 (1599) 87 12,347 (1013) 614 (–3178 to 4406)
Intervention + societale 92 13,117 (1614) 84 12,535 (1045) 582 (–3291 to 4455)
*p < 0.05, **p < 0.01, ***p < 0.001.
a Funded by the NHS or Personal Social Services.
b Unpaid caregivers’ time in care and support to participant.
c Expenditure by self or family on equipment purchases.
d Expenditure by self or family on travel to appointments.
e Societal costs: participant’s health and social care costs; unpaid caregivers’ time in care and support to participant;
and expenditure by self or family on travel to appointments, equipment purchases.
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Follow-up time points
The 3-month hospital costs were higher in the control group than in the intervention group at the
24-week follow-up (–£552, 95% CI –£1098 to –£7; p = 0.047). Average health and social care costs
(including the intervention) were similar to those prior to baseline at the first two follow-ups. Costs
in the intervention sample remaining in the community were 36% higher at 52 weeks than at the
24-week point and 72% higher at 104 weeks than at the 24-week point; costs of controls were
8% higher at 52 weeks than at the 24-week point and 41% higher at 104 weeks than at 24 weeks.
The 3-month costs of unpaid care were higher in the control group than in the intervention group at
52 weeks (–£2151, 95% CI –£4040 to –£262; p = 0.026). Societal costs at 12 weeks were approximately
13% higher than baseline in the intervention group, but had changed little in the control group. Societal
costs at 52 weeks were 15% higher than at 24 weeks in the intervention group, and 18% higher than at
24 weeks in the control group. At 104 weeks, the societal costs of intervention group participants were
14% higher than at 52 weeks, whereas the societal costs of control group participants were similar to
those at 52 weeks.
The costs of ATT devices varied little among the groups over the follow-ups. Unsurprisingly, the
3-month costs of the full ATT package were significantly higher than those of the basic package at
each time point; however, the additional cost was low in absolute terms (ranging between £11 at
baseline and £21 at week 12).
Estimated costs for intervals not covered by the CSRI are given in Appendix 5. The raw mean
cumulative costs (see Appendix 6) of ATT over the 2-year follow-up were estimated to be £322
(SE £18) in the intervention group and £214 (SE £16) in the control group. The raw mean cumulative
costs of ATT over the baseline and follow-up period were estimated at £408 (SE £18) in the intervention
group and £288 (SE £16) in the control group (a difference of £119, 95% CI £71 to £168; p = 0.000).
Cumulative costs were estimated at £19,649 (SE £3206) and £15,186 (SE £2102) in the intervention and
control groups, respectively.
Cost-effectiveness analyses
Model results: outcomes and costs
Institutionalisation-free days
The regression estimate of the between-group difference in days lived in the community to 104 weeks was
7.9 days (95% CI –26.2 to 42.2 days) (Table 17). Adjusted mean days in the intervention group were 597
and 589 in the control group (approximately 85 weeks and 84 weeks, respectively). Total health and social
TABLE 17 Institutionalisation-free days and costs at 104 weeks (450 participants)































a Bias-corrected bootstrapped 95% CIs, bootstrapped estimates (25,000 replications). Difference in QALY rounded to
the third decimal place.
Note
Costs are in 2016–17 Great British pounds.
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care costs over 104 weeks were £909 lower in the intervention group, but with very wide CIs that crossed
zero (95% CI –£5336 to £3345), indicating that the costs did not differ between the intervention and
control groups. Adjusted mean health and social care costs per participant over 2 years were £20,616




Difference-in-difference coefficients and bootstrapped CIs are presented in Table 18. Model estimates
of group means, within-group differences from baseline to follow-up and model-based SEs are presented
in Table 17 and in Appendix 7, Tables 30–35.
TABLE 18 Difference-in-difference estimates: differences in between-group differences on participant and proxy-rated
EQ-5D scores and 3-month costs. Sample: available cases
Time point Difference 95% CIa ICERb (difference in costs/MCID)
24 weeks
Participant reported (n= 287)
EQ-5Dc score –0.011 –0.052 to 0.028 367/–0.148 = –2475
Health and social cared costs (£) 367 –850 to 1474
Participant reported (n= 284)
EQ-5Dc score –0.015 –0.056 to 0.024 251/–0.204 = –1231
Societald costs (£) 251 –1164 to 2005
Proxy reported (n= 309)
EQ-5Dc score 0.034 –0.007 to 0.074 313/0.463 = 677
Health and social cared costs (£) 313 –949 to 1313
Proxy reported (n= 308)
EQ-5Dc score 0.033 –0.008 to 0.073 110/0.448 = 246
Societald costs (£) 110 –1569 to 1630
52 weeks
Participant reported (n= 229)
EQ-5Dc score –0.056 –0.617 to 0.5 534/–0.004 = –9595
Health and social cared costs (£) 534 –748 to 2082
Participant reported (n= 227)
EQ-5Dc score –0.105 –0.675 to 0.441 116/–0.008 = –1103
Societald costs (£) 116 –1765 to 2185
Proxy reported (n= 257)
EQ-5Dc score 0.027 –0.015 to 0.068 442/0.360 = 1226
Health and social cared costs (£) 442 –926 to 1502
Proxy reported (n= 257)
EQ-5Dc score 0.027 –0.015 to 0.068 –220/0.360 = –611
Societald costs (£) –220 –2175 to 1443
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
50
At the 24-week follow-up, the between-group difference in change from baseline EQ-5D scores was
positive in both groups, but the change was larger in the control group than in the intervention group.
At the 52-week follow-up, the between-group difference in change from baseline to follow-up EQ-5D
scores was negative because, although changes were negative in both groups, the change was larger
in the intervention than in the control group. At the 104-week follow-up, the between-group difference in
change from baseline to follow-up EQ-5D scores was negative because the change was negative in the
intervention group and positive in the control group. However, at each time point, the bootstrapped CIs of
the difference-in-difference coefficient crossed zero, indicating no significant difference in between-group
change in outcome. The difference between groups in the change in 3-month costs from baseline to
follow-up was positive at each of these time points, but bootstrapped CIs of the difference-in-difference
coefficient again crossed zero. Health and social care costs and societal 3-month costs were
(non-significantly) higher in the intervention group than in the control group.
Proxy reported
At the 24-, 52- and 104-week follow-ups, the between-group difference in change from baseline scores
(see Table 18) was positive, but CIs of the difference crossed zero, indicating no difference between groups
in this outcome. At all time points, proxy-rated EQ-5D scores were lower than participant-rated scores.
The difference in average follow-up health and social care 3-month costs from baseline were
(non-significantly) higher in the intervention group than in the control group. The difference in
average follow-up societal 3-month costs from baseline were slightly (non-significantly) lower in
the intervention group than in the control group (reflecting the larger size of the sample with
proxy-reported outcomes available than on the participant-reported measure).
TABLE 18 Difference-in-difference estimates: differences in between-group differences on participant and proxy-rated
EQ-5D scores and 3-month costs. Sample: available cases (continued )
Time point Difference 95% CIa ICERb (difference in costs/MCID)
104 weeks
Participant reported (n = 243)
EQ-5Dc score –0.016 –0.056 to 0.021 698/–0.217 = –3221
Health and social cared costs (£) 698 –919 to 2309
Participant reported (n = 243)
EQ-5Dc score –0.019 –0.06 to 0.017 153/–0.262 = –584
Societald costs (£) 153 –1969 to 2248
Proxy reported (n= 266)
EQ-5Dc score 0.021 –0.022 to 0.06 478/0.281 = 1699
Health and social cared costs (£) 478 –938 to 1946
Proxy reported (n= 266)
EQ-5Dc score 0.021 –0.022 to 0.06 –32/0.281 = –113
Societald costs (£) –32 –1956 to 1908
MCID, minimal clinically important difference.
a Bias-corrected bootstrapped 95% CIs, bootstrapped estimates (5000 replications). EQ-5D scaled by MCID rounded
to three decimal points.
b Cost per gain of 0.074 in EQ-5D.78,79
c Estimates from outcome equation: covariates are allocation to ATT, BADLS categories and stratifiers.
d Estimates from costs equation: covariates are allocation to ATT, BADLS categories and stratifiers.
Note
Available cases at 24 weeks = cost and outcome data available from baseline and at least one follow-up point; available
cases at 52 and 104 weeks = cost and outcome data available from baseline and at least two follow-up points.
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Quality-adjusted life-years
Results are given in Tables 19 and 20.
Derived from the participant-rated EuroQol-5 Dimensions
At 24 weeks, in terms of QALYs derived from the participant-rated EQ-5D, the intervention group had
0.016 fewer QALYs than the control group; the CIs of the difference crossed zero, indicating that the
groups did not differ on this outcome. At 52 weeks, in terms of QALYs derived from the participant-rated
EQ-5D, the intervention group had 0.044 fewer QALYs than the control group; the CIs did not cross
zero, although the upper confidence limit was very close to it (p = 0.0498). At 104 weeks, in terms of
QALYs derived from the participant-rated EQ-5D, the intervention group had 0.105 fewer QALYs than
the control group, and the CIs did not cross zero. Thus, at 52 and 104 weeks, the intervention group
participants had a worse outcome on this measure than the control group participants.
Derived from the proxy-rated EuroQol-5 Dimensions
There were small gains in QALYs in the intervention group at 24, 52 and 104 weeks (of 0.01, 0.016
and 0.03, respectively), but the CIs of the differences crossed zero in each case, indicating that the
groups did not differ on this outcome.
TABLE 19 Quality-adjusted life-years and costs at 24, 52 and 104 weeks (450 participants)
Time point
Trial arm, mean (95% CIa)
Intervention – control,
mean difference (95% CIa)Intervention Control
24 weeks
Costs (£)
Health and social care 4455 (3428 to 5883) 4964 (3672 to 6975) –509 (–1883 to 579)
Societal 14,109 (12,251 to 15,738) 15,368 (13,083 to 18,233) –1258 (–4680 to 1461)
QALY (EQ-5D-5L)
Participant reported 0.334 (0.319 to 0.348) 0.350 (0.336 to 0.364) –0.016 (–0.036 to 0.003)
Proxy reported 0.245 (0.231 to 0.258) 0.234 (0.220 to 0.248) 0.010 (–0.009 to 0.029)
52 weeks
Costs (£)
Health and social care 9363 (7296 to 11,999) 10,122 (7843 to 13,332) –759 (–3109 to 1430)
Societal 28,180 (24,733 to 31,839) 29,293 (25,648 to 33,414) –1114 (–6186 to 3701)
QALY (EQ-5D-5L)
Participant reported 0.680 (0.646 to 0.712) 0.724 (0.692 to 0.754) –0.044 (–0.088 to –0.000)
Proxy reported 0.485 (0.453 to 0.516) 0.470 (0.439 to 0.499) 0.016 (–0.026 to 0.057)
104 weeks
Costs (£)
Health and social care 20,524 (16,109 to 26,413) 21,602 (17,234 to 28,395) –1078 (–5648 to 3062)
Societal 56,745 (50,085 to 64,530) 60,399 (52,804 to 69,823) –3654 (–13,884 to 6316)
QALY (EQ-5D-5L)
Participant reported 1.201 (1.127 to 1.271) 1.306 (1.234 to 1.376) –0.105 (–0.204 to –0.007)
Proxy reported 0.828 (0.762 to 0.894) 0.798 (0.733 to 0.861) 0.030 (–0.058 to 0.117)
a Bias-corrected bootstrapped 95% CIs, bootstrapped estimates (25,000 replications).
Note
Costs are in 2016–17 Great British pounds.
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Incremental cost-effectiveness ratios and probability of cost-effectiveness
Institutionalisation-free days
At 104 weeks, the cost per institutionalisation-free day from either health and social care or societal
perspectives was negative (see Table 17) because the point estimate for cost difference (from either
perspective) was negative and the point estimate for institutionalisation was positive. The CEAC
indicates that there is no WTP value in the range of WTP values of between £0 and £50,000 at
which we could be certain that either the basic or full ATT package was better value for money (see
Appendix 7, Figure 13), as the probability of cost-effectiveness did not exceed 72% (health and social
care) and 80% (societal perspective) over that range.
Proxy-reported EuroQol-5 Dimensions
At the 24-week point, on the proxy-reported EQ-5D (see Table 18), the ICERs for health and social
care costs and societal costs were positive because the estimates of both costs and outcomes
differences were positive. The CEAC (see Appendix 7, Figure 14) indicates that the probability of
cost-effectiveness on achieving a minimal clinically important difference from either perspective is
approximately 90% at a WTP of £5200 and just under 95% across WTP values of between £25,700
and £50,000. We cannot, however, be confident from either perspective at the 95% level that the full
ATT package strategy is more cost-effective than the basic ATT package over the range.80 At the later
time points, the ICERs from the health and social care perspective were positive (small positive
differences in outcomes and costs), and from the societal perspective they were negative (small
positive differences in outcomes and small negative differences in costs). At 52 weeks, the probability
of cost-effectiveness (see Appendix 7, Figure 15) did not exceed 90% from either perspective over a
range of WTP of between £15,000 and £50,000; at 104 weeks, the probability of cost-effectiveness
did not exceed 84% from either perspective over this range (see Appendix 7, Figure 16). As with the
24-week results, we cannot be confident from either perspective at the 95% level that the full ATT
package strategy is more cost-effective than the basic ATT package over this range. The probability of
cost-effectiveness at WTP values of £20,000 was highest in the short term (24 weeks) and lowest in
the long term (104 weeks), from both perspectives.
TABLE 20 Incremental cost-effectiveness ratio: 24-, 52- and 104-week QALYs (EQ-5D)
Time point and costs






Health and social care –509/–0.016 = 31,561 –509/0.010 = –49,656
Societal –1258/–0.016 = 77,994 –1258/0.010 = –122,711
52 weeks
Health and social care –759/–0.044 = 17,279 –759/0.016 = –48,861
Societal –1114/–0.044 = 25,339 –1114/0.016 = –71,654
104 weeks
Health and social care –1078/–0.105 = 10,237 –1078/0.030 = –35,432
Societal –3654/–0.105 = 34,706 –3654/0.030 = –120,125
a Cost of achieving a QALY gain over the follow-up period; difference in QALY is rounded to the third decimal place.
Note
Point ICER for intervention over control, from health and social care and societal perspectives (n= 450).
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Participant-reported EuroQol-5 Dimensions
In the case of ICERs produced for participant-reported EQ-5D (see Table 18) the outcome was (non-
significantly) worse in the intervention group and costs were (non-significantly) higher or lower in the
intervention group, depending on perspective and time horizon. The CEACs have not been presented
for this reason.
Quality-adjusted life-years
Derived from the proxy-rated EuroQol-5 Dimensions
At the 24-, 52- and 104-week time points, in terms of the QALYs generated from the proxy-reported
EQ-5D (see Table 19), the ICERs for health and social care costs and societal costs were negative
because of negative cost difference estimates and positive QALY difference estimates. The CEAC (see
Appendix 7, Figure 17) indicates that the probability of cost-effectiveness was highest at the 24-week
point from the health and social care perspective, but this did not exceed 90% across a range of WTP
values of £0–50,000. Curves for the later time points were lower than those at 24 weeks, with the
104-week probabilities being the lowest (not exceeding 82%, from the societal perspective, over the
£0–50,000 range).
Derived from the participant-rated EuroQol-5 Dimensions
The ICERs for QALYs based on the participant-reported EQ-5D were positive, but this was because the
costs were slightly lower and the outcomes somewhat worse in the intervention group than in the
control group. The CEAC is not presented for this reason.
Sensitivity analysis: replacement cost of unpaid care
The impact on societal costs and the ICER of valuing unpaid care at replacement cost at 104 weeks
was explored in a sensitivity analysis. The costs of unpaid care and societal and intervention costs
using replacement costs are presented in Appendix 7, Table 36. Cost-effectiveness analysis results are
presented in Appendix 7, Tables 37–39.
Institutionalisation-free days
Valuation of caregiver time at replacement cost resulted in a smaller difference between groups in
total societal costs over 104 weeks, but, as with the main results, the 95% CIs of the difference
crossed zero. The ICER remained negative, in line with the main results.
EuroQol-5 Dimensions
Valuation of caregiver time at replacement cost yielded larger estimates of the difference-in-difference
between groups in societal costs. For the participant-reported EQ-5D, this yielded a larger negative
ICER (because the difference-in-difference in cost was non-significantly positive and the outcome was
non-significantly worse in the intervention group than in the control group); for the proxy-completed
EQ-5D, this also yielded a larger negative ICER (because the difference-in-difference in cost was
non-significantly negative and because the outcome was non-significantly better in the intervention
group than in the control group). The results were in line with the main results valuing caregiver time
at opportunity cost.
Quality-adjusted life-years
As with the main results, the ICER for QALYs based on the participant-reported EQ-5D remained
positive (with non-significantly lower total costs and with fewer QALYs for the intervention group
than the control group), but was lower (approximately half). The ICER for QALYs based on the
proxy-reported EQ-5D remained negative (with non-significantly lower total costs and with
non-significantly more QALYs for the intervention group than the control group) and was lower
(approximately half).
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Discussion
The additional 3-month cost of a full ATT package over a basic package at each time point was modest
(ranging from £11 at baseline to £21 at week 12). Although the cumulative cost estimated for the full
package was significantly greater than that of the basic package (an additional £119), the average costs
of ATT were modest in both the intervention and control groups (£408 and £288, respectively). Mean
(unadjusted) societal costs were in the order of three times that of health and social care costs. Total
health and social care and societal costs over 104 weeks, taking censoring into account, did not differ
between groups. Average 3-month costs estimated in difference-in-difference analyses did not differ
between groups at 24, 52 or 104 weeks. Change in proxy-rated and participant-rated EQ-5D index
scores estimated in difference-in-difference analyses also did not differ between groups at those time
points. For the institutionalisation-free days outcome, there was no statistical difference between the
intervention and control groups in days spent in the community. Groups did not differ on proxy-
reported QALYs. The mean participant-reported QALY was lower in the intervention group than in the
control group at the 52- and 104-week time points. The probability of cost-effectiveness on a measure
of change in proxy-rated health-related quality of life was greater in the short term than in the long
term from the health and social care and societal perspectives, at a WTP of £20,000. A similar pattern
was seen in proxy-rated QALYs from the health and social care perspective, but the probability of
cost-effectiveness was higher in the long term from the societal perspective.
Some limitations must be acknowledged. Costs were measured by asking caregivers to retrospectively
report service use, so the results could be subject to recall bias. The costs accrued during the intervals
between periods with CSRI data available were estimated by carrying forward most costs, although the
costs of inpatient and emergency department use were estimated from the SAE data available over
these times. Costs of regularly used services were thus assumed to be constant over these intervening
periods. Participant-reported EQ-5D data were missing for one-quarter of intervention group
participants and for one-third of control group participants who had participated in assessments at
104 weeks. Although difference-in-difference analyses controlled for baseline covariates (stratification
variables and dependency, as measured by the BADLS) that might have accounted for differences in
data availability between groups on this measure, QALY analyses drew on group mean utilities at each
time point and did not adjust for baseline characteristics. Therefore, the finding that the intervention
group had fewer QALYs derived from participant-reported EQ-5D must be interpreted with some
caution as substantial rates of missingness in that measure could be a concern. Generalisability of
these findings may also be limited because all assessment data were missing from some participating
dyads at the baseline and follow-up points (8% of the sample at baseline and between 16% and 19% of
the community-dwelling sample still participating in the study over the follow-ups did not participate in
an interview).
The study sample size was powered to detect a delay to entry to permanent care home residence of
55 days over 24 months. As can be seen from the measures of uncertainty around all point estimates
of cost differences, there was substantial variability in the cost data (as might be expected). It is
possible that, because the variance around the mean difference in costs was of a greater magnitude
than the variance around the survival outcome, a larger sample size would have been required to
detect a between-group difference in costs than in days.
The mean EQ-5D proxy-rated index scores were consistently lower than index scores derived from the
participant-rated version of the measure. This pattern is in line with that reported in other studies
involving people with dementia and caregiver proxy raters.81 The EQ-5D has been reported to be more
reliable than some dementia-specific quality-of-life measures in terms of agreement between caregiver
proxy-rated and self-rated total scores, in a population with mild and moderate dementia participating
in a psychosocial intervention.82 The divergence we observed between proxy and participant raters’
EQ-5D and QALY outcomes may relate to selection effects, validity of the instrument when used
for people with more advanced dementia and genuine differences in perspectives between raters.81
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The participant–proxy inter-rater reliability of the EQ-5D index scores from this study merits further
investigation, as does the response rate of participants at different stages of dementia.
Conclusions
The results suggest that the health and social care and societal costs of a full package of ATT were
not greater than those of a basic package of ATT for people with dementia. There was little evidence
that the intervention influenced the length of time lived in the community over 104 weeks, improved
health-related quality of life as rated by participants and proxies or increased participants’ QALYs
based on quality of life as rated by proxies. The results suggest that the intervention reduced
participants’ QALYs based on quality of life rated by people with dementia themselves. Generalisability
of findings based on the dyad-reported outcomes data is limited by the extent of missing data at the
individual outcome measure and at the assessment level.
ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
56
Chapter 6 Impact of assistive technology
for people with dementia on burden and
psychological well-being in unpaid caregivers
People living with dementia increasingly depend on informal caregivers who assist with ADL,ensure safety, manage challenging behaviours and provide company to the cared-for person.
The majority of caregivers for people with dementia are family members, and approximately 60–70%
of them are women.83 It is estimated that 11% of all caregivers in the UK provide care to someone
with dementia in a home setting.84 As caregivers are frequently middle-aged or older children of the
person with dementia, many may be in part- or full-time employment, which results in difficulties in
balancing work and care commitments that are likely to diminish their ability to provide care.85
Moreover, a large number of people providing unpaid care have a long-standing illness or
disability themselves.86
These caregivers are normally untrained to deliver care and the performance of the caring role is a
potential source of substantial psychosocial stress. There is some evidence showing that this stress is
manifested in some measures of immunity and may also affect cognition.87 Caregivers report worsening
of their mental health and physical health due to their caring role.88 Importantly, caregivers of people
with dementia show higher levels of anxiety and depression than caregivers of other conditions.89,90
Caring for a person with dementia has been found to adversely affect a caregiver’s financial resources
through early retirement, reduced paid working hours or reliance on benefits.91,92 The physical health
of these caregivers is also adversely affected.93–95
As this care is provided informally and is generally unfunded, the savings to the public purse are
extensive. The annual cost of unpaid care in the UK has been estimated to be £11.6B.96 One study
estimated that the total societal worldwide costs of unpaid care for dementia at US$329B per year.97
This is a rough estimate and assumes informal care time of 3.7 hours per day. It is cheaper to care for
people with mild dementia at home (£26,000 per annum) than in residential care (£31,000 per year).96
‘Carer burden’ refers to ‘the degree to which a carer’s emotional or physical health, social life or
financial status had suffered as a result of caring for their relative’;98 it is often used to describe the impact
of providing unpaid care. Both patient and caregiver characteristics have been found to contribute to
caregiver burden, for example the type of dementia, the extent of personality change, cognitive changes
and the presence of behavioural and psychiatric symptoms due to the dementia. Importantly, a systematic
review99 confirmed that a person with dementia’s functional status, prevalence of behavioural disturbances
and level of neuropsychiatric symptoms, such as wandering and delusions, were found to be the most
burdensome characteristics for caregivers. Factors that influence the impact of caregivers include gender;
age; cultural values; the nature of the relationship with the person with dementia; the amount of unpaid
and paid care available; the caregiver’s physical and mental status, personality and coping strategies; and
the duties of caregiving.99
Nonetheless, it should be acknowledged that providing unpaid care may also benefit these caregivers.
For example, there are some reports of caregivers gaining satisfaction by performing the caregiver
role and developing a close relationship with the recipient.100–102 To this end, interventions to support
caregivers that aim to minimise the negative impacts and enhance the benefits of the caregiving
relationship, both for the cared-for person and the caregiver, have been developed.
A number of psychosocial interventions are specifically directed to caregivers of people with dementia.
The bulk of these involve face-to-face delivery. Some other interventions involve telephone delivery.103
An early systematic review of 40 studies found that the content of these interventions varied a lot.104
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Approximately two-thirds of the interventions did not result in improvements in any outcome measure,
but, of those that were successful, the inclusion of a social component, with or without a cognitive
component, proved to be important. The small numbers in the studies as well as a number of
methodological issues were noted as limitations of the review.104 It has been reported that, in the
30 years up to 2015, > 200 interventions for caregivers have been tested in randomised trials and
found to have some efficacy on caregivers’ outcomes.105
Some of these have used information and communications technology (ICT) to facilitate collecting, capturing,
storing, processing, transmitting, exchanging and presenting information and/or communication.106,107
A 2019 systematic review108 examined the impact of ICT interventions on dementia caregivers’
outcomes. Of the six studies that used telephone interventions, three resulted in significant effects on
a range of caregiver outcomes, including reducing caregivers’ depressive symptoms. Three of the four
studies evaluating video interventions had an effect on a range of caregiver outcomes, as did the two
computer-based interventions. The authors108 conclude that interventions that use the telephone show
the most evidence to support their use. Similarly to interventions directed at the person with dementia,
interventions for caregivers can be delivered to the individual, in a group setting, online or to the
caregiver–cared-for person dyad. However, the evidence is as yet unclear about which is the most
effective delivery method for caregiver outcomes.
An alternative to interventions that are specifically directed to caregivers are interventions that aim
to remotely monitor and manage the care recipient. Commonly termed telecare, these interventions
involve installing ATT devices to remotely monitor the care recipient. The devices are generally
employed to continuously, automatically and remotely monitor for real-time emergencies and lifestyle
changes to manage risks of living at home. Although directed at the care recipient, these may also
affect caregiver outcomes by improving sleep and reducing worry and stress by preventing serious
incidents such as falls, cooking accidents, or wandering. A systematic review109 explored the evidence
for the use of these devices on caregiver well-being across several types of care recipient and identified
seven studies, all of which were rated as having weak methodological quality. The most common types of
equipment were passive sensors such as bed and door sensors, and sensors to monitor home emergencies
such as flood and gas alarms. However, a tentative conclusion was that the evidence indicated that
telecare exerts a positive effect on caregiver stress and strain. Only one study evaluated the impact of
telecare on quality of life110 and one study investigated caregiver burden;111 neither study found evidence
for a positive impact of their interventions. Two112,113 of the seven studies in the systematic review109
examined caregivers of people with dementia. Holthe112 reported on 25 caregivers of people with
dementia, of whom slightly more than 50% lived with a person being cared for; Woolham113 reported
on 123 caregivers. Although limitations of the studies’ methodologies were identified, they reported a
positive impact on caregiver stress, suggesting a potential benefit of telecare for caregivers as well as
care recipients that is deserving of further investigation.
Aims
We aimed to assess and compare the use of ATT with usual care for people with dementia on caregiver
psychosocial and health outcomes, namely caregiver burden, depression and anxiety.
Methods
Design and participants
Participants were caregivers of participants recruited to the main ATTILA RCT, and, as such, were
recruited and allocated to their study group according to their care recipient’s randomisation allocation.
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Eligibility criteria for the recruited care recipient participants are discussed in detail in Chapter 2. They
were adults, and were spouses, partners or children of the care recipient. Caregivers could be resident
or non-resident with the trial participant. Caregivers remained in the trial until their care recipient left
owing to death or a move to residential care.
Intervention and control conditions
Caregivers were not the direct recipient of the ATT assessment and interventions. The related care
recipient received the intervention ATT assessment and installation or control package, randomly
allocated as described in Chapter 2.
Recruitment
The recruitment of participants is described in Chapter 2.
Sample size
The sample size was estimated on the expected effect size of the intervention on the primary outcome
for the ATT recipients. No required number of participants was identified for the caregiver sample.
Procedure
Outcome rating scales were completed by caregivers at the same time points as data collections for
their care recipient: baseline (0 weeks) and 12, 24, 52 and 104 weeks. Participants completed the
baseline paper outcome rating scales at home, with or without the assistance of the data collection
assistants. Further assessments were mailed to participants or completed at the care recipients’
follow-up appointments.
Data collection
Outcome rating scales relevant to the assessment of caregiver outcomes are reported here.
Descriptive data and covariates
Data about the caregiver, their caring responsibilities, and their relationship to the participant were
collected: (1) caregiver age; (2) frequency of caring responsibility – lives with the care recipient, visits
once per day or visits fewer times than once per day; and (3) who lived with the care recipient –
spouse or partner, care recipient lives alone or other. Data about the severity of the care recipient’s
dementia symptoms were captured using the SMMSE.114
Caregiver outcome data
Data were collected about carer outcomes on three scales:
1. Caregiver burden – the ZBI115 is a 22-item scale assessing the burden of caregiving. Participants
respond on a five-point Likert scale ranging from 0 (never) to 4 (always). A single score is calculated
by summing the responses to the 22 items. A higher score indicates greater burden, with 0–20
indicating little or no burden, 21–40 indicating mild to moderate burden, 41–60 indicating moderate
to severe burden and 61–88 indicating severe burden.
2. Depression – CES-D-10: a 10-item scale. Participants respond on a four-point Likert scale ranging
from 0 (rarely/none of the time) to 3 (all of the time). A single score is calculated by reverse-scoring
two items and summing the 10 item scores. A score of ≥ 10 indicates depression.
3. STAI-6 – short form of the state scale of the STAI:116 a six-item scale on which participants
rate anxiety symptoms on a four-point Likert scale ranging from 1 (not at all) to 4 (very much).
Three items are reverse-scored, followed by a sum of items multiplied by 20/6. A single
score is calculated ranging from 20–80. A ‘normal’ score is 34–36; higher scores indicate
greater anxiety.
It was also planned to use the Short Form questionnaire-12 items to assess quality of life, but there
were some difficulties in registering the use of this instrument; therefore, it was not deployed.
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We analysed the data with IBM SPSS Statistics version 25 (IBM Corporation, Armonk, NY, USA)
(alpha level = 0.05). Preliminary analyses provided descriptive details for all the measures at the item
or scale level, as appropriate. We explored normality of the data by visually inspecting histograms and
conducting the Shapiro–Wilk test of normality. We also conducted a principal component analysis with
an oblimin rotation on the ZBI. We used the Kaiser–Meyer–Olkin measure to check the suitability of
the data for principal component analysis. We then used a scree plot to determine the number of
factors to retain and decided to extract three components (see Appendix 7, Table 40).
Selection of cases for inclusion in analyses
There were several sources of attrition across time points, including loss to follow-up, death and
institutionalisation of the care recipient. Because the attrition rate was substantially higher at the last
two time points (i.e. weeks 52 and 104), reaching approximately 50% by week 104, than at the first
three time points (i.e. baseline and weeks 12 and 24), we excluded the last two time points from the
analyses. We conducted our analyses according to the intention-to-treat principle.
Imputation
To account for missing data across demographic variables and outcomes, we conducted multiple
imputation for baseline only by including all predictors to fill the missing data. We used data from all
time points (baseline, week 12 and week 24) within the same multiple imputation model. We produced
10 imputed data sets; each of the multiply imputed data sets was analysed as usual, after which the
10 sets of results produced for each analysis were combined using Rubin’s rules.117–119
Descriptive data, randomisation and loss to follow-up analyses
Means and standard deviations (SDs) were calculated for continuous data, and frequencies and
percentages were calculated for categorical data. We conducted linear mixed modelling (LMM) to analyse
between-group differences, change over time (baseline, week 12, week 24) as well as interaction effects of
group and time. An initial set of analyses was conducted to examine the assumption that within-participant
scores are highly correlated by calculating the intraclass correlation. The second set of models included
covariates. Time was entered as a fixed effect for each linear mixed model, with participants’ identification
numbers as a random effect with the default variance components structure.
In addition to the main effects of group and time, the effects of the time–group interaction were
examined and interpreted where a significant interaction term indicating differential treatment
effectiveness was found. The decomposition of interaction effects for (1) group differences at each
time point and (2) changes over time within each group individually were examined. Significant effects
were investigated using pairwise comparison with the estimated marginal means. The 95% CI around
the estimated marginal means on each outcome for each group were also calculated.
Results
The findings reported here consist of the first three waves of data collection in the ATTILA trial: at
baseline and at 12 and 24 weeks. All LMM analyses in each section were adjusted for each of the
demographic variables presented in Tables 21 and 22. The tables below (see Tables 23–26) provide
the adjusted means of both groups on each outcome variable. We conducted a whole-sample analysis
and two secondary subgroup analyses. The results are broken up into three sections:
l section 1 – all caregivers in the study
l section 2 – caregivers who were living with the person with dementia (co-resident)
l section 3 – caregivers who were partners of the person with dementia (spousal care partners).
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Caregiver participants
Of the 495 caregivers in the trial, 354 provided data on age (control group, n = 182; intervention
group, n = 172). Therefore, we imputed the remaining 141 missing data for age; SMMSE scores were
also imputed. Details of caregivers’ ages, the SMMSE scores of the people with dementia and the living
status and frequency of caregiver visits to the person with dementia are provided in Tables 21 and 22.
Section 1: findings for all caregivers
Caregiver burden
The ZBI was analysed as a total score, and into its three component factors following a principal
component analysis. The three components were defined as:
l component 1 – negative appraisal of the care partner role
l component 2 – adequacy as a care partner
l component 3 – caregiver burden and strain.
TABLE 21 Caregiver and care recipient demographics (whole sample, N= 495)
Variable Mean SEM 95% CI p-value
Caregiver age 62.5 0.60 61.3 to 63.7
Control 62.1 0.85 60.4 to 63.7 0.455
Intervention 63.0 0.85 61.3 to 64.6
Care recipient SMMSE score 17.8 0.30 17.2 to 18.4
Control 17.0 0.43 16.2 to 17.8 0.006
Intervention 18.6 0.41 17.8 to 19.4
SEM, standard error of the mean.
Note
Alpha level was set at 0.05.





Living alone 229 46.3




Caregiver visits at least once per day 121 24.4
Caregiver visits less than once per day 134 27.1
Live-in caregiver 240 48.5
Total 495 100
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Total scores for the ZBI were not significantly different between the control and intervention groups
at week 24. Furthermore, there were no significant within-group or interaction effects across all time
points. Similarly, we found no significant between-group differences at week 24 for component 1,
2 or 3. There were no significant within-group or interaction effects for any of the components.
Parameter estimates and adjusted mean scores for each group at each time point are presented
in Tables 23 and 24.
Caregiver mood
Total scores for the CES-D-10 (depressed mood) were not significantly different between the control
and intervention groups at week 24. There were no significant group or interaction effects across all
time points. Similarly, total scores for the STAI-6 (anxiety) were also not significantly different between
the control and intervention group at week 24. Group and interaction effects across all time points for
the STAI-6 were also not statistically significant. Parameter estimates and adjusted mean scores for
each group at each time point are presented in Tables 25 and 26.
Section 2: spousal caregivers who were living with the person with
dementia (co-resident)
The sample of caregivers in the ATTILA trial were diverse in their living arrangements with the person with
dementia. Some lived in the same home as the person with dementia. Others were resident in proximity,
but living separately, and some were located some distance from the person with dementia. As there is
some evidence that co-location of the caregivers with the person in receipt of care implies a more involved
role in caring for the person with dementia,120 this group was selected for secondary analysis, whereby
effects of the telecare intervention on caregivers’ outcomes were examined only for those who were
living in the same household. Details of the group in this substudy are presented in Table 27.






Time 0.472 2 1438503 0.623
Group 0.036 1 161355 0.849
Interaction 0.172 2 2228089 0.842
Component 1: negative appraisal of caring
Time 0.127 2 645845 0.881
Group 0.042 1 654751 0.838
Interaction 0.200 2 4649804 0.819
Component 2: adequacy as a caregiver
Time 1.259 2 318819 0.284
Group 0.144 1 37476 0.704
Interaction 0.653 2 50769 0.520
Component 3: caregiver burden and strain
Time 1.696 2 250490 0.183
Group 0.030 1 272088 0.863
Interaction 1.657 2 578798 0.191
df, degrees of freedom.
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TABLE 24 Zarit Burden Interview mean and component scores, SEs and 95% CIs for each group at each time point
Time point Trial arm Mean SE 95% CI
Total score
Baseline Control 29.6 1.36 26.9 to 32.3
Intervention 29.3 1.44 26.4 to 32.1
Week 12 Control 29.7 1.41 27.0 to 32.5
Intervention 30.0 1.48 27.1 to 32.9
Week 24 Control 30.0 1.43 27.2 to 32.7
Intervention 29.7 1.48 26.7 to 32.6
Component 1: negative appraisal of caring
Baseline Control 13.8 0.67 12.5 to 15.1
Intervention 14.0 0.70 12.6 to 15.4
Week 12 Control 14.3 0.70 13.0 to 15.7
Intervention 14.2 0.73 12.8 to 15.6
Week 24 Control 14.3 0.70 13.0 to 15.7
Intervention 14.2 0.73 12.8 to 15.6
Component 2: adequacy as a caregiver
Baseline Control 3.8 0.25 3.3 to 4.3
Intervention 3.9 0.26 3.4 to 4.4
Week 12 Control 3.9 0.27 3.3 to 4.4
Intervention 4.1 0.27 3.5 to 4.6
Week 24 Control 3.9 0.27 3.3 to 4.4
Intervention 3.7 0.28 3.2 to 4.3
Component 3: caregiver burden and strain
Baseline Control 7.8 0.503 6.8 to 8.8
Intervention 7.4 0.527 6.4 to 8.5
Week 12 Control 7.5 0.526 6.5 to 8.6
Intervention 8.0 0.544 6.9 to 9.1
Week 24 Control 7.7 0.532 6.6 to 8.7
Intervention 7.8 0.547 6.7 to 8.8






Time 1.726 2 935042 0.178
Group 0.282 1 341074 0.596
Interaction 0.595 2 830859 0.551
STAI-6
Time 1.110 2 4613788 0.329
Group 0.539 1 2187757 0.463
Interaction 0.713 2 896778.4 0.490
df, degrees of freedom.
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
63
The analyses presented in the following sections mirror those conducted for all caregivers in the
previous sections.
Caregiver burden
Total scores for the ZBI were not significantly different between the control and intervention groups
at week 24. There were no significant group or interaction effects across all time points. Similarly, we
found no significant between-group differences at week 24 for any of the three subcomponents of the
ZBI. There were no significant group, time or interaction effects for any of the components. Parameter
estimates and adjusted mean scores for each group at each time point are presented in Appendix 7,
Tables 41 and 42.
TABLE 26 Anxiety and Depression mean scores, SEs and 95% CIs for each group at each time point
Time point Trial arm Mean SE 95% CI
CES-D-10
Baseline Control 9.6 0.56 8.5 to 10.7
Intervention 8.7 0.59 7.5 to 9.8
Week 12 Control 9.8 0.59 8.6 to 10.9
Intervention 9.1 0.61 7.9 to 10.3
Week 24 Control 9.7 0.59 8.5 to 10.8
Intervention 9.3 0.61 8.1 to 10.5
STAI-6
Baseline Control 40.3 1.22 37.9 to 42.7
Intervention 39.7 1.28 37.2 to 42.2
Week 12 Control 39.9 1.30 37.4 to 42.5
Intervention 40.2 1.34 37.6 to 42.8
Week 24 Control 40.1 1.33 37.5 to 42.7
Intervention 41.2 1.36 38.5 to 43.9
TABLE 27 Demographic characteristics of participants with dementia in the subgroup analysis including only caregivers
who lived with the cared-for person (n = 195)
Variable Mean SEM 95% CI p-value
Age (years) 71.8 0.80 70.2 to 73.4
Control 71.9 1.12 69.7 to 74.1 0.901
Intervention 71.7 1.14 69.5 to 73.9
SMMSE scorea 17.4 0.49 16.5 to 18.4
Control 17.0 0.68 15.6 to 18.3 0.344
Intervention 17.9 0.71 16.5 to 19.3
SEM, standard error of the mean.
a Score of the person with dementia.
Note
Alpha level was set at 0.05.
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Caregiver mood
Total scores for the CES-D-10 (depressed mood) were not significantly different between the control
and intervention groups at week 24. Furthermore, there were no significant within-group or
interaction effects across all time points. Similarly, total scores for the STAI-6 were also not
significantly different between the control and intervention groups at week 24. Within-group and
interaction effects across all time points for the STAI-6 were also not statistically significant. Parameter
estimates and adjusted mean scores for each group at each time point are presented in Appendix 7,
Tables 43 and 44.
Section 3: caregivers who were the spouse or partner of the person
with dementia
Much of the literature on caregivers has selected spousal care partners for special attention, and there
is evidence that spouses are particularly vulnerable to burden and poor psychological well-being.121–123
Spousal caregivers of people with dementia have to live with an altered relationship with the person
they elected to partner and live with as the mental faculties of the person with dementia alter.
Furthermore, spousal carers may be of similar age to the care recipient and, therefore, may be
experiencing physical or cognitive difficulties themselves. A secondary analysis was conducted on
spousal caregivers of the person with dementia in the sample, so as to keep the relationship between
the caregivers and the person with dementia constant. Details of their age and the SMMSE score of
the person with dementia are provided in Table 28.
Caregiver burden
In this subgroup analysis, total scores for the ZBI were not significantly different between the
control and intervention groups at week 24. Furthermore, there were no significant within-group or
interaction effects across all time points. Similarly, we found no significant between-group differences
at week 24 for components 1, 2 or 3. There were no significant within-group or interaction effects for
any of the components. Parameter estimates and adjusted mean scores for each group at each time
point are presented in Appendix 7, Tables 45 and 46.
Caregiver mood
Total scores for the CES-D-10 (depressive mood) were not significantly different between the
control and intervention groups at week 24. Furthermore, there were no significant within-group or
interaction effects across all time points. Similarly, total scores for the STAI-6 (state anxiety) were not
significantly different between the control and intervention groups at week 24. Within-group and
TABLE 28 Demographic characteristics of participants with dementia in the subgroup analysis including only carergivers
who were the spouse or partner of the care recipient (n = 240)
Variable Mean SEM 95% CI p-value
Age 68.6 0.83 66.9 to 70.2
Control 68.7 1.14 66.5 to 70.9 0.863
Intervention 68.4 1.23 66 to 70.8
SMMSE scorea 17.3 0.45 16.4 to 18.2
Control 16.8 0.62 15.6 to 18 0.255
Intervention 17.8 0.65 16.5 to 19.1
SEM, standard error of the mean.
a Score of the person with dementia.
Note
Alpha level was set at 0.05.
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interaction effects across all time points for the STAI-6 were also not statistically significant. Parameter
estimates and adjusted mean scores for each group at each time point are presented in Appendix 7,
Tables 47 and 48.
Discussion
The impact on caregivers’ health and well-being of caring for someone with dementia has led to the
development of interventions to reduce the burden they face. It has also been recognised that these
interventions may have a broader impact, as the alleviation of caregiver burden may reduce the
likelihood of the cared-for person being institutionalised, thereby reducing social and health-care costs.
In this study within the ATTILA trial, we investigated the effects of using ATT for people with dementia
on the outcomes of the participants’ caregivers, namely caregiver burden and psychological well-being
in the first 24 weeks following installation of the ATT intervention.
No effects of the installation of ATT compared with usual care were found on caregiver burden and
its subcomponents, or depression and state anxiety. We also conducted post hoc subgroup analyses
among live-in caregivers, and among caregivers who were the spouse or partner of the cared-for
person, in whom we might expect poorer psychological well-being and levels of burden. Neither of
these subgroup analyses revealed differences between the two groups in any of these outcomes. It is
notable that the levels of caregiver burden, depression and anxiety remained stable during the course
of the trial. Although this is not a non-inferiority trial, the data suggest no negative impact of receiving
the ATT interventions.
One explanation for the lack of impact on these outcomes is the relatively low levels of burden, depression
and state anxiety reported in the sample at baseline.124 The mean levels of burden across both the
intervention and control groups for the overall sample and the examined subgroups were in the mild to
moderate range. Similarly, mean levels of depression in this sample were below the clinically relevant
threshold on the CES-D-10 scale, for which a score of > 10 indicates depression. Mean scores on the
STAI-6 at baseline were 9.6 and 8.7 for control and intervention group participants, respectively. These
data suggest that there may have been limited scope to reduce burden, depression and anxiety among
the sampled caregivers. A previous study125 indicated higher levels of depression and anxiety at baseline
in its study population, and a 2016 study,126 using the same instrument for assessing depression as used
in this study, found higher scores, above the clinically relevant threshold, in its sample.
Alternatively, it is possible that the effects of ATT interventions may be limited in effecting change
in these outcomes, and that interventions specifically targeting caregivers’ well-being may be more
effective than those aiming to support the cared-for person. Meta-analyses indicate that caregiver-
directed interventions have demonstrated effectiveness in reducing burden, depression and anxiety in
this population. Effective interventions include cognitive–behavioural therapy, cognitive reframing and
educational interventions.127–130 Therefore, to optimise the benefits of the installation of ATT for both
the care recipient and the caregiver, it may be important to provide additional caregiver-directed
support. Effective and potentially low-burden and low-cost interventions include the use of telephone-
and internet-based interventions to improve caregiver outcomes.131,132
In the current sample, the mean scores on the SMMSE indicated moderate levels of cognitive
impairment in the cared-for participant sample (mean 10–19). There is some evidence indicating that
the severity of the dementia is related to levels of depression and anxiety, with only severe dementia
leading to caregivers having high levels of depression and anxiety,133 although this relationship has
not always been supported.134 It is possible that the level of dementia in the current study was not
sufficiently severe to produce high scores at baseline in the caregivers such that they may have been
reduced by the intervention.
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Strengths, limitations and suggestions for future research
This study provides the first insight into the potential impact of up-to-date technological interventions
for people with dementia on outcomes for their informal caregivers within 6 months of deployment.
A large data set to assess impact of ATT is available; however, the extent of missing data at follow-up
precluded investigation of longer-term effects of the technology on caregiver outcomes. Furthermore,
loss to follow-up in the caregiver data set was non-random, introducing some degree of bias. This is
because dropout among some caregivers was partly due to the care recipient moving into residential
care or dying. Furthermore, power analysis was conducted on the study primary outcome (time to
institutionalisation), rather than on caregivers’ outcomes. Therefore, it is possible that our analyses
were statistically underpowered.
A general limitation of the trial should also be recognised, as we have reported elsewhere51 that there
was limited fidelity of technology deployment in relation to the recommendations arising out of the
needs assessment. This mismatch may have also contributed to the lack of any impact on caregiver
burden and mood.
Future work will need to determine the minimum sample size required to detect an effect of the ATT
intervention based on expected effect size for caregiver outcomes. It may well be that longer follow-up
times with additional caregiver support are necessary to produce any intervention effects for
caregivers’ outcomes.
Conclusions and implications for practice
This study provides a first insight into the potential impact of ATT on caregiver burden, psychological
well-being and quality of life. No impact of ATT on caregiver burden, depression and anxiety was
identified. As key drivers of transfer to long-term residential care, interventions aiming to specifically
target these aspects of caregiver psychosocial well-being along with the deployment of ATT may be
important for delaying institutionalisation and preventing the costs associated with this, both for social
care services and for the individual and their family members. Evidence-based effective interventions
to prevent negative impact of caregiving may include care partner-directed psychological and
educational techniques, as well as ensuring that caregivers have an appropriate understanding of the
role of ATT.
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Chapter 7 Practices of people with
dementia and caregivers using assistive
technologies and telecare at home: a
community-based ethnographic study
Industry, government and care service providers see ATT services as likely to enable people withdementia to continue living independently and safely in their communities. There is relatively little
research to examine how people with dementia and their caregivers actually use these technologies
in their everyday lives and how such experiences may affect their well-being and ability to sustain
their community-based care arrangements. The little research that exists is limited in scale and
quality. The ethnographic ATTILA substudy described here [referred to elsewhere as ACCOMMODATE
(A Collaborative COMMunity-based ethnography Of people with Dementia using Assistive technology
and Telecare at home in England)] aimed to address this empirical research gap from a subsample of
ATILLA trial participants and to complement the ATTILA trial findings on the effects of participants’
technology use in their everyday routines. In-depth participant cases presented here are pseudonymised
to ensure anonymity and confidentiality.
Aims and research questions
The study aimed to exemplify and examine how and why people with dementia and their caregivers
used or chose not to use ATT in their lives and the ways in which ATT use affected their environments
and relationships.
To address this research aim, the study team sought to answer three research questions:
1. How and why do people with dementia and their caregivers use ATT at home?
2. How does ATT fit into people’s lives and care in their homes?
3. How does ATT affect people’s lives and care in their homes?
Methods
This study used a qualitative ethnographic observational, longitudinal design to investigate how and why
people with dementia in the intervention arm of the ATTILA trial used or did not use the ATT offered to
them. This section describes the study design, sampling strategy, data collection and analysis methods.
Design
Ethnographic approaches have commonly relied on sustained fieldwork, whereby a researcher takes
part in a group’s practices while observing them, so as to rigorously interpret how people make sense
of their everyday lives and social systems.135 The ethnographic approach used in this study, however,
drew on recent multidisciplinary research in trials to design a study ‘embedded’ in the ATTILA trial136,137
to collect focused138,139 observational data on situated practices of people with dementia and their
caregivers when using ATT in their everyday lives. We used these data to construct in-depth extended
cases140,141 of how people with dementia and caregivers used (or chose not to use) these technologies,
to help explain how and to what extent specific technologies for supporting people with dementia may
be relevant in the context of their everyday places and interactions in home and community settings.
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This study demonstrates how technology-enabled dementia care systems work with and for people,
how they attempted to fit ATT into their lives and homes and how ATT-related processes affected
their activities and care relationships.
To provide ‘trustworthy’142,143 findings and interpretations, we formulated credible, transferable,
dependable, and confirmable processes for data collection and analysis through:
l Extensive and intensive data collection from participants (see Participant observation and Analysis)
and critically discussing anonymised data (credibility) findings within the study teams
(credibility, dependability).
l Noting in contextualised detail participants’ situated practices and how noting these may affect
interpretation of findings to other contexts (transferability).
l Reflecting on researcher role in the process and how this could affect interpretations. Detailed
fieldnotes and accounts of the research context to allow future research to confirm, challenge or
otherwise build on findings from this study (confirmability).
Ethics approval for the study was granted by the National Research Ethics Services Committee East of
England, Norfolk (reference number 15/EE/0015) on 3 February 2015.
Sample
A purposive sampling strategy was used to select potential participants from the wider ATTILA trial
population who were able to provide data relevant to examining care practices and specific reasons for,
and ways of, their uptake (or not) of diverse technological interventions.
This strategy, therefore, had to incorporate the ATTILA trial inclusion and exclusion criteria (see
Chapter 2), but also ethnographic-specific purposive sampling criteria that would provide contextually
relevant and diverse types of participants’ experiences from three characteristics:
1. severity of the person’s dementia, as recorded by ATTILA trial research workers
2. type of family relationship between the caregiver and person with dementia
3. types of ATT equipment provided to the person with dementia.
Settings
To recruit participants, we collaborated with local ATTILA trial research workers, who collected data
across three distinct authorities in east and south-east England: ‘Shire’, ‘Metropolitan’ and ‘Coast’.
They included a mix of urban and rural populations in areas of economic wealth and areas of economic
deprivation.144 These are pseudonymised to ensure anonymity and confidentiality:
l ‘Shire’ – participants from this area lived in large villages or small market towns with independent
vendors and occasional high-street shops.
l ‘Metropolitan’ – a major city divided into different districts. Trial participants lived in two adjoining
districts with historical reputations of poverty. More recent gentrification is transforming
these areas.
l ‘Coast’ – two counties with a seaside border, sharing service responsibilities for adult services.
Participants from this area lived predominantly in large market towns or in villages near major
regional city hubs.
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These brief setting descriptions highlighted distinct features of the wider areas where people with
dementia lived to contextualise wider relations with their environment.
Recruitment
The ethnographic team recruited prospective participants alongside three ATTILA trial research
workers responsible for recruiting and collecting data from ATTILA trial participants in Metropolitan,
Shire or Coast. This process to embed ethnographic recruitment in the ATTILA trial involved four steps:
1. The fieldworker (ML) collaborated with an ATTILA trial research worker to identify prospective
ACCOMMODATE participants from the existing ATTILA trial sample. The fieldworker selected
people based on how they aligned with the purposive sampling criteria for ACCOMMODATE. He
selected participants to ensure a maximum variation across all three purposive sampling criteria.
2. The fieldworker attended the pre-arranged ATTILA trial follow-up visit with the area’s local research
worker to meet with prospective participants to discuss participation in the ethnographic substudy.
3. The fieldworker sought substudy informed consent from people with dementia and their caregiver
to take part in the ethnography substudy, or a consultee declaration from the caregiver for the
person with dementia to participate.
4. The fieldworker continually renegotiated informed consent or consultee declaration for each
subsequent monthly visit during independent fieldwork.
Participant observation
The study included nine ethnographic cases, each consisting of at least one person with dementia
(n = 10) and their caregiver (n = 10). Two cases included more than one caregiver (the Campbells
included two caregivers) or more than one person with dementia (the Stewarts included two people
with dementia). Data collection involved up to six visits over 6 months (one per month) to the home
of each person with dementia. These monthly visits lasted between 1 and 5 hours (mean 3.5 hours).
A total of 208 hours of observation took place over 60 visits. Each visit involved Matthew Lariviere
observing the practices of people with dementia and their caregivers, focusing particularly on whether
or not and how they were using ATT and unstructured ethnographic interviews with participants to
elicit their reasons for using or not using ATT.
Analysis
Initial notes from observations were written in a journal during or immediately after the visit and maps
were drawn to illustrate objects and people’s places in settings. The initial notes were later transcribed
and developed into field notes with any accompanying audio-recordings from conversations. Additional
researcher memos identified where participants were interacting with or discussing the technologies.
We analysed each case using situational analysis of longitudinally extended cases.8,11 The main themes
identified from early memos highlighted how people with dementia and caregivers attempted to fit
ATT into their everyday practices, leading to placing, replacing and displacing care and uses of spaces
inside and outside the home. Focused coding was used to identify instances of these themes during
different visits for each ethnographic case, which informed comparisons within and across cases and
contextualised specific instances of these analytical themes. The findings are presented in the following
section as extended cases that highlight everyday features seen as common to several cases. These are
depicted further through indicative maps.
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Findings
Each of these ethnographic cases provides in-depth representations of how participants enacted their
practices with ATT in their homes. Table 29 provides descriptions of the nine ethnographic cases to
highlight the diversity of the nine cases based on their case name, location, the severity of the person’s
dementia, the nature of participant’s family or care relationship, and the types of assistive technologies
and/or telecare devices in place. Ethnographic cases were evenly distributed across different levels
of dementia severity (i.e. three mild, three moderate and three severe cases). Participants in the
ethnographic substudy most commonly received a falls detector (n = 6) and door sensors (n = 4).
TABLE 29 Description of ethnographic cases
Case names and location
Dementia
severity
Nature of relationship with
caregiver(s) ATT devices
Clydes – Coast Moderate Father (person with dementia)
lived in his own house. Son and
daughter-in-law (caregivers) lived
in separate house, but they
worked from an office in the
front room of the father’s house
Automatic falls detector
(wristband model), keysafe
Drapers – Coast Mild Mother (person with dementia)
lived in her own home. Son
(caregiver) lived in his own
separate home, but visited her
for up to 6 hours every day
Calendar-clock, bed sensors,
automatic falls detector, falls
alarm (wrist version; replaced
pendant after first visit), keysafe
Stewarts – Coast Moderate
(both parents)
Mother and father (people with
dementia) lived in an annex of
the daughter’s house (caregiver)
Door sensors
Betty and Rose – Shire Severe Betty (caregiver) is Rose’s (person
with dementia) neighbour. They
each lived in their own house
Automatic falls detector
(pendant), keysafe
Anthony and Mrs Archer –
Metropolitan
Severe Mrs Archer (person with
dementia) lived in a sheltered
housing flat. Anthony (caregiver;
friend of family) lived his own
flat in the same neighbourhood
as Mrs Archer. He visited her a
few days each week
GPS tracking device, calendar-
clock, automatic falls sensor
(pendant), cooker-timer
Campbells – Metropolitan Severe Son (caregiver) lived in mother’s
(person with dementia) home
Bed sensor, door sensor/alarm,
pendant alarm
Browns – Shire Mild/MCI Wife (caregiver) shared house
with husband (person with
dementia); daughter (caregiver)
and son-in-law lived in annex
Door sensors, object finder
Anansis – Metropolitan Moderate Father (person with dementia)
lived alone in a flat; daughter
(caregiver) visited him regularly
from her home across the city
Automatic falls detector
(pendant), GPS ‘watch’ and
pendant (Buddi; Buddi,
Rickmansworth, UK)
Smiths – Shire Mild Father lived alone in his own
house. Daughter (caregiver) lived
with her family in village in
another county and tended to
arrange her visits to coincide with
other activities, such as doctor
visits. Her visits appeared more ad
hoc than those in the other cases
in which caregivers all lived closer
to the people under their care
Wrist alarm, automatic falls
detector (waist), calendar-clock
(self-purchased), door sensors,
networked smoke alarm, activity
monitoring sensors and software
(Just Checking Ltd, Lapworth, UK)
GPS, Global Positioning System; MCI, mild cognitive impairment.
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Keysafes (n = 3) and calendar-clocks (n = 3) were also relatively common. In most cases, an adult child
was caring for an older parent with dementia (n = 6). Caregivers rarely co-resided with the person with
dementia under their care (n = 3).
This diverse range of characteristics across all cases supported robust interpretation of how this
diversity shaped differences and similarities across the nine ethnographic cases. Three key themes
were identified as relevant to understanding the ATT-relevant and care-relevant everyday practices,
routines and relationships of study participants:
1. Placing technology in care.
2. Replacing care with technology.
3. Technology displacing care and everyday life. Displacing everyday life refers to how people’s
everyday routines and built environments become disrupted and altered.
Placing technology in care
The theme ‘placing technology in care’ refers to instances when people with dementia and/or
caregivers fit ATT products into their existing care arrangements. It addresses participants’ processes
and practices in incorporating and adapting technologies into their everyday lives with varying degrees
of success.
The Drapers showed initial troubles in how they placed a falls detector within their pre-existing
everyday practices. The person with dementia, Violet Draper, received a neck-worn falls detector
pendant, after experiencing several falls. Around the when time research visits began, she had another
fall, but the alarm did not trigger. She decided not to trigger the alarm manually as she ‘did not want
to be a bother’ to her son and caregiver, Thomas, or to the emergency response services. Thomas also
commented that his mother frequently forgot to wear the pendant or took it off in the evening with
her bed having been moved down to the sitting room (Figure 11 shows a map). After this fall, Thomas
changed two elements of his mother’s care. First, he asked the local ATT provider to swap the
pendant-style detector for one worn around the wrist. Second, he reminded Violet every day to ‘press
the button’ if she ever fell again. A couple of months later, Violet had another much more serious fall in
which she broke her leg; this time, the falls detector did not detect the fall automatically, but Violet did











FIGURE 11 Map of sitting room in Violet Draper’s home.
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This case highlights that both Thomas and Violet acted to make the falls detector fit into their lives.
Their case illustrates the work of caregivers to instruct and to reinforce any such instruction to ensure
‘successful’ implementation of ATT that would otherwise be invisible to care workers and designers of
the technology. Such work was even more important here because the falls detector did not activate
automatically. This raises further questions about the different types of technologies designed to
enhance the safety of people with dementia. The key distinction here is between ‘passive’ devices
that automatically trigger, not requiring the user to perform any actions, and devices that require an
action to be performed to activate them. It seems important to consider what use of passive devices is
appropriate in the case of people with dementia, especially where they are either reluctant to trigger
alarms or have memory difficulties that lead them to fail to remember to trigger a device. This case
demonstrated how social connections and support were important even for enacting ‘technology-
enabled’ care systems.
In contrast, the Stewarts’ case illustrates how people with dementia or caregivers may appropriately
place assistive technology, yet find that other objects in the home may suitably address problems when
they arise. Mary and Michael are a married couple, both of whom have dementia. Their daughter, Sally,
moved them into an annex of her home to support them full time. During one fieldwork visit, Sally
asked her parents for the date. Neither Michael nor Mary knew the date. They also did not appear
to notice the nearby calendar-clock that had been provided to display this information but did
perceive wooden calendar blocks across the room, which helped orientate them. Michael told Sally the
correct date.
This case highlights the importance of appropriately placing ATT in a person’s home. Here, a wooden
calendar may be seen to serve as more ‘assistive’ than the ‘formally provided’ calendar-clock. Although
the calendar-clock did not disrupt or disorientate Michael or Mary, the technology did not actively
facilitate them to be orientated to date and time. Someone still had to interact with the regular
calendar to make it work by changing the date each day, but its familiar location and design may have
more easily supported their orientation because it relied in part on older memory and was perhaps
more readily recognisable than more recent digital counterparts.
The Browns’ case raises further questions about how researcher and practitioners come to define
‘use’ of ATT. Sam Brown, a person with mild cognitive impairment, had a memo minder in his house
entrance. A recording of his daughter’s voice reminded him to lock the front door whenever anyone
walked in front of the infrared motion sensor. Sam told the researcher that he always remembered to
lock the door because of it. Sam also shared his home with his wife and with his adult daughter and
son-in-law, who lived in a converted garage annex. The other household residents became annoyed
with the memo minder repeatedly going off whenever they went to put on or remove their shoes
and outerwear. Sam decided to turn off the recording but leave the memo minder in its place next
to the front door. He insisted, and the researcher observed and confirmed, multiple times, that seeing
the now-silent memo minder, still beside the door, reminded him to close and lock it when he left the
house to go back home.
Such practices blur ‘use’ of ATT and its ‘non-use’. Although the person with dementia switched off
this device, its co-location with him in its ‘appropriate’ place provided the prompt he needed to remember
to lock up. This case, alongside others, illustrates both the importance of ‘place’ in sustaining appropriate
technology-enabled care for people with cognitive impairments, and how people are able to actively
accommodate technology to work in their shared spaces and their relationships with others, including
their caregivers.
Technology replacing care
This theme, ‘technology replacing care’, particularly addresses how caregivers, through ATT, replaced or
reconfigured their practices of caring for people with dementia.
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The Clydes’ case involved Arthur Clyde, an older person with dementia, who received a falls detector
from his local authority. His son and daughter-in-law, Mark and Cathy, visited his home every weekday
to work from the front room of his house, which they had converted into an office for Mark’s business.
Mark also used to visit his father at least 1 day over the weekend to see whether or not he remembered
to heat up and eat his pre-prepared meals. However, after Arthur started to wear the falls detector
around his wrist, Mark visited his father less frequently. Mark told the researcher that he had ‘peace of
mind’ that the call centre would notify him if his father had a fall. Mark decided instead to telephone
Arthur on Saturdays and Sundays to ask him whether or not he had eaten his meals instead of visiting
to confirm this.
This case illustrates how caregivers may change their care practices for a person with dementia after
they introduce ATT into their arrangements. Here, the caregiver visited his father less frequently
and relied on the falls detector and telephone to monitor his father with dementia. Falls detectors
and telephones reconfigure monitoring practices to be mediated through technologies rather than
face-to-face interactions. Caregivers’ sense of security, often articulated as their ‘peace of mind’, was
a common response across cases, including the case that follows.
In the Smiths’ case, Lauren had the local service provider install an activity monitoring system in the
living room of her father’s bungalow. Lauren thought her father, Christopher Smith, frequently got up
from his favourite chair to walk around the house based on activity reported on the monitoring
system’s accompanying application for her tablet. Lauren told the researcher that she had ‘peace of
mind’ that her father remained active even when home alone, especially as she lived in another county,
distant from her father. However, the researcher rarely saw Christopher move from his chair during his
visits (Figure 12 shows a map). During one visit, Lauren and the researcher noticed the dog jumping on
the couch. The activity monitoring system’s motion sensors happened to be at the same height as the
dog. The researcher asked Lauren whether or not she possibly monitored the dog instead of her father.
She looked at the application and noticed recent activity when no one else appeared to have moved in
















JustChecking sensor installed on wall above cabinet
FIGURE 12 Map of Christopher Smith’s bungalow.
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The Smiths’ case highlights how people use the devices for reassurance and peace of mind. In this case,
the poorly placed product led to inaccurate information and misguided reassurance. Once this was
established, the caregiver’s ‘peace of mind’ became replaced by concern as she could no longer be
certain whether the activity monitoring system monitored only her father’s movement or also that of
other people or animals.
In contrast to the other two cases exemplifying this theme, the case of the Campbells demonstrates
how people can independently adopt ‘other technologies’, and how this will also shape their care
practices. Kenneth Campbell shared his home with Lillian, his mother living with dementia. They
were offered door and bed sensors, but Lillian tore out the cable of the bed sensor from under the
mattress. They did not have a telephone line for the door sensor to connect with. Instead, Kenneth
independently purchased and used a closed-circuit television (CCTV) system to monitor the downstairs
rooms of the house, where his mother lived, through monitors in his living room upstairs.
The Campbells’ case displays marked changes in how caregivers may provide care with the addition
of technologies. Notably, here, the ATT did not appear to fit into the lives of Kenneth or Lillian.
Rather than reconfigure their practices or home, Kenneth adapted security equipment, namely CCTV,
as a means to monitor his mother in their home. This case raises further questions about how we
characterise means to monitor people with dementia in their home as appropriate yet still ensure
dignity and safeguard them against harm. It also calls into question, as noted in Chapter 6, whether
or not carers’ work here may have changed rather than diminished.
Technology displacing care and everyday life
The final theme, ‘technology displacing care and everyday life’, refers to cases in which people with
dementia experienced their care arrangements and everyday practices as being displaced from their
usual routines by ATT.
In the Rose and Betty case, Rose previously visited the local chapel in her village every Sunday for
her church service. She received a lift from another neighbour to attend this service. Rose became
increasingly frail, which affected her ability to move safely around in, and leave, the house. To support
her living safely, she received a falls detector. However, the neighbouring family decided to stop
attending the same service. Rose did not have the physical capacity to walk to the chapel herself,
so she had to stop going to the local service.
Here the technology she received, a falls detector, could not facilitate her social participation in
activities centrally important to her. The ATT here was not necessarily designed to facilitate these
connections, but it shows how, as people with dementia encounter increased challenges in their
participation in everyday activities, technology cannot facilitate and support every connection and
activity in a person’s life. Other interventions from friends and family may support such inclusion for a
person with dementia, but they may not sustain support for social participation indefinitely. Other
participants with dementia became increasingly isolated as their dementia progressed and they
experienced more acute care needs that were met in only limited ways by home monitoring.
In some cases, technology played a greater role in displacing people’s activities and care. In the Anansi
case, for example, technology seemed to constrain how William Anansi could engage as he wanted
with his wider community. William received a Global Positioning System (GPS) tracking system from his
local council. Claire, his daughter and primary caregiver, told the researcher that she hoped this device
would allow both her father to leave the house when he wished but also for her to locate him if he
became lost. During one research visit, William left his flat without telling Claire. She called the call
centre for the GPS tracking device, which located him in a nearby market that he frequented for his
favourite Caribbean cuisine. Claire called her father on his mobile phone to tell him to return home.
She also told the call centre operator to contact him through the speaker on the GPS tracking device.
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William initially did not answer any calls. After 10 minutes of her calling him, he answered his mobile
phone and told Claire that he had had lunch. Claire again told him to return home. The call centre
operator confirmed that William appeared to be on a bus on his way back to his flat.
This case illustrates how caregivers can use technologies to affect how people with dementia interact
with spaces outside their home and engage with their wider community. Here, Claire tracks her
father’s location through the GPS system worn on his person, with the assistance of a call centre
operator to confirm his movement and changes to his location. Such practices with ATT illustrate how
people can attempt to control the movements and behaviour of people with dementia, even when this
may contest how they want to live their lives. Again, as noted in Chapter 6, new challenges and
concerns for caregivers may be raised, rather than removed, by ATT.
Discussion
These findings illustrate how technological mediation through ATT with associated applications and
screens could replace, displace and disrupt co-located, face-to-face interactions. The reported findings
suggest that how policy-makers and industry imagine community care through ATT service provision
may not always reflect actual practices in technology-enabled dementia care. As previous research has
also suggested, people with dementia and caregivers may make ATT work for them in contingently,
rather than systematically.145–147 This study, however, highlights not only the role taken by caregivers to
fit these technologies into care practices, but also how their use of ATT can change the spaces and
placement of care and everyday life. It shows how people’s practices with ATT may shift dependencies
in care arrangements as a result of actual or perceived changes or disruptions in care.147,148 These
findings identify limitations for ATT to enable people with dementia to ‘live independently in the
community’ if they do not also have added support from caregivers to help adapt technologies to fit
into their lives.
Strengths and limitations
Study findings highlighted granular details of how people with dementia and their caregivers do and
could use assistive technologies. We adopted systematic measures to ensure that the findings were
trustworthy. However, these findings only exemplify practices of participants taking part in a trial and
agreeing to receive this intervention. It may have limited transferability to how people with dementia
and caregivers may use other current or emergent technologies. Caregivers also have diverse living
arrangements and familial ties and relationships, and it was not possible to sample all of these.
Nonetheless, it provides critical insights into the complexity of technology-enabled dementia care to
consider in current and future design and provision of such technologies. Transparent reporting of this
study’s methods of data collection and analysis allows other researchers to challenge, confirm or add
to understandings and implications of the findings.
Conclusions and implications
These ethnographic findings flag up unintended and unanticipated consequences for ATT implementation
and uptake in ‘real-world’ community-based dementia care contexts. The ethnographic approach details
how people’s use of ATT shifted over time. Nonetheless, even temporary use of ATT may have deferred
more complex and more acute care crises for the person with dementia or caregiver. Transient effects or
limited engagement with technology should not necessarily be interpreted, therefore, as a failure in its
uptake or effect. It underlines the need to identify and map the context of ATT provision over time
within the changing lives of people with dementia and their caregivers, and relative to service provider
organisations, as revealed in these cases.
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These findings have relevance for technology developers and providers in indicating how to consider
more appropriate products and services that can support more sustainable technology-enabled care for
people with dementia and their partners in care. Designers and service provider organisations should
also work with caregivers and people with dementia, including charities representing these groups,
such as Carers UK and the Alzheimer’s Society, to co-produce suitable technological interventions.
This study suggests that we must more fully appreciate the importance of people’s activities and
relationships in continuously shaping care, including dementia care involving the implementation and
uptake of technology in community settings to improve their effectiveness and sustainability.
COMMUNITY-BASED ETHNOGRAPHIC STUDY




To the best of our knowledge, this study is the first RCT of ATT for people living with dementia in
the community. Despite the large increase in available products and their promotion as effective,
cost-saving ways of helping people with dementia remain at home, there has been a paucity of robust
research on how beneficial these products and services can be.37 The main outcomes of this trial were
whether or not ATT could help keep people living at home longer and whether or not this was more
cost-effective than a basic ATT package and alternative support. The answer to both questions was no:
there were no significant differences found between the ATT and groups on any outcomes.
Home-based dementia care is a policy prioritised across the world,149,150 including in the UK.151
Remaining at home to maintain a higher quality of life is preferred by people with dementia, is more
cost-effective than residential care and can provide continuity and familiarity that is beneficial to those
experiencing a decline in cognitive and functional abilities.152 ATT has been marketed as an aid to
keeping people with dementia safely at home by providing monitoring of movement, safety and
well-being; reminders for events and medication; and social support, among other things.
There have been many studies conducted around ATT, but all have been very small and/or have had
poor methodology. The results of these have often been conflicting, with some viewing ATT very
positively,153 others finding no benefits154 and some even regarding it negatively, for example although
surveillance can be enabling, it can also be an invasion of privacy.8 A 2017 Cochrane Review37 found
that there were no studies sufficiently robust to make a judgement and cited our study as being the
only ongoing research that met their criteria. The lack of evidence to date makes the contribution of
this study to the evidence base vital.
Dementia is an increasing challenge for health-care systems across the world, with 43.8 million cases
in 2016;11 this is predicted to rise to 75 million by 2030.155 With no treatment for dementia, or many
of its causes, currently available, and medication to slow development showing only marginal clinical
improvement,156 it is increasingly important to help people with dementia and their families to live well
in the community for as long as is safe for them to do so. Caregivers provide 42% of the estimated
US$604B spent globally on dementia,37 so supporting their role is also vital.
There are a number of possible reasons for the lack of efficacy shown in the current study. Previous
research has suggested that ATT are often introduced when the cognitive decline is too great and the
ability to adapt is too impaired for the user to incorporate it into their routines, and, at all stages of
dementia, devices are seen as most useful when they are simple.157 Aids that do not need adjusting
have been considered most useful by caregivers, whereas complex interfaces and connection problems
reduce the perceived utility of ATT.158 However, other studies have found that a lot of ATT devices lack
user-centred design approaches,159 and user experience can be improved by optimising specific details
of a product.160
Conclusions from Chapter 6
Evidence from the ethnographic study (see Chapter 7) may also provide some insight into the lack
of effects on caregiver outcomes. The ethnographic study indicates that, although technology was
deployed, how it was used by caregivers and the cared-for person in the context of their own home
and lifestyle may be important in determining the effectiveness and beneficial impact of the technology
on their well-being. Data from the ethnographic study reported issues with reliability, situations in
which the cared-for person did not use it as instructed or as intended, and that it may not have
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reduced the amount of time spent caregiving, even if the caregiving was carried out remotely rather
than as visits to the home.
How ethnographic findings complement ATTILA trial findings
As detailed in Chapter 4, the primary outcomes from the ATTILA trial demonstrated no significant
effect of ATT on reducing mortality or on care home use by the person with dementia. Ethnographic
findings illustrate how ATT provision could, nonetheless, provide participants, especially caregivers,
with a sense of security or ‘peace of mind’, which they specifically valued, yet could also pose other
challenges to caregivers.
These findings demonstrate the need to understand specifically how the ATT devices are incorporated
into people’s space and behaviours. Appreciating the specific context is important for fully understanding
how ATT came to work as an intervention. Here, the technology’s ‘effectiveness’ was influenced by
participants’ social relations (e.g. instructing how to use the device) and environment (e.g. in-home object
placement, other occupants). This emphasises the need for complementary studies on the effectiveness of
ATT as an intervention, while also appreciating the ways in which people with dementia and caregivers
make sense and work to include these devices within their care practices and other arrangements.
Technology takes up space on a person or in their home; this requires people to make choices about
whether or not and how it fits on people’s bodies and in domestic spaces. As the findings illustrated,
these choices come packaged with value judgements about what care practices and interventions people
find suitable in their everyday routines for people living with dementia in the community. People with
dementia, caregivers and care workers may often contest the suitability of ATT, and extent to which they
allow ATT to intervene in their lives.
The diverse range of experiences of living with dementia and caring for a person with dementia, and
the wide variety of different ATT devices available through local authorities and on the consumer
market, make it difficult to understand what may make ATT an appropriate and effective intervention
for community-based dementia care. Individual caregivers and people with dementia may find that a
specific ATT product helps them to manage their specific care responsibilities or ADL. Yet, these may
be time bound, as care needs can rapidly fluctuate as a person experiences further limitations owing to
their dementia progression, and there are fresh challenges for caregivers to negotiate, emphasising the
need to incorporate a review process in providing ATT in dementia care.
Limitations
There was great variation across sites in the assessment and provision of ATT, and the study was not
powered or intended to examine the impact of local configurations of ATT. The trial was designed to
embrace the heterogeneous nature of local ATT assessment and equipment provision for people with
dementia. As discussed in Chapter 3, the way in which ATT was delivered locally varied considerably:
two types of value networks were found to be operating in our relatively small sample of local
authority areas. A mixture of models of providing and financing ATT was encountered across trial sites.
The extent to which councils and providers charged user fees varied depending on the nature of local
markets and on the needs profiles of ATT users. The extent of information on locally available ATT
services and charges is limited in the UK; most ATT services, including ASCDs, charge fees.161 We did
not investigate the impact of deficiencies in service information or the presence of user charges,
although such barriers might have affected the uptake of ATT and reduced the use of potentially
beneficial devices.
Delivery systems were investigated and described as planned (see Chapter 3 and Appendix 2), but it
proved difficult to collect data from sites in a consistent manner sufficient to calculate a unit cost of
ATT. The unit costs of ATT devices, installation, monitoring and response were drawn from databases
of prices set by public sector procurement frameworks. This approach allowed a realistic costing of
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ATT services and equipment provided by the public sector (e.g. in comparison to pricing devices via
telecare providers’ and online technology retailers’ websites); prices paid for ATT devices and services
by private individuals might be higher, and so ATT costs, which made up a very modest proportion of
participants’ total costs, might have been somewhat higher. Because control participants were also in
receipt of at least a basic ATT package over the course of the study, their costs could equally be higher
and differences in costs between groups little affected overall. We explored the feasibility of collecting
providers’ data on ATT devices used by participants; however, as the study was not resourced to
negotiate data-sharing arrangements with all the providers involved, we relied on researcher-collected
technology checklist data.
The CSRI was reliant on participant recall, which may have affected the precision and size of cost
estimates. Costs were measured by asking caregivers to retrospectively report service use, so the
results could be subject to recall bias. Costs of the intervals between periods with CSRI data available
were estimated by carrying forward most costs, although costs of inpatient and emergency department
use were estimated from the SAE data available over these times. Costs of regularly used services
were thus assumed to be constant over these intervening periods. Participant-reported EQ-5D data
were missing for one-quarter of intervention participants and for one-third of control participants who
had participated in assessments at 104 weeks. Although difference-in-difference analyses controlled for
baseline covariates (stratification variables and dependency, as measured by the BADLS) that might have
accounted for differences in data availability between groups on this measure, QALY analyses drew on
group mean utilities at each time point and did not adjust for baseline characteristics. Therefore, the
finding that the intervention group had fewer QALYs derived from participant-reported EQ-5D data must
be interpreted with some caution, as substantial numbers of missing data in that measure could be a
concern. Generalisability of these findings may also be limited because all assessment data were missing
from some participating dyads at the baseline and follow-up points (8% of the sample at baseline and
between 16% and 19% of the community-dwelling sample still participating in the study over the
follow-ups did not participate in an interview).
Future research
An official national collection of data on local authority ATT provision, the size of contracts with
provider partners and total expenditure and unit costs would shed light on the variety of delivery and
financing models in place, and the relationship with expenditure. A study on the nature and size of the
private ATT market (including internet of things and smart home applications) would shed light on the
relative importance of public and private sectors in ATT provision.161
An observational study of telecare for dementia could be designed, which could employ a larger sample
than would be achievable with an experimental design, and observe longer and continuous durations
of service use. Such research could also identify processes and mechanisms of implementation
(procurement, clinical and care decision-making, maintenance of technologies, call centre activities, etc.)
of ATT in health and care systems to support people with dementia. If routine data from health and
social care providers could be linked162 to telecare providers’ data, further research could examine
associations between ATT (activations and device types) and hospital and care home admissions.
Implications
This study found that a full package of ATT did not result in a significant increase in the length of time
a person with dementia can remain living in the community, nor did it achieve decreases in caregiver
burden, depression or anxiety. The findings of Chapter 3 suggest that providers of assessments and
providers of ATT do not always work in tandem. Work to understand why local delivery systems were
producing such mismatches should be conducted with local authorities, not-for-profit providers and the
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NHS in England. Meanwhile, the use of ATT that extend beyond basic devices (including pendant
alarms) as support for people with dementia should not be unconditionally adopted and should be
subject to the same rigorous evaluation as other interventions. However, ATT recommended on the
basis of need and installed and used as intended might be very useful for people with dementia and
their caregivers. Designers and service provider organisations should work with caregivers and people
with dementia and their advocates to co-produce suitable technological interventions. Alternatives to
technological solutions to difficulties should also be actively sought.
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NIHR Journals Library www.journalslibrary.nihr.ac.uk
82
Acknowledgements
The ATTILA trial triallists group
Writing Committee
Rebecca Gathercole, Catherine Henderson, Rosie Bradley, Anna Davies, Shashivadan Hirani,
Stefano Brini, Stanton Newman, Kirsty Forsyth, Matthew Lariviere, Chris Fox, Fiona Poland,
Martin Knapp, Iracema Leroi, John Woolham, Richard Gray and Robert Howard.
Data Monitoring Committee
Professor Ian McKeith, Institute for Ageing and Health, Newcastle University (chairperson);
Professor James Lindesay, Department of Health Sciences, Leicester University Hospitals NHS Trust;
and Dr Tracey Young, School of Health and Related Research, University of Sheffield.
Trial Steering Committee
Dr Peter Bentham, The Barberry Centre, Birmingham and Solihull Mental Health NHS Foundation
Trust (chairperson); Dr Louise Brown, Medical Research Council Clinical Trials Unit at University
College London; and Mrs Gillian Harrison and Mrs Sue Tucker, Service User Representatives,
Alzheimer’s Society.
Trial Management Group
Rebecca Gathercole, Emma Harper, Linda Kelly, Natalie Lam, Lynn Pank, Rosie Bradley and
Richard Gray and Robert Howard.
Health Economics
Catherine Henderson and Martin Knapp (London School of Economics and Political Science).
Participating centres
South London and Maudsley NHS Foundation Trust: Robert Howard (principal investigator),
Rebecca Gathercole, Heather Westwood, Bethany Scutt and Grace Lavelle.
Cambridge Community Services NHS Trust, Cambridgeshire and Peterborough NHS Foundation
Trust, Cambridge University Hospitals NHS Foundation Trust: John O’Brien (principal investigator),
Andrew Bateman (principal investigator), Rachel Winson, Samantha Nunn and Victoria Ordonez Montano.
Oxford and Buckinghamshire Mental Health NHS Foundation Trust: Rupert McShane (principal
investigator), Sarah-Jane Cellan-Jones, Marni Moran and Rowena Johns.
Norfolk and Suffolk NHS Foundation Trust: Chris Fox (principal investigator) and Emma Talbot.
Lancashire Care NHS Foundation Trust: Iracema Leroi (principal investigator) and Emma Hooper.
Nottinghamshire Healthcare NHS Foundation Trust: Dr Anand Ramakrishnan (principal investigator)
and David Trevor.
South West Yorkshire Partnership NHS Foundation Trust: Seelam Kalyan (principal investigator),
Lubena Mirza and Amber Hemmingway.
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
83
Contributions of authors
Rebecca Gathercole (https://orcid.org/0000-0002-6380-2655) (Trial Manager, Old Age Psychiatry) ran
the trial, contributed to the paper, interpreted the data and wrote the initial draft paper.
Rosie Bradley (https://orcid.org/0000-0002-0758-4905) (Medical Statistician, Medical Statistics)
analysed the survival data, contributed to the paper, interpreted the data and wrote the initial
draft paper.
Emma Harper (https://orcid.org/0000-0001-5651-6258) (Clinical Trials Co-ordinator, Population
Health) ran the trial.
Lucy Davies (https://orcid.org/0000-0001-6632-7215) (Medical Statistician, Medical Statistics)
analysed the survival data.
Lynn Pank (https://orcid.org/0000-0001-6398-6565) (Administrative Assistant, Medical Statistics) and
Natalie Lam (https://orcid.org/0000-0001-8591-444X) (Data Manager, Medical Statistics) provided
data management support and data entry at the Clinical Trials Unit.
Anna Davies (https://orcid.org/0000-0003-0743-6547) (Senior Research Associate, Health
Psychology) analysed the caregiver outcome data, contributed to the paper, interpreted the data and
wrote the initial draft paper.
Emma Talbot (https://orcid.org/0000-0002-7614-9683) (Research Practitioner, Mental Health
Research), Emma Hooper (https://orcid.org/0000-0002-4059-6035) (Research Practitioner, Mental
Health Research), Rachel Winson (Research Practitioner, Mental Health Research), Bethany Scutt
(https://orcid.org/0000-0003-0456-2556) (Research Worker, Old Age Psychiatry), Victoria Ordonez
Montano (https://orcid.org/0000-0002-3500-1922) (Research Practitioner, Mental Health Research),
Samantha Nunn (https://orcid.org/0000-0002-2853-9652) (Research Practitioner, Mental Health
Research) and Grace Lavelle (https://orcid.org/0000-0003-3768-1797) (Research Worker, Old Age
Psychiatry) recruited and retained participants.
Matthew Lariviere (https://orcid.org/0000-0001-6901-3115) (Research Fellow, Anthropologist of
Care, Ageing and Technology) designed and analysed the ethnographic study.
Shashivadan Hirani (https://orcid.org/0000-0002-1577-8806) (Senior Lecturer, Health Services
Research) and Stefano Brini (https://orcid.org/0000-0002-1909-1796) (Research Fellow, Health
Services Research and Management) analysed the caregiver outcome data and contributed to
the paper.
Andrew Bateman (https://orcid.org/0000-0002-2547-5921) (Clinical Manager, Neuropsychological
Rehabilitation), Peter Bentham (https://orcid.org/0000-0002-6443-3353) (Consultant, Psychiatry),
Alistair Burns (https://orcid.org/0000-0002-9837-0645) (Professor, Old Age Psychiatry) and
Barbara Dunk (https://orcid.org/0000-0002-6363-5009) (Senior Occupational Therapist, Older Adult
Memory Services) were principal investigators.
Kirsty Forsyth (https://orcid.org/0000-0002-6732-1699) (Professor, Occupational Therapy) analysed
the needs assessment data and contributed to the paper.
Chris Fox (https://orcid.org/0000-0001-9480-5704) (Clinical Professor, Psychiatry) designed and
analysed the ethnographic study, contributed to the paper and was a principal investigator.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
84
Catherine Henderson (https://orcid.org/0000-0003-4340-4702) (Assistant Professorial Research
Fellow, Health Policy) analysed the health economic data, contributed to the paper, interpreted the
data and wrote the initial draft paper.
Martin Knapp (https://orcid.org/0000-0003-1427-0215) (Professor of Social Policy, Health Policy)
analysed the health economic data and contributed to the paper.
Iracema Leroi (https://orcid.org/0000-0003-1822-3643) (Professor, Psychiatry in Ageing and
Dementia) contributed to the paper and was a principal investigator.
Stanton Newman (https://orcid.org/0000-0001-6712-6079) (Professor, Health Psychology) analysed
the caregiver outcome data and contributed to the paper.
John O’Brien (https://orcid.org/0000-0002-0837-5080) (Professor, Old Age Psychiatry) was a
principal investigator.
Fiona Poland (https://orcid.org/0000-0003-0003-6911) (Professor, Social Research Methodology)
designed and analysed the ethnographic study and contributed to the paper.
John Woolham (https://orcid.org/0000-0003-3128-7756) (Senior Research Fellow, Social Care
Research) designed the trial and contributed to the paper.
Richard Gray (https://orcid.org/0000-0003-4440-574X) (Professor, Medical Statistics) designed and
ran the trial, analysed the survival data, contributed to the paper, interpreted the data and wrote the
initial draft paper.
Robert Howard (https://orcid.org/0000-0002-3071-2338) (Professor, Old Age Psychiatry) designed
and ran the trial, contributed to the paper, was a principal investigator, interpreted the data and wrote
the initial draft paper.
All authors assume responsibility for the accuracy and completeness of the data and for the overall
content and integrity of the paper.
Publications
Leroi I, Woolham J, Gathercole R, Howard R, Dunk B, Fox C, et al. Does telecare prolong community
living in dementia? A study protocol for a pragmatic, randomised controlled trial. Trials 2013;14:349.
Forsyth K, Henderson C, Davis L, Roy AS, Dunk B, Curnow E, et al. Assessment of need and practice
for assistive technology and telecare for people with dementia – The ATTILA (Assistive Technology and
Telecare to maintain Independent Living At home for people with dementia) trial. Alzheimers Dement
2019;5:420–30.
Howard R, Gathercole R, Bradley R, Harper E, Davis L, Pank L, et al. The effectiveness and cost-effectiveness
of assistive technology and telecare for independent living in dementia: a randomised controlled trial.
Age Ageing 2021:afaa284.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
available anonymised data may be granted following review.
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
85
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to
make better use of information from people’s patient records, to understand more about disease,
develop new treatments, monitor safety, and plan NHS services. Patient data should be kept safe
and secure, to protect everyone’s privacy, and it’s important that there are safeguards to make sure
that it is stored and used responsibly. Everyone should be able to find out about how patient data
are used. #datasaveslives You can find out more about the background to this citation here:
https://understandingpatientdata.org.uk/data-citation.
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Appendix 1 Costing the intervention
The ATTILA trial: proposal for costing the assistive technology and
telecare intervention
In this appendix, we set out the proposed plan of methods to calculate the costs of providing the ATT
intervention, written while the trial was still in progress. The proposal begins with an overview of
the trial as a whole and of the economic evaluation in particular, and lists the data collections that
supported the economic evaluation. The costs that we proposed to collect are then summarised, and
the methods for these data collections are outlined.
Trial overview
The ATTILA trial is evaluating the impacts of ATT on people with dementia and their carers. ATT is
defined for the purposes of the trial as ‘simple, battery-operated, standalone technologies and/or
telecare (a range of devices and sensors that communicate and relay messages to an external call
centre where an appropriate response is arranged)’ (see Additional interviews and correspondence to
support the economic evaluation: sample selection and recruitment of key informants). The trial is designed
as a pragmatic RCT. Participants randomised to the intervention will receive an ATT needs assessment,
followed by the installation of ATT devices and response services deployed by the host local authority,
in addition to usual health and social care services. Control group participants will receive an ATT needs
assessment followed by a package of ATT that is limited to smoke/carbon monoxide detectors and
pendant alarms, in addition to usual health and social care services. Thirteen sites in England (Lambeth,
Southwark, Croydon, Lancashire, Oxford, Suffolk, Norfolk, Cambridgeshire, Nottingham, Blackpool,
West Sussex, Barnsley and Blackburn) are currently involved in the trial. As the trial design is pragmatic,
all aspects of the intervention (ATT assessment, choice of devices, or ordering and installation of
devices) are determined by staff from the participating local authorities or telecare providers.
Economic evaluation activities
The economic evaluation will investigate service use and costs associated with the introduction of the
ATT intervention, and examine the relationship between service costs and other impacts. The co-primary
trial outcomes are (1) time, in days, from randomisation to institutionalisation and (2) cost-effectiveness
of the ATT intervention. The economic evaluation addresses the second outcome. The methods of the
cost-effectiveness analysis described in the trial protocol (see Additional interviews and correspondence to
support the economic evaluation: sample selection and recruitment of key informants) are summarised in Box 1.
Trial data collections
Current data collections include:
l Participants and their identified carers will be visited by study research assistants to complete a
battery of questionnaires covering self-reported quality of life, acceptability of the technology, ATT
in situ (using a technology checklist) and service use and costs (using the CSRI44). These visits will
take place at five time points: baseline and 12, 24, 52 and 104 weeks thereafter. Questionnaire
packs will be sent to the Oxford Clinical Trials Service Unit for data entry or data will be entered
directly into an electronic database.
l Data on ATT assessments are gathered by Kirsty Forsyth. Forms completed by assessors in order to
recommend a package of ATT are rated against the MOHOST.
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Proposed methods for calculating the costs of the assistive technology and
telecare intervention
In this section, we set out options for collecting information sufficient to describe, measure and value
the ATT intervention.
In the ATTILA trial, there is no funding provided alongside the trial for ATT equipment and there is
no definitive list of ATT equipment to be provided across sites. ATT packages provided to ATTILA
trial participants are likely to be highly heterogeneous across and between sites. It will be necessary
to describe those packages to understand the relationship between participant outcomes and the
intervention, but we face considerable challenges in collecting these data. Local authority budgets
are under great pressure and the team is aware of the resultant constraints on frontline and senior
management staff time.
We propose to calculate the ATT intervention costs as follows:163,164
l We will describe the interventions in terms of typical resource inputs and associated activities. This
will entail creating descriptions of the organisations involved in producing the ATT intervention,
including details of staffing and overheads.
l We will calculate a relevant service unit, in this case the weekly per-person cost of the intervention.
l We will collect cost data. Several elements make up the total cost of an ATT package –
¢ Costs of ATT needs assessment.
¢ Assessment costs will be calculated based on attaching a per-minute staff cost (including
relevant overheads) of local authority and NHS staff to the estimated length of time spent
in carrying out and writing up ATT assessments, including travel time, and allowing for travel
costs. Data on average length of ATT assessments will be sought from key informants.
Some providers may be able to make use of routinely collected data on time spent in ATT
assessment, whereas others may provide their best estimate through less formal means.
BOX 1 Methods of cost-effectiveness analysis
Cost-effectiveness of the ATT intervention: costs related to the use of ATT, health-care and other service
use patterns and (unpaid) caregiver inputs will be calculated for each participant using a modified version
of the CSRI.
The cost-effectiveness analyses will be of two types, each conducted from two perspectives: (1) health and
social care, and (2) societal, whereby the first type will measure costs only up to the point that a trial
participant goes into a care home or hospital, and not beyond (‘community costs’), and then examine
cost-effectiveness in achieving the primary outcome (days from randomisation to institutionalisation in the
2-year period). This analysis will show the incremental cost of community-based support of each additional
institutional day avoided. The second analysis type will measure costs for the whole 2-year period, including
costs of care home and hospital stays (‘total costs’), and then examine cost-effectiveness for which the
outcome is change in EQ-5D score, over the 2-year period.
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¢ ATT service and equipment costs.
¢ Costs of equipment.
¢ Monitored equipment: ideally, sites will be able to provide lists of equipment used by
each participant so that prices can be attached to establish their costs. The appropriate
data-sharing agreements must be in place with the ATTILA trial team at KCL prior to
requesting such lists. Price lists of standalone and networked equipment will be sought
from the appropriate organisation or obtained from publicly available lists, where
these exist.
¢ Standalone equipment as (a).
¢ Costs of ATT support.
¢ Costs to the local authority. We would expect that a unit cost of a telecare package
would comprise:
¢ costs of installation, routine maintenance and upgrading of equipment
¢ call centre infrastructure – operators’ staff costs (and on-costs), capital, premises and
administrative overheads
¢ Response-related costs.
¢ Costs of any contracts with response service dedicated to telecare.
¢ Other responders, for example emergency services – this information will be partly
captured via CSRI (responses reported within the 3 month retrospective period). To
avoid double-counting, these costs will be for the most part estimated by weighting
units of service use as reported in the self-completed CSRI by unit costs from the
PSSRU Unit Costs.165
¢ Costs to carers.
¢ Carers’ time spent responding to ATT-related sensor and other alerts can be captured
via the CSRI question on time spent in caring tasks such as supervision (responses
reported within the 3-month retrospective period).
The exact strategy for costing these elements is dependent on the extent of available financial and
activity information from sites. Ideally, key informants in each site would be able to provide budgetary/
expenditure and activity data for use in calculating the unit cost of an ATT package. However it would
also be acceptable to use a unit cost of a telecare package if the site has already made that calculation.
We will calculate a unit cost for the intervention.
The methods required to make this calculation again depend on the availability of financial or local
authority -calculated unit cost data, of already established unit costs, and of equipment data. The total
ATT package cost will be calculated by summing the costs of ATT assessment, telecare and standalone
devices, and telecare support services.
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The cost of the ATT assessment and of a telecare support package will be estimated at the site level; that
is, all participants in that site would be considered to have incurred the same cost for these elements of
the intervention. Networked and standalone devices should be available for each participant and the
costs will be unique to that participant. In the case that providers cannot or decline to assemble a list
of equipment provided, prices will be assigned to devices as recorded on the technology checklist
administered to participants, and costs estimated on this basis.
Proposed new data collections relevant to the economic evaluation
As a first step in the proposed costing strategy, we devised a pro forma (see Appendix 2) to support a
desk-based review of ATT assessment and provision processes in each site. The pro forma was devised
by the economic evaluator and completed in co-operation with the researchers at Queen Margaret
University, Edinburgh, the ATTILA trial project manager and the study’s local researchers, who are
embedded in each site. In this pro forma are listed any relevant documents already shared by the sites
with the project team, brief descriptions of the processes for ATT assessment and provision already
known to the local researchers in the execution of their role and suggestions for potential local key
informants (e.g. operational managers, commissioners and managers of telecare providers). We now
wish to proceed with collecting information from the following personnel in participating sites:
l Local authority operational managers – operational managers will probably have an overview of the
mechanisms in place in their site for assessment and referral for ATT. These managers may also be
able to advise on whether or not their local authority databases encompass telecare and standalone
equipment records.
l Local authority commissioners of telecare – it is likely that the commissioners of telecare have
information on the cost of telecare services within their local authority (including situations in which
all telecare provision is contracted out), they may have calculated a unit cost of telecare for their
local authority, and might be able to provide equipment price lists.
l Managers of telecare providers – it is likely that the providers of telecare have information on their
own staff costs, premises, costs of installation/de-installation and maintenance if provided, also
server costs and database maintenance. The managers would be able to advise on whether or not
their databases contain records of the telecare equipment in place and might be able to provide
equipment price lists.
Proposed activities
l Seek NHS Research Ethics Committee permission for interviews with key informants.
l Local researchers to provide the economic evaluator with a set of current contact details for
potential key informants, with their permission:
¢ local authority operational/middle managers in adult services
¢ local authority commissioners of telecare
¢ telecare providers managers.
l Researchers from the project team to set up and carry out interviews with key informants in each
site (after Research Ethics Committee approval). Contact to be made by e-mail or telephone and a
list of the relevant questions sent to the potential participants, who can then decide whether or not
to participate. Interviews to be carried out via site visits or over the telephone. Interviews will not
be recorded but handwritten notes will be taken.
l Project team to request relevant budget/expenditure data from key informants (local authority and
telecare providers’ managers).
l Project team to update data-sharing agreements as required prior to requesting participants’
equipment data from relevant local authority and telecare providers; project team to establish
procedures for transferring these data to the project team.
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Additional interviews and correspondence to support the economic
evaluation: sample selection and recruitment of key informants
Recruitment targets for key informants
Cross-
reference Participants Numbers Nature of contact Time taken Information sought
Figure 18 Local authority
commissioners
of telecare




Costs of telecare services





Figure 19 Local authority
operational
managers






Mechanisms in place for
assessment and referral








Table 38 Managers of
telecare
providers




















a The exact number depends on whether or not the means of delivery varies considerably from district to district
within each site.
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motivation put them at
risk when doing daily
activity?
Does the person’s insight









If no . . . choose
either:
l 4, no risk, OR
l 3, mostly risk free
If yes . . . choose
either:
l 2, some risk OR
l 1, significant,
multiple risks
Does what is important to
the person put them at
higher or lower risk?
Choices
Do the person’s routines
and responsibilities put
them at risk when doing
daily activity?
Do the person’s routines










place them at risk when
doing daily activity?
Does the person’s ability to
have a conversation put




Does the person’s ability to
express their needs put




cognitive skill place them
at risk when doing daily
activity?
Does memory and
understanding of how to do
things put the person at
higher/lower risk?
Knowledge Process skills
Does the ability to problem





physical skill place them
at risk when doing daily
activity?
Does the person’s mobility





Does the person’s grip/




Do the features of the
physical environment put
the person at risk when
doing daily activity?
Does the person’s physical




Does the persons physical




Does who is involved
and how activities are
completed put the
person at risk when
doing daily activity?
Does the support available




Does the way the person
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Motivation
ATTILA trial sites’ questions Score ATT needs scale
Key question: Does the person’s motivation put them at risk when doing daily activity?
Insight
Does the person’s insight put them at higher/lower
risk?
l Has service user insight and ability to activate a
pendant alarm if requiring assistance e.g. if they
have a fall?
l What is the extent to which the service user is
able to be involved in the telecare process?
l Was the assessment carried out jointly with the
service user?
l If the person has a history of falls, or has poor
mobility, do they avoid mobilising because they
lack confidence in their ability to do so safely?
l If the person lacks confidence in their physical
skills, what attempts have been made to date to
address this?
4 Accurately assesses own capacity, recognises
strengths, aware of limitations. No risk when doing
daily activity because the person is mostly doing
activities within their ability (appropriately
confident), mostly has insight to activate ATT if
required, has involvement in ATT process
3 Reasonable tendency to over/underestimate own
abilities, recognises some limitations. Mostly risk free
when doing daily activity, the person is mostly doing
activities within their ability (appropriately confident),
mostly has insight to activate ATT if required, has
involvement in ATT process. Difficulty understanding
strengths and limitations without support
2 Some risk when doing daily activity related to
the person being overconfident (thinking they
have the ability to do activity when they do not),
underconfident (can do the activity but do not think
they can), difficulty knowing to activate ATT owing to
some lack of insight, difficulty being involved in ATT
process. Does not reflect on skills, fails to realistically
estimate own abilities
1 Significant multiple risks when doing daily activity
due to no insight into their lack of ability to safely do
everyday activity (may appear overconfident), lacks
confidence to do activities leading to risks, lack
insight to activate ATT if required, not able to be
involved in ATT process
Values
Does what is important to the person put them at
higher or lower risk?
l Has what is important to the service user been
considered in the assessment process, including
discussion of options available?
l Are there domestic or other tasks, which the
service user has identified as important which
they are currently unable to carry out, for which
ATT would be helpful? This may require a
functional assessment. Does the service user find
the ATT suggested acceptable to their lifestyle,
including cultural considerations? Can the
deployment of ATT be in keeping with the service
user needs, e.g. weighing up the consequences of
not using ATT compared with using it?
l Did user request support, and if so for
what purpose?
l Has the service user/carer been able to trial a
device prior to making a final decision?
l Is the service user willing to explore or trial ATT
options before a longer-term option is agreed?
l Is the service user willing to take medication
and/or use a medication reminder?
4 Clear preferences and sense of what is important,
motivated to work towards occupational goals. No
risk when doing daily activity, the person’s skills
matches what they think is really important to do,
they have things that are important to them and are
active, support is acceptable to them, willing to
explore options
3 Mostly able to make choices, may need
encouragement to set and work towards goals.
Mostly risk free when doing daily activity, the
person’s skills mostly match what they think is really
important to do, they have some things that are
important to them and are mostly active, support is
marginally acceptable to them but they feel it is
important to be independent, reluctantly willing to
explore options, that is they do not want ugly
equipment as they are house proud.
2 Difficulties identifying what is important or setting
and working towards goals, inconsistent. Some risk
when doing daily activity because the person’s skills
do not always match what they think is really
important to do, some things are important to them
but can be passive, support is marginally acceptable to
them but they feel it is important to be independent,
reluctantly willing to explore options, that is they do
not want ugly equipment as they are house proud
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ATTILA trial sites’ questions Score ATT needs scale
1 Cannot set goals, impulsive, chaotic, goals are
unattainable or based on antisocial values. Significant
multiple risks when doing daily activity because the
person’s skills do not match what they think is really
important to do; nothing important to them, leading
to passivity; support is not acceptable to them as
they feel that it is important to be independent; not
willing to explore options, that is they do not want
ugly equipment as they are house proud
Routine
ATTILA trial questions Score ATTILA trial scale
Key question: Do the person’s routines and responsibilities put them at risk when doing daily activity?
Wandering/disorientation
Do the person’s routines put them at higher/lower
risk?
l What are the service user’s daily practices e.g.
times and day(s) of the week spent shopping,
visiting friends and family, attending day centre?
State times that user is alone, usual sleep
pattern, etc.
l Are there risks associated with user’s routines,
e.g. smoking, abusing alcohol, drugs?
l Is there a lack of understanding of routines
and risks? Are there concerns with regards to
‘wandering’, disturbances to day/night activity
levels, food preparation?
l Are there any behavioural routines such as
restlessness, periods of agitation, verbal or
physical aggression or passivity?
l Does the service user sleep in a bed or chair,
and in which room?
l Does the service user get up during the night?
Is the reason for this known (how much activity
during the day, usual routine, going to the toilet,
medication for sleeping)?
l How often do they get up? What happens
when they get up (do they go back to bed or
get disorientated)?
l Does the service user turn on lights as needed
during the night?
l Is the service user at risk of becoming lost if
leaving their property alone? Specify related
history, including night/day, frequency, regular
destinations and patterns
4 Able to arrange a balanced, organised and productive
routine of daily activates. No risk when doing daily
routine, for example productive routine, no
wandering, balance of sleeping at night and
productive activity during day, up at night but able to
go back to bed, calm settled routine
3 Generally able to maintain or follow an organised
and productive daily schedule. Mostly risk free when
doing daily routine including sporadic wandering,
disturbance in day/night activity levels, getting up
at night and become disoriented, kitchen routines
not effective, periods of restlessness, periods of
agitation/aggression
2 Difficulty organising balanced, productive routines of
daily activities without support. Some risk when
doing daily routine including some wandering,
disturbance in day/night activity levels, getting up
at night and become disoriented, kitchen routines
not effective, periods of restlessness, periods of
agitation/aggression
1 Chaotic or empty routine, unable to support
responsibilities and goals, erratic routine. Significant
multiple risks when doing daily routines including
wandering, disturbance in day/night activity levels,
getting up at night and become disoriented, kitchen
routines not effective, periods of restlessness,
periods of agitation/aggression
Daily activity
Do the person’s responsibilities put them at higher/
lower risk?
l Specify the service user’s chosen responsibilities
identified as important for their wellbeing,
including leisure, domestic and other activities.
l Does the service user bath/shower independently?
l Can the service user cook, bathe, dress/undress,
shop unaided, do they need help, or are they
unable to do these things safely?
4 Reliably completes activities and meets the
expectations related to role obligations. No risk
when doing daily responsibilities, for example
including managing medication, safely doing their
cooking, able to safely make a hot drink/snack, safely
bathe/dress
3 Copes with most responsibilities, meets most
expectations, able to fulfil most role obligations.
Mostly risk free when doing daily responsibilities
including sporadic difficulties with managing
medication, safely do their cooking, make a hot
drink/snack, safely bathe/dress
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ATTILA trial questions Score ATTILA trial scale
l Can they manage medication safely, i.e. not
overdosing and reliability (not forgetting)?
2 Difficulty being able to fulfil expectations and meet
role obligations without support. Some risk related
to doing daily responsibilities including difficulties
managing medication, difficulty to safely do their
cooking, make a hot drink/snack, difficulty to safely
bathe/dress
1 Limited ability to meet demands of activities or
obligations, unable to complete role activities.
Significant multiple risks doing daily responsibilities,
for example cannot manage medication, cannot safely
do their cooking, make a hot drink/snack, cannot
safely bathe/dress
Communication
ATTILA trial questions Score ATTILA trial scale
Key question: Does the person’s communication skill place them at risk when doing everyday things?
Conversation
Does the person’s ability to have a conversation put
them at higher or lower risk?
l Would the service user be able to communicate
reliably via the lifeline and/or will they
confabulate e.g. if their fire alarm goes off, saying
there is not fire, when there is?
l Is the service user able to verbally communicate
their needs effectively?
l Have the service user and carer been able to
discuss different ATT options?
l Would the service user be able to communicate
through the lifeline unit without becoming
disorientated, considering communication and
cognitive issues?
l Is the service user able to use a telephone
appropriately? Is this a picture or standard phone?
4 Appropriately initiates, discloses and sustains
conversation (clear/direct/open). Mostly risk
free when doing daily activity as a result of no
confabulation, able to communicate their needs,
ability to use a telephone or lifeline unit without
becoming disorientated in conversation
3 Generally able to use language or signing to
effectively exchange information. Mostly risk
free when doing daily activity owing to limited
confabulation, mostly able to communicate their
needs, mostly able to use a telephone or lifeline unit
without becoming disorientated in conversation
2 Difficulty initiating, disclosing or sustaining
conversation (hesitant/abrupt/limited/irrelevant).
Some risk when doing daily activity owing to some
confabulation, only able to communicate some of
their needs, some ability to use a telephone or lifeline
unit without becoming disorientated in conversation
1 Uncommunicative, disjointed, bizarre or inappropriate
disclosure of information. Significant multiple risks
when doing daily activity owing to confabulation,
unable to communicate their needs, unable to use
a telephone or lifeline unit without becoming
disorientated in conversation
Express needs
Does the person’s ability to express their needs put
them at higher or lower risk?
l Does the service user have speech impairment?
Specify how this would impact on ATT, and what
adaptations and response procedures would be
required to support the user?
l Has the ability to express themselves
verbally limited?
4 Assertive, articulate, uses appropriate tone, volume
and pace. Mostly risk free when doing daily
activity owing to no speech impairment, no word
substitutions, no stammering, adequate vocabulary
3 Vocal expression is generally appropriate in tone,
volume and pace. Mostly risk free when doing daily
activity owing to minimal speech impairment, minimal
word substitutions, minimal stammering, mostly
adequate vocabulary
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ATTILA trial questions Score ATTILA trial scale
l Is there a family member/carer usually present in
the property, who can communicate on behalf of
the service user?
l What is the service user’s preferred language?
Do they speak another language? Specify if
special arrangements, including a language line,
are required
2 Difficulty with expressing self (mumbling/pressured
speech/monotone). Some risk when doing daily
activity owing to speech impairment, as there are
word substitutions for words that sound the same,
stammering, function of items described rather than
the names of items, limited vocabulary
1 Unable to express self (unclear/too quiet or loud/too
fast or too passive). Significant multiple risks when
doing daily activity owing to speech impairment, an
inability to express their needs, incomplete sentence
structure, mute, speak in another language only
Cognitive skills
ATTILA trial questions Score ATTILA trial scale
Key question: Does the person’s cognitive skill place them at risk when doing everyday things?
Memory
Does memory and understanding of how to do things
put the person at higher/lower risk?
l Would the service user understand and be able to
use a pendant alarm appropriately?
l Would the service user benefit from prompting to
take medication?
l Does the service user have the ability to learn
how to use a medication reminder device?
l Does the service user ever forget to close doors
and windows?
l Does the service user leave external doors open
at the wrong time of day or time of year?
l Is heating system switched on in cold weather by
the service user?
l Is service user able to turn on/off taps
appropriately and remember to turn them off?
l Does the person know how to safely turn on/off
gas cooker and/or other appliances?
l Is there a history of unsafe use of gas or electrical
appliances such as iron marks, covering the heater
up, tampering with controls, cigarette burn marks
or scalding?
l Would the person know how to respond if smoke,
carbon monoxide or other alarms activated?
4 Seeks and retains relevant information, know how
to use tools appropriately. No risk when doing
daily activity inclusive of not needing prompting,
remembering to take medication, remembering to
close doors/turn off taps, aware of how to use
appliances, aware of how to respond to alarms
3 Generally able to seek and retain information and
know how to use tools. Mostly risk free when doing
daily activity inclusive of occasionally needing
prompting, occasionally forgetting to take medication,
occasionally forgetting to close doors/turn off taps,
mostly awareness of how to use appliances, mostly
aware of how to respond to alarms
2 Difficulty knowing how to use tools, difficulty in
asking for or retaining information. Some risk when
doing daily activity inclusive of needing some
prompting, sometimes forgetting to take medication,
sometimes forgetting to close doors/turn off taps,
some awareness of how to use appliances, some
awareness of how to respond to alarms
1 Unable to use knowledge/tools, does not retain
information, asks repeatedly for same information.
Significant multiple risks when doing daily activity
inclusive of needing prompting, forgetting to take
medication, forgetting to close doors/turn off taps,
no awareness of how to use appliances, no
awareness of how to respond to alarms
Problem-solving
Does the ability to problem solve put the person at
higher/lower risk?
l Does the service user let in strangers?
l Does the service user leave water taps running,
leading to flooding?
l Is there a history of service user leaving gas
appliance on unlit?
l Is there evidence or history of burning food or
pans during domestic activities?
l Would the service user know what to do if an
alarm signal was generated, such as the activation
of a smoke detector?
4 Shows good judgement, anticipates difficulties and
generates workable solutions (rational). No risk
when doing daily activity inclusive of never letting in
strangers, always closes doors in winter, never burns
food, no cigarette burn marks, gas use always safe,
no tampering with controls, heating always switched
on in cold weather
3 Generally able to make decisions based on difficulties
that arise. Mostly risk free when doing daily activity
inclusive of rarely letting in strangers, mostly closes
doors in winter, rarely burns food, one or two
cigarette burn marks, gas use mostly safe, minimal
tampering with controls, rarely heating not switched
on in cold weather
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
109
ATTILA trial questions Score ATTILA trial scale
2 Difficulty anticipating and adapting to difficulties that
arise, seeks reassurance. Some risk when doing daily
activity inclusive of sometimes letting in strangers,
sometimes leaving doors open in winter, sometimes
burns food, some cigarette burn marks, some
flooding, sometimes gas left on despite smell,
sometimes tampering with controls, heating
sometimes not switched on in cold weather
1 Unable to anticipate and adapt to difficulties that
arise and makes inappropriate decisions. Significant
multiple risks when doing daily activity inclusive of
letting in strangers, leaving doors open in winter,
history of burning food, cigarette burn marks,
flooding, gas left on despite smell, tampering with
controls, heating not switched on in cold weather
Physical skills
ATTILA trial questions Score ATTILA trial scale
Key question: Does the person’s physical skill place them at risk when doing everyday things?
Mobility
Does the person’s mobility put them at higher/lower
risk?
l Can the service user move around effectively
during their daily routine?
l Does the service user use any mobility aids?
Stick/frame/wheelchair/rails/ramps/stair lifts?
l Is the service user’s mobility around the home
good/poor/requires assistance?
l Is the service user’s ability to negotiate stairs –
good/poor/requires assistance?
l Is the service user’s mobility outside the home –
good/poor/requires assistance?
l Does the service user have a history of falls?
Where and when did these happen? Are the
causes known? What were the causes?
l Has the service user had any falls in the previous
6 months? Have the issues related to this specific
fall been resolved?
l Does the service user have an unsteady gait/
adequate sense of balance? Is the service user
unsteady when reaching for objects e.g. reaching
into cupboards or for mail at the door?
l Is the service user able to remember to use a
mobility aid appropriately?
4 Stable, upright, independent, flexible, good range of
movement (possibly agile). No risk when doing daily
activity as posture and stability adequate, walking
indoors is safe, the person is safe using stairs, safe
walking outdoors, walking is stable enough not to put
person at risk of falls
3 Generally able to maintain posture and mobility in
occupation, independently or with aids. Mostly risk
free when doing daily activity as posture and
stability/balance mostly adequate, walking indoors
is mostly safe, mostly safe using stairs, mostly safe
walking outdoors, mostly walking is stable enough
not to put person at risk of falls
2 Unsteady at times despite any aids, slow or manages
with difficulty. Some risk when doing daily activity
including some poor posture and instability/balance
when walking indoors, some safety issues using stairs,
some safety issues walking outdoors, walks with a
shuffle or a stoop putting person at some risk of falls
1 Extremely unstable, unable to reach and bend or
unable to walk. Significant multiple risks when doing
daily activity owing to poor posture and instability/
poor balance when walking indoors, unsafe using
stairs, unsafe walking outdoors, walks with a shuffle
or a stoop putting person at risk of falls
Grip/dexterity
Does the person’s grip/dexterity put them at higher/
lower risk?
l Does the service user have adequate manual
dexterity, grip, in hand manipulation of
everyday objects?
l Does the person use two hands together to open
packets or jars, spread butter on bread, turn gas
cooker knobs?
l Can the person apply enough pressure to trigger
alarm, if appropriate?
4 Grasps, moves and transports objects securely with
adequate force/speed (possibly strong). No risk
when doing daily activity as grip is adequate, hand
strength is adequate, able to carry hot liquids, able to
use grip when turning on/off domestic appliances,
can operate ATT as required
3 Strength and effort are generally sufficient for most
tasks. Mostly risk free when doing daily activity
as grip is mostly adequate, hand strength mostly
adequate, mostly able to carry hot liquids, mostly
able to use grip when turning on/off domestic
appliances, can mostly operate ATT as required
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ATTILA trial questions Score ATTILA trial scale
l Does the person have enough grip to carry hot
liquid without burning themselves?
l Does the person have enough grip/strength/
dexterity to use the device (e.g., fasten/unfasten
device, pull handle, push button, pull cord)?
2 Has difficulty with grasping, moving, transporting
objects with adequate force and speed. Some risk
when doing daily activity due poorer grip, poorer
hand strength, may drop hot liquids, some challenge
effectively using domestic appliances owing to poorer
grip, difficulty to operate ATT owing to poorer grip
and some limitation in strength
1 Unable to grasp, move, transport objects with
appropriate force and speed (weak/frail). Significant
multiple risks when doing daily activity owing to
poor grip, poor hand strength, drops hot liquids/burn
risk, cannot effectively use domestic appliances
owing to poor grip, cannot operate ATT owing to
poor grip and lack of strength
Physical environment
ATTILA trial questions Score ATTILA trial scale
Key question: Do the features of the physical environment put the person at risk when doing daily activity?
Mobility
Does the person’s physical space put them at higher/
lower risk?
l The general state of repair, including electrics,
heating system, adequate lighting, working
landline, level of safety of gas or electric appliances
l Is there access for emergency responses (note: bolts,
chains, keys left in doors)?
l Are there trip hazards on the property (e.g. rugs,
clutter, cables tidy, pets)?
l Are there risks to service user when entering any
part of the property alone, e.g. stairs, kitchen
or bathroom?
l Are there environmental hazards (e.g. blocked
access, poisonous substances)?
l Is there anything in the vicinity that may interfere
with the operation of the unit?
l Are there any special materials or conditions that
need to be considered when mounting sensors
(e.g. concrete/high ceilings, potential asbestos)?
4 Space affords a range of opportunities, supports and
stimulates valued occupations. No risk when doing
daily activity in the physical space, e.g., clear access,
appropriate flooring, no trailing cables, uses bolts/
chains effectively, good state of repair, good lighting,
safe on stairs, can access rooms
3 Space is mostly adequate, allows daily occupations
to be pursued. Mostly risk free when doing daily
activity in physical space, e.g. occasional low risk
i.e., blocked access, rugs, cables, bolts/chains, poor
state of repair, poor lighting, negotiating stairs,
accessing rooms
2 Affords a limited range of opportunities and curtails
performance of valued occupations. Some risk in
some aspects of the physical space when doing daily
activity, e.g. including blocked access, rugs, cables,
bolts/chains, poor state of repair, poor lighting,
negotiating stairs, accessing rooms
1 Space restricts opportunities and prevents
performance of valued occupations. Significant
multiple risks when doing activity in physical space,
e.g. blocked access, rugs, cables, bolts/chains, poor
state of repair, poor lighting, negotiating stairs,
accessing rooms
Grip/dexterity
Do the persons physical resources put them at
higher/lower risk?
l Does the service user use a gas cooker? Detail the
cooker type e.g. hob, freestanding, servicing
l Is there a bath, walk-in shower, over bath shower
or bathing equipment?
l Are there other appliances in use by the service
user (in the home/outside the home)?
l Does the service user have electrical appliances
such as a kettle, microwave, electric blanket,
toaster, or cooker?
4 Enable occupational goals to be achieved with ease,
equipment and tools are appropriate. No risk when
using appliances/objects to do daily activity, e.g.
appliances are in good repair i.e., electric fire,
cookers, smoke alarm fitted, hot water not a risk
for scalding, bath available and person uses safely,
shower available as required
3 Generally allow occupational goals to be achieved;
may present some obstacles. Mostly risk free when
using appliances/objects to do daily activity, e.g.
mostly appliances are in good repair, that is electric
fire, cookers, smoke alarm fitted, an episode of
excessively hot water/risk of scalding, only bath
available and person mostly uses safely
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ATTILA trial questions Score ATTILA trial scale
l Are there any potential fire hazards as appliances
are in disrepair (e.g. evidence of burns
from cooking)?
l Is there smoke, carbon monoxide or other alarms
already fitted?
l Is the water excessively hot, with potential
for scalding?
l What is the source of hot water (immersion tank,
combi-boiler, back-boiler i.e. behind gas fire, over
sink heater)?
l Risk of fall in night because of lack of night light
2 Impede ability to achieve occupational goals safely,
equipment and tools are inadequate. Some risk in
some aspect of using appliances/objects to do daily
activity, e.g. some appliances are in disrepair and a
fire risk, that is electric fire, cookers, no smoke
alarms, an episode of excessively hot water/risk of
scalding, only bath available and person not safe to
use, no night light when needed
1 Have major impact on ability to achieve occupational
goals, lack of tools lead to high risks. Significant
multiple risks when using appliances/objects to do
daily activity, e.g. appliances are in disrepair and a
fire risk, that is electric fire, cookers, no smoke
alarms, excessively hot water/risk of scalding, only
bath available and person not safe to use, no night
light when needed
Social environment
ATTILA trial questions Score ATTILA trial scale
Key question: Does who is involved and how activities are completed put the person at risk when doing daily activity?
Social support
Does the support available put them at higher/lower
risk?
l Does the service user live alone or with others?
l Is the service user receiving formal care services?
Does the service user have adequate social
support, including medication management?
l Who will remind/assist the service user to use the
device if they need help?
l Has emergency access been agreed (e.g. key safe,
key holding)?
l Are the primary carer’s needs being met?
l Is the service user receiving help from unpaid
carers, e.g. relative’s informal support, and if so,
is anyone able to respond? Would there be any
risks to them? Are they able to respond to sensor
alerts? Are potential responders acceptable to the
service user?
l Would the service user accept an unfamiliar
person visiting in response to an alert?
l Who will be responsible for maintenance?
4 Social groups offer practical support, values and
attitudes support optimal functioning. No risk due to
carer(s) when doing daily activity, e.g. appropriate
family support, carer’s needs being met, carer
available when needed to prompt, provide
emergency access or respond to an alert, accepting
of a non-familiar person, clarity around who
maintains ATT
3 Generally able to offer support but may be some
under or over involvement. Mostly risk free due
to carer(s) when doing daily activity, e.g. mostly
appropriate family support, carer’s needs mostly
being met, mostly carer available when needed to
prompt, provide emergency access or respond to
an alert, mostly accepting of a non-familiar person,
mostly clarity around who maintains ATT
2 Offer reduced support, or detracts from
participation, some groups support but not others.
Some risk due to carer(s) when doing daily activity,
e.g. minimal family support, carer’s needs not fully
being met, minimal carer availability when needed to
prompt, provide emergency access or respond to
an alert, minimal acceptance of a non-familiar person,
lack of clarity around who maintains ATT
1 Do not support participation due to lack of interest
or inappropriate involvement. Significant multiple
risks due to carer(s) when doing activity, e.g. no
family support, carer’s needs not being met, no
carer currently available when needed to prompt,
provide emergency access or respond to an alert,
no acceptance of a non-familiar person, no one to
maintain ATT
APPENDIX 2
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ATTILA trial questions Score ATTILA trial scale
The way the activity is completed
Does the way the person completes activity put them
at higher/lower risk?
l Does the person wear appropriate clothing when
going outdoors?
l Does the person use their gas fire/cooker even
when they are not safe? Is an alternative
available?
l Does the person repeatedly go to toilet at night
without putting the light on and increases risk
of falls?
4 Demands of activities match well with abilities,
interests, energy and time available. No risk due to
the way the activity is being done, e.g. safe when
using an overhead gas grill, safe going to the toilet
at night by putting light on, safe having a night-time
bath, safe using stairs repeatedly in the day, evidence
of wearing shoes/coat outdoors in wet weather
3 Generally consistent with abilities, interest, energy or
time available, may present challenges. Mostly risk
free due to the way the activity is being done, e.g.
mostly safe when using an overhead gas grill instead
of a toaster, mostly safe going to the toilet at night
by putting light on, mostly safe having a night-time
bath, mostly safe using stairs repeatedly in the day,
some evidence of wearing shoes/coat outdoors in
wet weather
2 Some clear inconsistencies with abilities and interest,
or energy and time available. Some risk due to the
way the activity is being done, e.g. can be unsafe
when using an overhead gas grill instead of a toaster,
can be unsafe going to the toilet at night owing to
lack of light, can be unsafe having a night-time bath
when tired, can be unsafe using stairs repeatedly in
the day when physically not able, minimal evidence
of wearing shoes/coat outdoors in wet weather
1 Mostly inconsistent with abilities, construction of
activity is under- or over-demanding. Significant
multiple risks due to the way the activity is being
done, e.g. unsafely using an overhead gas grill instead
of a toaster, unsafely going to the toilet at night
owing to lack of light, unsafely having a night-time
bath when tired, using stairs repeatedly in the day
when physically not able, not wearing shoes/coat
outdoors in wet weather
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Appendix 3 Unit costs table
Variable name
Unit cost
(£, 2016/17) Unit Source Notes/assumptions
Respite and care home use
Private-sector residential
care for older people, cost
of stay
94 Per day PSSRU 2017,43 table 1.2 Includes personal living
expenses
Local authority residential
care for older people, cost
of stay
162 Per day PSSRU 2017,43 table 1.3 Includes personal living
expenses
Private sector nursing
home for older people,
cost of stay
119 Per day PSSRU 2017,43 table 1.1 Includes personal living
expenses
Community health and social care services
GP time, home visit 88 Per visit PSSRU 2017,43 table 10.3b
for costs; PSSRU 2013,165
table 10.3b, for ratios
No information about
home visits in PSSRU
2017.43 Assumed ratio of
clinic-to-home cost per
minute remained the same
and average duration of
visit remained the same as




GP time, home visit 3.7 Per minute PSSRU 2017,43 table 10.3b
for costs; PSSRU 2013,165
table 10.3b, for ratios
No information about
home visits in PSSRU
2017.43 Assumed ratio of
clinic-to-home cost per
minute remained the same
and average duration of
visit remained the same as
given in PSSRU 2013165














9.30 Per consultation PSSRU 2017,43 table 10.2 Per 15.5-minute
consultation. Excludes
qualification costs
Community nursing time 0.73 Per minute PSSRU 2017,43 table 10.1 Assumes AfC band 6





0.73 Per minute PSSRU 2017,43 table 10.1 Assumes average hourly
cost of a member of a
community mental health
team for older people
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(£, 2016/17) Unit Source Notes/assumptions
Nurse (mental health)
time
44 Per contact PSSRU 2017,43 table 12.1 Assumes average visit
duration in community
mental health teams for
older people, 60 minutes
Consultant: psychiatrist
time









59 Per visit PSSRU 2017,43 table 11.2 Excludes qualification




0.98 Per minute PSSRU 2017,43 table 11.2 Excludes qualification
costs. Assumes 1 hour of
client-related work
Physiotherapist 0.72 Per minute PSSRU 2017,43 table 9 Assumes AfC band 61





0.72 Per minute PSSRU 2017,43 table 9 Assumes AfC band 61
NHS occupational
therapist




health team worker for
older people with mental
health problems, per team
member
44 Per contact PSSRU 2017,43 table 12.1 Assumes average visit
duration in community
mental health teams for
older people, 60 minutes
Dietitian 84.85 Per contact NHS reference costs
2016/1742
CHS tab
Home care – average of
independent and social
services
0.44 Per minute PSSRU 2017,43 table 11.6 Face-to-face time: average
cost of private and social
services costs; weighted
average of weekday and
weekend costs
Home care – average of
independent and social
services
13.21 Per contact PSSRU 2017,43 table 11.6 Face-to-face time: average
cost of private and Social
Services costs; weighted
average of weekday and
weekend costs. Assumes
30 minute visit
Cleaner 20 Per visit Internet search. Assumes
2-hour visit




(Canvey Island, UK); carer
support worker
45 Per visit Evaluation of the East
Sussex Carers’ Breaks
Demonstrator Site167
Cost of short break for
carers of 2.5 hours.
Uprated using HCHS Pay
& Prices Index





Optician – office 21.31 Per visit Department of Health and
Social Care, FODO168–170
Cost of a sight test
APPENDIX 3




(£, 2016/17) Unit Source Notes/assumptions












153.88 Per visit NHS reference costs
2016/1742
CHS tab
Day care for older people,
per session
63 Per session PSSRU 2017,43 table 1.4
Day care in NHS facilities,
per attendance
132.23 Attendance NHS reference costs
2016/1742 CHS tab
Day care facilities regular
attendances – elderly
Day care for people with
mental health problems,
per session
34 Per session PSSRU 2017,43 table 2.4
Lunch club 8 Per session Romeo et al.171 Uprated using HCHS Pay
& Prices index
Paramedic visit, see and
treat and refer
181.25 Per attendance NHS reference costs
2016/1742
ASS01: see and treat or
refer
ATT assessment 36 Per working
hour
PSSRU 2017,43 table 9 Assumes the following:
health and social care
assessor is on AfC band 5
(cost per working hour:
£33); specialist ATT
assessor is on AfC band 6
(cost per working hour:
£43); of assessors where
assessor type was known,
70% were health and
social care assessors and









over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172




over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172




over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172
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(£, 2016/17) Unit Source Notes/assumptions




over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172




over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172




over 5 years at 3.5%
discount rate; 3-month









over 5 years at 3.5%
discount rate; 3-month








over 5 years at 3.5%
discount rate; 3-month








over 5 years at 3.5%
discount rate; 3-month








over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172
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(£, 2016/17) Unit Source Notes/assumptions
PIR movement and exit
detectors




over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172




over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172
Telecare base units and
pendants




over 5 years at 3.5%
discount rate; 3-month
cost. Uprated to 2017
prices using CPIH172
Key safes 7 Per item NHC68 Mean price for device
type. Annuitised over
5 years at 3.5% discount
rate; 3-month cost.




2 Per item NHC68 Mean price for device-
type. Annuitised over
5 years at 3.5% discount
rate; three-month cost.




4 Per item NHC68 Mean price for device
type. Annuitised over
5 years at 3.5% discount
rate; 3-month cost.
Uprated to 2017 prices
using CPIH172
Fall detectors 5 Per item NHC68 Mean price for device
type. Annuitised over
5 years at 3.5% discount
rate; 3-month cost.
Uprated to 2017 prices
using CPIH172
Standalone gas detectors 8 Per item NHC68 Mean price for device
type. Annuitised over
5 years at 3.5% discount
rate; 3-month cost.




11 Per item NHC68 Mean price for device
type. Annuitised over
5 years at 3.5% discount
rate; 3-month cost.
Uprated to 2017 prices
using CPIH172
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(£, 2016/17) Unit Source Notes/assumptions
Intercoms 5 Per item NHC68 Mean price for device
type. Annuitised over
5 years at 3.5% discount
rate; 3-month cost.
Uprated to 2017 prices
using CPIH172
Adapted telephones 2 Per item NHC68 Mean price for device
type. Annuitised over
5 years at 3.5% discount
rate; 3-month cost.




Per item NHC68 3-month cost. Uprated to
2017 prices using CPIH172
ATT maintenance 10 Per ATT
package
NHC68 3-month cost. Uprated to





NHC68 3-month cost. Uprated to




24.00 Per item PSSRU 2017,43 table 7.2 Annuitised over 5 years;
3-month cost
Outdoor rail 1.35 Per item PSSRU 2017,43 table 7.2 Annuitised over 10 years;
3-month cost








155.00 Per item PSSRU 2017,43 table 7.2 Annuitised over 10 years;
3-month cost
Perching stool 1.00 Per item PSSRU 2013,165 table 7.3.1 Annuitised over 10 years;
3-month cost. Uprated
using HCHS Pay & Prices
index43
Commode 2.00 Per item PSSRU 2013,165 table 7.3.1 Annuitised over 10 years;
3-month cost. Uprated




4.00 Per item PSSRU 2013,165 table 7.3.1 Annuitised over 10 years;
3-month cost. Uprated
using HCHS Pay & Prices
inflator
Chair/bed raisers 4.00 Per item PSSRU 2013,165 table 7.3.1 Annuitised over 10 years;
3-month cost. Uprated
using HCHS Pay & Prices
index43
All four-wheeled and four-
footed walking frames
9.00 Per item PSSRU 2013,165 table 7.3.1 Annuitised over 10 years;
3-month cost. Uprated
using HCHS Pay & Prices
index43
Bath seat 10.00 Per item PSSRU 2013,165 table 7.3.1 Annuitised over 10 years;
3-month cost. Uprated
using HCHS Pay & Prices
index43
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(£, 2016/17) Unit Source Notes/assumptions
Bed rail 4.00 Per item PSSRU 2017,43 table 7.2 Annuitised over 10 years;
3-month cost. Uprated
using HCHS Pay & Prices
index43
Incontinence pads 88.00 Per 3-month
supply
Uprated from 2011 prices












chapter 4, Hypnotics and
Anxiolytics (section 1),





(section 8), Drugs Used in
Parkinsonism/Related




National average wage –
value of lost work time
16.20 Per hour Annual survey of hours
and earnings66
Gross mean wage for all
employee jobs, 2017
National average wage –
value of lost leisure time
5.67 Per hour Annual survey of hours
and earnings66
35% of gross mean wage
for all employee jobs,
2017
Travel costs
Cost per mile of travel for
carer (car running costs),
per mile
0.16 Per mile Automobile Association175
Ambulance to A&E 247.5 Attendance NHS reference costs
2016/1742


























477.75 Day NHS reference costs
2016/1742
NEL tab
295.42 Excess day NEL_XS tab
Subchapter AB: pain
management
563.14 Day NHS reference costs
2016/1742
NEL tab
507.96 Excess day NEL_XS tab
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(£, 2016/17) Unit Source Notes/assumptions
Subchapter BZ: eyes and
periorbita procedures and
disorders
666.23 Day NHS reference costs
2016/1742
NEL tab
342.52 Excess day NEL_XS tab
Subchapter CB: Ear, nose,
mouth, throat and neck
disorders
521.46 Day NHS reference costs
2016/1742
NEL tab




402.23 Day NHS reference costs
2016/1742
NEL tab
271.11 Excess day NEL_XS tab
Subchapter EB: cardiac
disorders
452.02 Day NHS reference costs
2016/1742
NEL tab




1368.01 Day NHS reference costs
2016/1742
NEL tab




820.12 Day NHS reference costs
2016/1742
NEL tab
383.32 Excess day NEL_XS tab
Subchapter FD: digestive
system disorders
452.79 Day NHS reference costs
2016/1742
NEL tab




517.57 Day NHS reference costs
2016/1742
NEL tab




825.31 Day NHS reference costs
2016/1742
NEL tab





435.85 Day NHS reference costs
2016/1742
NEL tab
288.25 Excess day NEL_XS tab
Subchapter HC: spinal
procedures and disorders
540.73 Day NHS reference costs
2016/1742
NEL tab




731.69 Day NHS reference costs
2016/1742
NEL tab










460.64 Day NHS reference costs
2016/1742
NEL tab
307.37 Excess day NEL_XS tab
Subchapter KB: diabetic
medicine
413.93 Day NHS reference costs
2016/1742
NEL tab




415.24 Day NHS reference costs
2016/1742
NEL tab





505.19 Day NHS reference costs
2016/1742
NEL tab
304.76 Excess day NEL_XS tab
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1172.12 Day NHS reference costs
2016/1742
NEL tab




549.53 Day NHS reference costs
2016/1742
NEL tab
349.89 Excess day NEL_XS tab
Subchapter VC:
rehabilitation
Day NHS reference costs
2016/1742
NEL tab






356.25 Day NHS reference costs
2016/1742
NEL tab






440.99 Day NHS reference costs
2016/1742
NEL tab




569.10 Day NHS reference costs
2016/1742
NEL tab
294.38 Excess day NEL_XS tab
Inpatients, weighted
average across specialties
645 Day NHS reference costs
2016/1742
NEL tab










709.80 Day NHS reference costs
2016/1742
DC tab
Subchapter BZ: eyes and
periorbita procedures and
disorders

























386.87 Day NHS reference costs
2016/1742
DC tab
Day-case radiotherapy 132.69 Day NHS reference costs
2016/1742
RAD tab
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(£, 2016/17) Unit Source Notes/assumptions
Outpatients

















CL and NCL tabs









CL and NCL tabs









CL and NCL tabs









CL and NCL tabs

















CL and NCL tabs



















CL and NCL tabs



















CL and NCL tabs









CL and NCL tabs









CL and NCL tabs
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(£, 2016/17) Unit Source Notes/assumptions





























CL and NCL tabs
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CL and NCL tabs
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CL and NCL tabs
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CL and NCL tabs
Weighted average across
laboratory tests








Memory clinic 406.45 Follow-up
attendance





















































A&E, accident and emergency; AfC, Agenda for Change; CHS, Community Health Services; CL, consultant led;
CPI, Consumer Prices Index; DAPS, directly accessed pathology services; DC, day case; ENT, ear, nose and throat;
FODO, Federation of (Ophthalmic and Dispensing) Opticians; HCHS, Hospital and Community Health Service;
NCL, non-consultant led; NEL, non-elective; NEL-XS, non elective: excess bed days; OPROC, outpatient procedures;
PIR, passive infrared sensor; PSSRU, Personal Social Services Research Unit; REHAB, rehabilitation; RENAL, renal dialysis.
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Appendix 4 Baseline demographic
characteristics of the sample with dyads
participating in full baseline assessments
Characteristic
Trial arm, n (%)
Total, n (%)Intervention Control
Female 131 (57) 131 (58) 262 (58)
Age (years)
< 65 11 (5) 3 (1) 14 (3)
65–80 83 (36) 89 (40) 172 (38)
> 80 135 (59) 132 (59) 267 (59)
Risk of wandering
Low 164 (72) 167 (75) 331 (73)
Moderate 48 (21) 40 (18) 88 (19)
High 17 (7) 17 (8) 34 (8)
Safety risk in the home
Low 116 (51) 113 (50) 229 (51)
Moderate 95 (41) 93 (42) 188 (42)
High 18 (8) 18 (8) 36 (8)
Caregiver involvement
Visits at least once/day 51 (22) 54 (24) 105 (23)
Visits less than once/day 64 (28) 56 (25) 120 (26)
Live in 114 (50) 114 (51) 228 (50)
Caregiver–participant relationship
Spouse/partner 88 (38) 82 (37) 170 (38)
Sibling/child/child-in-law 119 (52) 122 (54) 241 (53)
Other relative 18 (8) 8 (4) 26 (6)
Non-relative 4 (2) 12 (5) 16 (4)
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Appendix 5 Use of health, social and
unpaid care over the previous 3 months






n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Baseline Expected = 229 Expected = 224
Community health
GP Visits 229 159 (69) 1.82 (0.13) 223 146 (65) 1.54 (0.13)
Practice nurse Visits 229 88 (38) 0.94 (0.16) 223 84 (38) 0.69 (0.12)
Community nurse Visits 229 52 (23) 2.76 (0.86) 223 42 (19) 1.26 (0.45)
Physiotherapist Visits 229 33 (14) 1.04 (0.28) 223 22 (10) 0.23 (0.06)
Occupational
therapist
Visits 229 61 (27) 0.44 (0.06) 223 52 (23) 0.39 (0.06)
Dietitian Visits 229 3 (1) 0.02 (0.01) 223 11 (5) 0.06 (0.02)
Paramedic Visits 228 24 (11) 0.13 (0.03) 223 30 (13) 0.26 (0.07)
Specialist nurse Visits 229 22 (10) 0.22 (0.07) 223 19 (9) 0.23 (0.08)
Dentist Visits 229 55 (24) 0.33 (0.05) 223 45 (20) 0.26 (0.04)
Optician Visits 229 46 (20) 0.24 (0.04) 223 43 (19) 0.23 (0.04)
Chiropodist Visits 229 84 (37) 0.60 (0.06) 223 79 (35) 0.65 (0.15)
Mental health
Mental health nurse Visits 229 78 (34) 0.78 (0.10) 223 57 (26) 0.58 (0.10)
Psychiatrist Visits 229 52 (23) 0.75 (0.38) 223 47 (21) 0.25 (0.03)
Psychologist Visits 229 4 (2) 0.03 (0.02) 223 6 (3) 0.06 (0.03)
Mental health team Visits 229 17 (7) 0.29 (0.08) 223 11 (5) 0.13 (0.06)
Community care
Home care Visits 229 91 (40) 56.79 (6.79) 223 96 (43) 59.70 (6.89)
Home care Hours 229 91 (40) 49.69 (11.06) 223 96 (43) 64.29 (15.09)
Social worker Visits 229 75 (33) 0.51 (0.06) 223 76 (34) 0.66 (0.12)
Cleaner Visits 229 59 (26) 2.90 (0.37) 223 40 (18) 2.22 (0.35)
Meals on wheels Visits 229 9 (4) 1.41 (0.66) 223 16 (7) 3.45 (1.06)
Laundry service Visits 229 7 (3) 0.43 (0.17) 223 3 (1) 0.14 (0.09)
Sitting service Visits 229 6 (3) 0.41 (0.19) 223 9 (4) 0.33 (0.16)
Carer support
worker
Visits 229 11 (5) 0.18 (0.12) 222 12 (5) 0.07 (0.02)
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n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Day services
Day centre Attendances 229 38 (17) 3.34 (0.76) 223 36 (16) 2.73 (0.53)
Lunch club Attendances 229 19 (8) 0.64 (0.20) 223 26 (12) 0.99 (0.23)




Attendances 229 29 (13) 0.14 (0.03) 223 39 (17) 0.20 (0.03)
Inpatients services Days 229 24 (10) 1.24 (0.35) 223 36 (16) 2.39 (0.57)
Day hospital services Days 229 2 (1) 0.01 (0.01) 223 2 (1) 0.01 (0.01)
Outpatients services Visits 229 100 (44) 0.95 (0.11) 223 92 (41) 1.00 (0.14)
Residential respite
Residential home Days 228 1 (0) 0.00 (0.00) 223 0 (0) 0.00 (0.00)
Nursing home Days 228 5 (2) 0.37 (0.20) 223 8 (4) 0.91 (0.43)
Medications
Any medications Units 225 144 (64) 0.94 (0.06) 221 142 (64) 0.90 (0.06)
Dementia Units 226 116 (51) 0.56 (0.04) 221 115 (52) 0.56 (0.04)





Items 217 48 (22) 0.47 (0.07) 202 51 (25) 0.43 (0.06)
Unpaid care; out of pocket
Equipment (private) Items 217 9 (4) 0.04 (0.01) 202 10 (5) 0.06 (0.02)
Travel to
appointment
Trips 219 111 (51) 2.50 (0.45) 202 91 (45) 1.30 (0.21)
Unpaid care Hours 214 212 (99) 563.95 (43.71) 201 200 (100) 661.00 (46.31)
Carer cut down
work
Hours 205 3 (1) 1.00 (0.69) 195 4 (2) 1.57 (1.06)
Carer stopped work Weeks 207 1 (0) 0.02 (0.02) 199 2 (1) 0.05 (0.04)
Unpaid care other
carersa
Hours 216 124 (57) 121.63 (17.86) 202 96 (48) 87.80 (14.63)
Time off work other
carersa
Days 215 15 (7) 0.00 (0.00) 202 20 (10) 0.01 (0.00)
ATT devices
(including basicb)
Items 223 217 (97) 2.66 (0.10) 203 187 (92) 2.01 (0.09)
12 weeks Expected = 189 Expected = 188
Community health
GP Visits 188 118 (63) 1.35 (0.12) 186 119 (64) 1.62 (0.14)
Practice nurse Visits 188 72 (38) 0.65 (0.09) 186 72 (39) 0.91 (0.24)
Community/district
nurse
Visits 188 36 (19) 3.64 (1.11) 186 32 (17) 2.10 (0.77)
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n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Physiotherapist Visits 188 21 (11) 0.73 (0.22) 186 20 (11) 0.32 (0.13)
Occupational
therapist
Visits 188 24 (13) 0.23 (0.06) 186 29 (16) 0.23 (0.05)
Dietitian Visits 188 3 (2) 0.02 (0.01) 186 6 (3) 0.03 (0.01)
Paramedic Visits 188 18 (10) 0.12 (0.03) 186 20 (11) 0.20 (0.06)
Specialist nurse Visits 188 18 (10) 0.15 (0.04) 186 15 (8) 0.19 (0.07)
Dentist Visits 189 33 (17) 0.33 (0.07) 186 33 (18) 0.21 (0.04)
Optician Visits 189 39 (21) 0.24 (0.04) 186 26 (14) 0.19 (0.04)
Chiropodist Visits 189 77 (41) 0.65 (0.07) 186 67 (36) 0.57 (0.07)
Mental health
Mental health nurse Visits 188 34 (18) 0.25 (0.04) 186 31 (17) 0.41 (0.11)
Psychiatrist Visits 188 24 (13) 0.26 (0.11) 186 24 (13) 0.19 (0.05)
Psychologist Visits 187 2 (1) 0.04 (0.03) 186 1 (1) 0.02 (0.02)
Mental health team Visits 188 7 (4) 0.21 (0.09) 186 12 (6) 0.18 (0.07)
Community care
Home care Visits 189 81 (43) 67.14 (8.16) 186 87 (47) 66.00 (8.22)
Home care Hours 189 81 (43) 65.94 (14.18) 186 87 (47) 73.21 (19.04)
Social worker Visits 188 41 (22) 0.29 (0.05) 186 55 (30) 0.43 (0.06)
Cleaner Visits 189 54 (29) 3.16 (0.43) 186 43 (23) 2.86 (0.47)
Meals on wheels Visits 189 11 (6) 3.41 (1.19) 186 12 (6) 3.55 (1.17)
Laundry service Visits 189 4 (2) 0.25 (0.12) 186 6 (3) 0.45 (0.20)
Sitting service Visits 189 8 (4) 0.29 (0.12) 186 5 (3) 0.11 (0.07)
Carer support
worker
Visits 189 10 (5) 0.12 (0.05) 186 10 (5) 0.18 (0.07)
Day services
Day centre Attendances 189 42 (22) 4.62 (0.82) 186 31 (17) 3.42 (0.74)
Lunch club Attendances 189 17 (9) 0.80 (0.27) 186 19 (10) 1.33 (0.40)




Attendances 189 30 (16) 0.20 (0.04) 186 27 (15) 0.19 (0.04)
Inpatients services Days 189 20 (11) 0.76 (0.28) 186 23 (12) 1.34 (0.41)
Day hospital services Days 189 1 (1) 0.19 (0.19) 186 1 (1) 0.01 (0.01)
Outpatients services Visits 189 74 (39) 0.79 (0.09) 186 76 (41) 0.78 (0.09)
Residential respite
Residential home Days 188 0 (0) 0.00 (0.00) 185 3 (2) 0.22 (0.16)
Nursing home Days 188 5 (3) 0.52 (0.28) 185 7 (4) 0.59 (0.26)
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n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Medications
Medications Units 187 122 (65) 0.98 (0.07) 186 115 (62) 0.88 (0.07)
Dementia Units 189 104 (55) 0.61 (0.04) 186 97 (52) 0.57 (0.04)
Mental health Units 187 58 (31) 0.40 (0.05) 186 47 (25) 0.31 (0.04)
Equipment and adaptations
Equipment (HSC) Items 184 27 (15) 0.28 (0.07) 181 28 (15) 0.22 (0.04)
Unpaid care; out of pocket
Equipment (private) Items 185 6 (3) 0.03 (0.01) 181 10 (6) 0.07 (0.02)
Travel to
appointments
Trips 188 85 (45) 2.12 (0.36) 184 62 (34) 1.01 (0.18)
Unpaid care Hours 186 186 (100) 641.24 (48.85) 182 182 (100) 721.37 (50.71)
Carer cut down
work
Hours 174 1 (1) 0.14 (0.14) 174 1 (1) 0.48 (0.48)
Carer stopped work Weeks 175 3 (2) 0.09 (0.07) 179 0 (0) 0.00 (0.00)
Unpaid care other
carersa
Hours 186 99 (53) 92.16 (13.09) 184 95 (52) 108.22 (19.21)
Time off work other
carersa
Days 184 9 (5) 0.00 (0.00) 183 15 (8) 0.01 (0.00)
ATT devices
(including basicb)
Items 188 164 (87) 3.33 (0.18) 166 120 (72) 1.98 (0.16)
Week 24 Expected = 178 Expected = 168
Community health
GP Visits 176 101 (57) 1.31 (0.17) 168 100 (60) 1.23 (0.13)
Practice nurse Visits 177 69 (39) 1.05 (0.25) 168 57 (34) 0.51 (0.07)
Community/district
nurse
Visits 177 30 (17) 2.45 (0.93) 168 33 (20) 2.73 (0.90)
Physiotherapist Visits 177 20 (11) 0.49 (0.14) 168 17 (10) 0.21 (0.06)
Occupational
therapist
Visits 177 18 (10) 0.14 (0.03) 168 20 (12) 0.14 (0.03)
Dietitian Visits 177 4 (2) 0.02 (0.01) 168 6 (4) 0.04 (0.01)
Paramedic Visits 177 12 (7) 0.08 (0.02) 168 8 (5) 0.06 (0.02)
Specialist nurse Visits 176 11 (6) 0.20 (0.09) 168 15 (9) 0.46 (0.28)
Dentist Visits 177 38 (21) 0.27 (0.05) 168 38 (23) 0.30 (0.06)
Optician Visits 177 37 (21) 0.26 (0.04) 168 28 (17) 0.21 (0.04)
Chiropodist Visits 177 65 (37) 0.54 (0.06) 168 52 (31) 0.52 (0.08)
Mental health
Mental health nurse Visits 177 24 (14) 0.26 (0.07) 168 25 (15) 0.26 (0.06)
Psychiatrist Visits 177 13 (7) 0.08 (0.02) 168 17 (10) 0.13 (0.04)
Psychologist Visits 177 1 (1) 0.02 (0.02) 168 2 (1) 0.04 (0.03)
Mental health team Visits 177 7 (4) 0.11 (0.07) 168 10 (6) 0.15 (0.07)
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n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Community care
Home care Visits 177 79 (45) 81.98 (9.66) 168 79 (47) 71.18 (8.49)
Home care Hours 177 79 (45) 88.09 (20.15) 168 79 (47) 74.56 (16.77)
Social worker Visits 177 29 (16) 0.24 (0.05) 168 35 (21) 0.33 (0.06)
Cleaner Visits 177 47 (27) 3.20 (0.48) 168 44 (26) 2.86 (0.42)
Meals on wheels Visits 177 10 (6) 4.05 (1.37) 168 11 (7) 3.86 (1.87)
Laundry service Visits 177 2 (1) 0.22 (0.16) 168 8 (5) 0.86 (0.56)
Sitting service Visits 177 8 (5) 0.61 (0.23) 168 7 (4) 0.12 (0.05)
Carer support
worker
Visits 177 3 (2) 0.01 (0.01) 168 8 (5) 0.16 (0.08)
Day services
Day centre Attendances 177 36 (20) 4.33 (0.89) 168 30 (18) 3.32 (0.67)
Lunch club Attendances 177 15 (8) 0.69 (0.21) 168 20 (12) 1.65 (0.47)




Attendances 177 23 (13) 0.17 (0.04) 168 25 (15) 0.18 (0.04)
Inpatients services Days 177 10 (6) 0.44 (0.20) 168 16 (10) 1.69 (0.69)
Day hospital services Days 177 3 (2) 0.02 (0.01) 168 2 (1) 0.02 (0.01)
Outpatients services Visits 177 62 (35) 0.78 (0.17) 168 68 (40) 0.91 (0.17)
Residential respite
Residential home Days 175 1 (1) 0.00 (0.00) 166 1 (1) 0.21 (0.21)
Nursing home Days 175 4 (2) 0.38 (0.23) 166 3 (2) 0.13 (0.07)
Medications
Any medications Units 175 122 (70) 1.05 (0.07) 168 110 (65) 0.88 (0.06)
Dementia Units 177 105 (59) 0.65 (0.04) 168 95 (57) 0.61 (0.04)




Items 175 28 (16) 0.25 (0.05) 167 20 (12) 0.22 (0.06)
Unpaid care; out-of-pocket
Equipment (private) Items 175 8 (5) 0.06 (0.02) 167 3 (2) 0.02 (0.01)
Travel to
appointments
Trips 177 58 (33) 1.91 (0.40) 168 66 (39) 1.24 (0.23)
Unpaid care Hours 175 173 (99) 667.58 (53.00) 168 168 (100) 732.41 (53.61)
Carer cut down
work
Hours 171 2 (1) 0.42 (0.42) 159 0 (0) 0.00 (0.00)
Carer stopped work Weeks 169 1 (1) 0.03 (0.03) 165 0 (0) 0.00 (0.00)
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n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Unpaid care other
carersa
Hours 175 102 (58) 135.57 (20.81) 167 91 (54) 115.89 (19.44)
Time off work other
carersa
Days 175 20 (11) 0.01 (0.01) 167 16 (10) 0.01 (0.00)
ATT devices
(including basicb)
Items 176 148 (84) 2.91 (0.17) 157 121 (77) 2.28 (0.17)
Week 52 Expected = 150 Expected = 139
Community health
GP Visits 148 96 (65) 1.41 (0.13) 137 80 (58) 1.35 (0.14)
Practice nurse Visits 148 64 (43) 0.87 (0.16) 137 50 (36) 0.70 (0.13)
Community nurse Visits 148 31 (21) 2.36 (0.88) 137 26 (19) 1.95 (0.77)
Physiotherapist Visits 148 9 (6) 0.34 (0.15) 137 9 (7) 0.66 (0.48)
Occupational
therapist
Visits 148 17 (11) 0.22 (0.06) 137 20 (15) 0.28 (0.07)
Dietitian Visits 148 4 (3) 0.03 (0.02) 137 9 (7) 0.09 (0.03)
Paramedic Visits 148 15 (10) 0.12 (0.03) 137 18 (13) 0.18 (0.05)
Specialist nurse Visits 148 17 (11) 0.14 (0.04) 137 16 (12) 0.21 (0.07)
Dentist Visits 148 33 (22) 0.32 (0.06) 137 38 (28) 0.40 (0.06)
Optician Visits 148 25 (17) 0.18 (0.03) 137 31 (23) 0.30 (0.05)
Chiropodist Visits 148 61 (41) 0.61 (0.07) 137 52 (38) 0.63 (0.08)
Mental health
Mental health nurse Visits 148 12 (8) 0.14 (0.04) 137 19 (14) 0.25 (0.07)
Psychiatrist Visits 148 7 (5) 0.05 (0.02) 137 10 (7) 0.08 (0.03)
Psychologist Visits 148 1 (1) 0.01 (0.01) 137 0 (0) 0.00 (0.00)
Mental health team Visits 148 4 (3) 0.18 (0.16) 137 3 (2) 0.10 (0.08)
Community care
Home care Visits 148 77 (52) 86.19 (10.48) 137 67 (49) 92.06 (11.46)
Home care Hours 148 77 (52) 122.81 (28.27) 137 67 (49) 77.20 (17.46)
Social worker Visits 148 29 (20) 0.26 (0.06) 137 33 (24) 0.30 (0.05)
Cleaner Visits 148 38 (26) 2.91 (0.46) 137 36 (26) 3.69 (0.81)
Meals on wheels Visits 148 5 (3) 2.82 (1.26) 137 12 (9) 4.98 (1.60)
Laundry service Visits 148 4 (3) 0.43 (0.22) 137 5 (4) 0.36 (0.17)
Sitting service Visits 148 5 (3) 0.61 (0.36) 137 9 (7) 0.94 (0.39)
Carer support
worker
Visits 148 1 (1) 0.00 (0.00) 137 6 (4) 0.15 (0.07)
Day services
Day centre Attendances 148 35 (24) 5.83 (1.18) 137 30 (22) 4.54 (0.97)
Lunch club Attendances 148 12 (8) 0.73 (0.22) 137 16 (12) 2.28 (1.12)
Patient education Attendances 148 7 (5) 0.48 (0.23) 137 7 (5) 0.42 (0.17)
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n (%) Mean (SE) Valid (n)
Users,




Attendances 148 25 (17) 0.18 (0.03) 137 24 (18) 0.24 (0.05)
Inpatients services Days 148 17 (11) 0.86 (0.33) 137 17 (12) 1.69 (0.51)
Day hospital services Days 148 0 (0) 0.00 (0.00) 137 3 (2) 0.02 (0.01)
Outpatients services Visits 148 52 (35) 0.65 (0.10) 137 56 (41) 1.13 (0.31)
Residential respite
Residential home Days 148 1 (1) 0.00 (0.00) 137 4 (3) 0.47 (0.32)
Nursing home Days 148 5 (3) 0.64 (0.39) 137 7 (5) 0.61 (0.24)
Medications
Any medications Units 145 101 (70) 0.99 (0.07) 137 92 (67) 0.93 (0.07)
Dementia Units 147 85 (58) 0.63 (0.05) 137 78 (57) 0.62 (0.05)




Items 147 22 (15) 0.24 (0.06) 137 18 (13) 0.21 (0.05)
Unpaid care; out of pocket
Equipment (private) Items 147 14 (10) 0.11 (0.03) 137 8 (6) 0.06 (0.02)
Travel to
appointments
Trips 147 49 (33) 2.27 (0.55) 136 47 (35) 1.11 (0.27)
Unpaid care Hours 145 145 (100) 653.68 (56.15) 135 135 (100) 793.88 (59.57)
Carer cut down
work
Hours 146 1 (1) 0.34 (0.34) 135 3 (2) 1.03 (0.71)
Carer stopped work Weeks 144 0 (0) 0.00 (0.00) 136 0 (0) 0.00 (0.00)
Unpaid care other
carersa
Hours 147 84 (57) 100.98 (17.96) 136 78 (57) 145.61 (28.77)
Time off work other
carersa
Days 146 7 (5) 0.00 (0.00) 134 16 (12) 0.01 (0.00)
ATT devices
(including basicb)
Items 146 131 (90) 3.70 (0.20) 129 111 (86) 2.63 (0.17)
Week 104 Expected = 96 Expected = 90
Community health
GP Visits 93 66 (71) 1.39 (0.15) 89 58 (65) 1.55 (0.18)
Practice nurse Visits 92 28 (30) 0.55 (0.14) 89 28 (31) 0.69 (0.22)
Community/district
nurse
Visits 93 20 (22) 2.35 (1.05) 89 31 (35) 4.29 (1.59)
Physiotherapist Visits 93 7 (8) 0.56 (0.31) 89 11 (12) 0.70 (0.38)
Occupational
therapist
Visits 93 8 (9) 0.12 (0.05) 89 8 (9) 0.18 (0.07)
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n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Dietitian Visits 93 2 (2) 0.02 (0.02) 89 6 (7) 0.12 (0.05)
Paramedic Visits 93 10 (11) 0.15 (0.06) 89 9 (10) 0.16 (0.06)
Specialist nurse Visits 93 11 (12) 0.23 (0.09) 89 8 (9) 0.15 (0.06)
Dentist Visits 93 16 (17) 0.26 (0.07) 89 18 (20) 0.29 (0.07)
Optician Visits 93 21 (23) 0.27 (0.06) 89 15 (17) 0.21 (0.06)
Chiropodist Visits 93 37 (40) 0.66 (0.11) 89 39 (44) 0.55 (0.07)
Mental health
Mental health nurse Visits 93 6 (6) 0.11 (0.06) 89 7 (8) 0.11 (0.04)
Psychiatrist Visits 93 1 (1) 0.01 (0.01) 89 6 (7) 0.07 (0.03)
Psychologist Visits 93 0 (0) 0.00 (0.00) 89 0 (0) 0.00 (0.00)
Mental health team Visits 93 0 (0) 0.00 (0.00) 89 4 (4) 0.07 (0.04)
Community care
Home care Visits 93 46 (49) 97.81 (15.06) 89 50 (56) 110.49 (16.87)
Home care Hours 93 46 (49) 169.38 (49.12) 89 50 (56) 113.33 (28.65)
Social worker Visits 93 11 (12) 0.24 (0.11) 89 19 (21) 0.33 (0.08)
Cleaner Visits 93 32 (34) 4.00 (0.65) 89 25 (28) 4.68 (1.59)
Meals on wheels Visits 93 2 (2) 1.96 (1.38) 89 8 (9) 8.13 (4.43)
Laundry service Visits 93 1 (1) 0.14 (0.14) 89 3 (3) 0.28 (0.20)
Sitting service Visits 93 6 (6) 1.44 (0.64) 89 7 (8) 1.10 (0.48)
Carer support
worker
Visits 93 2 (2) 0.29 (0.27) 89 3 (3) 0.25 (0.20)
Day services
Day centre Attendances 93 20 (22) 7.00 (1.72) 89 22 (25) 5.46 (1.26)
Lunch club Attendances 93 5 (5) 0.37 (0.20) 89 8 (9) 0.84 (0.39)
Patient education
group




Attendances 93 8 (9) 0.11 (0.04) 89 20 (22) 0.35 (0.08)
Inpatients services Days 93 6 (6) 1.00 (0.56) 89 16 (18) 1.33 (0.44)
Day hospital services Days 93 1 (1) 0.01 (0.01) 89 1 (1) 0.01 (0.01)
Outpatients services Visits 93 35 (38) 0.67 (0.12) 89 28 (31) 1.17 (0.54)
Residential respite
Residential home Days 93 0 (0) 0.00 (0.00) 89 1 (1) 0.15 (0.15)
Nursing home Days 93 1 (1) 0.03 (0.03) 89 4 (4) 0.57 (0.31)
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n (%) Mean (SE) Valid (n)
Users,
n (%) Mean (SE)
Medications
Any medications Units 92 61 (66) 0.99 (0.09) 89 63 (71) 0.98 (0.09)
Dementia Units 93 50 (54) 0.61 (0.06) 89 53 (60) 0.61 (0.05)




Items 92 10 (11) 0.15 (0.05) 89 9 (10) 0.16 (0.05)
Unpaid care
Equipment (private) Items 92 5 (5) 0.10 (0.05) 89 3 (3) 0.03 (0.02)
Travel to
appointments
Trips 93 35 (38) 1.41 (0.36) 89 29 (33) 2.97 (1.02)
Unpaid care Hours 91 88 (97) 656.30 (72.42) 88 87 (99) 776.74 (74.79)
Carer cut down
work
Hours 90 1 (1) 0.56 (0.56) 89 1 (1) 0.22 (0.22)
Carer stopped work Weeks 89 0 (0) 0.00 (0.00) 89 0 (0) 0.00 (0.00)
Unpaid care other
carersa
Hours 93 53 (57) 154.89 (36.97) 89 53 (60) 118.22 (29.03)
Time off work other
carersa
Days 93 3 (3) 0.01 (0.01) 88 4 (5) 0.00 (0.00)
ATT devices
(including basicb)
Items 93 85 (91) 3.63 (0.24) 87 72 (83) 2.78 (0.22)
a ‘Other carers’= other relatives and friends who provide care.
b ‘Including basic’ = all ATT devices recorded on ATT checklist including ‘basic’ ATT (e.g. key safes, standard
smoke alarms).
DOI: 10.3310/hta25190 Health Technology Assessment 2021 Vol. 25 No. 19
Copyright © 2021 Gathercole et al. This work was produced by Gathercole et al. under the terms of a commissioning contract issued by the Secretary of State for Health
and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use,
distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/.
For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited.
139

Appendix 6 Mean cumulative costs




Intervention – controlIntervention Control
n Mean SE n Mean SE
Mean
difference 95% CI










223 322 18 203 214 15 109*** 62 to 155
Health and
social care




205 19,649 3206 189 15,186 2102 4463 –3209 to 12,135
Societalb 208 55,209 4404 200 58,272 4473 –3064 –15,405 to 9277
Intervention +
societalb
203 56,000 4579 188 53,378 4441 2622 –9953 to 15,196
Sensitivity analysis
Societalc 208 128,935 8862 200 139,524 10,008 –10,589 –36,816 to 15,638
Intervention +
societalc
203 129,845 9163 188 125,952 10,026 3893 –22,756 to 30,543
*p < 0.05, **p < 0.01, ***p < 0.001.
a ATT costs: includes the costs of the ATT assessment and ATT package installed prior to baseline assessment.
b Societal costs: participant’s health and social care costs; unpaid carers’ time in care and support to participant
(opportunity cost valuation); expenditure by self or family on travel to appointments, equipment purchases.
c Societal costs: participant’s health and social care costs; unpaid carers’ time in care and support to participant
(replacement cost valuation); expenditure by self or family on travel to appointments, equipment purchases.
Note
Sample includes any participant who had participated in a baseline assessment and whose data for that cost at baseline
were not missing.
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Appendix 7 Economic evaluation and
caregiver data supplementary tables
and figures




Baseline Follow-up period Follow-up – baseline
Mean SE Mean SE Mean 95% CI
Health and social care N = 287
Intervention 2295 250 2785 384 490 –97 to 1078
Control 2541 356 2665 434 124 –917 to 1164
Societal N = 284
Intervention 8152 545 8978 553 825 –172 to 1823
Control 8558 614 9133 640 574 –730 to 1878
Note
Available cases at 24 weeks = cost and participant-reported EQ-5D data available from baseline and at least one
follow-up point.




Baseline Follow-up period Follow-up – baseline
Mean SE Mean SE Mean 95% CI
EQ-5D-5L-participant N = 287
Intervention 0.746 0.017 0.747 0.017 0.001 –0.027 to 0.028
Control 0.792 0.020 0.804 0.017 0.012 –0.017 to 0.04
EQ-5D-5L-proxy N = 309
Intervention 0.546 0.014 0.546 0.013 0.000 –0.026 to 0.026
Control 0.565 0.016 0.531 0.016 –0.034 –0.066 to –0.002
Note
Available cases at 24 weeks = cost and outcomes data available from baseline and at least one follow-up point.
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Baseline Follow-up period Follow-up – baseline
Mean SE Mean SE Mean 95% CI
Health and social cared N = 229
Intervention 2250 291 3239 493 989 158 to 1819
Control 2504 447 2959 497 455 –706 to 1616
Societal N = 227
Intervention 7961 584 9665 668 1704 569 to 2838
Control 8450 709 10,038 759 1588 3 to 3174
Note
Available cases at 52 and 104 weeks = cost and participant-reported EQ-5D data available from baseline and at least
two follow-up points.




Baseline Follow-up period Follow-up – baseline
Mean SE Mean SE Mean 95% CI
EQ-5D-5L-participant N = 229
Intervention 0.774 0.016 0.766 0.017 –0.008 –0.038 to 0.021
Control 0.774 0.016 0.766 0.017 –0.008 –0.038 to 0.021
EQ-5D-5L-proxy N = 257
Intervention 0.569 0.013 0.539 0.013 –0.031 –0.057 to –0.004
Control 0.575 0.018 0.517 0.016 –0.057 –0.089 to –0.025
Note
Available cases at 52 and 104 weeks = cost and outcome data available from baseline and at least two follow-up points.




Baseline Follow-up period Follow-up – baseline
Mean SE Mean SE Mean 95% CIb
Health and social cared N = 243
Intervention 2257 295 3639 538 1381 409 to 2360
Control 2502 40 3185 526 683 –547 to 1913
Societal N = 241
Intervention 8037 600 10,051 696 2013 640 to 3387
Control 8536 691 10,397 735 1860 273 to 3449
Note
Available cases at 52 and 104 weeks = cost and participant-reported EQ-5D data available from baseline and at least
two follow-up points.
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Baseline Follow-up period Follow-up – baseline
Mean SE Mean SE Mean 95% CI
EQ-5D-5L-participant N = 243
Intervention 0.767 0.016 0.752 0.017 –0.015 –0.043 to 0.012
Control 0.807 0.018 0.808 0.015 0.001 –0.026 to 0.027
EQ-5D-5L-proxy N = 266
Intervention 0.567 0.014 0.524 0.013 –0.064 –0.095 to –0.033
Control 0.573 0.018 0.509 0.015 –0.043 –0.07 to –0.017
Note
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FIGURE 14 The CEAC at the 24-week follow-up: EQ-5D-proxy index scores and health and social care costs.
MCID, minimal clinically important difference. MCID= 0.74.
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FIGURE 15 The CEAC at 52-week follow-up: EQ-5D-proxy index scores and health and social care costs.
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FIGURE 16 The CEAC at 104-week follow-up: EQ-5D-proxy index scores and health and social care costs.
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FIGURE 17 Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total
costs at the 24-week follow-up.
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FIGURE 18 Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total
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FIGURE 19 Cost-effectiveness acceptability curve: person with dementia QALY derived from the EQ-5D-proxy and total
costs at the 104-week follow-up.
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TABLE 37 Difference-in-difference estimates at 104 weeks: differences in between-group differences on participant and
proxy-rated EQ-5D scores and 3-month costs (unpaid care valued at replacement cost)
Difference 95% CIa ICERb (difference in costs/MCID)
Person with dementia-reported N = 241
EQ-5Dc –0.019 –0.06 to 0.017 316/–0.262 = –1209
Societald 316 –3457 to 3978
Person with dementia proxy-reported N = 266
EQ-5D-proxyc 0.021 –0.022 to 0.06 –288/0.281 = –1024
Societald –281 –3930 to 3249
MCID, minimal clinically important difference.
a 95% CIs, bootstrapped estimates (5000 replications).
b Cost per gain of 0.074 in EQ-5D.78,79
c Estimates from outcome equation: covariates are allocation to ATT, BADLS categories and stratifiers.
d Estimates from costs equation: covariates are allocation to ATT, BADLS categories and stratifiers.
Note
Available cases: cost and outcome data available from baseline and at least two follow-up points.
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Mean 95% CIb Mean 95% CIb Mean difference 95% CIb
Societal costs (£) 131,847 119,111 to 146,973 133,781 119,333 to 149,963 –1934 –19,986 to 16,892 –1934/7.898 = –245
Institutionalisation-free days 597.075 572.464 to 620.939 589.177 563.373 to 614.062 7.898 –26.438 to 42.425
a Difference in QALYs rounded to the third decimal place.
b 95% CIs, bootstrapped estimates (25,000 replications).





Mean 95% CIb Mean 95% CIb Mean difference 95% CIb
Societal costs (£) 131,847 119,111 to 146,973 133,781 119,333 to 149,963 –1934 –19,986 to 16,892
QALY – EQ-5D-participant 1.201 1.127 to 1.271 1.306 1.234 to 1.376 –0.105* –0.204 to –0.007 –1934/–0.105 = 18,371
QALY – EQ-5D-proxy 0.828 0.762 to 0.894 0.798 0.733 to 0.861 0.030 –0.058 to 0.117 –1934/0.030 = –63,587
*p < 0.05.
a Difference in QALYs rounded to the third decimal place.




































Do you feel your social life has suffered because
you are caring for the person you care for?
zarit12_rg.1 0.823
Do you feel that the person you care for is
dependent on you?
zarit8_rg.1 0.715
Do you feel that because of the time you spend
with the person you care for that you do not
have enough time for yourself?
zarit2_rg.1 0.710
Do you feel that you have lost control of your
life since the illness/disability of the person you
care for?
zarit17_rg.1 0.597
Do you feel that you do not have as much
privacy as you would like because of the
person you care for?
zarit11_rg.1 0.595
Do you feel that the person you care for seems
to expect you to take care of him/her as if you
were the only one he/she could depend on?
zarit14_rg.1 0.576
Do you feel stressed between caring for the
person you care for and trying to meet other
responsibilities for your family or work?
zarit3_rg.1 0.425 0.313
Do you feel that the person you care for asks
for more help than he/she needs?
zarit1_rg.1 0.424
Do you feel that the person you care for
currently affects your relationships with other
family members or friends in a negative way?
zarit6_rg.1 0.404
Do you feel your health has suffered because of
your involvement with the person you care for?
zarit10_rg.1 0.387 –0.378
Do you feel you should be doing more for the
person you care for?
zarit20_rg.1 0.855
TABLE 40 Principal component analysis of caregivers’ responses on the ZBI











Extraction method: principal component analysis.
Rotation method: oblimin with Kaiser normalisation.
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Do you feel you could do a better job in caring
for the person you care for? Values
zarit21_rg.1 0.806
Do you feel that you do not have enough
money to take care of the person you care for
in addition to the rest of your expenses?
zarit15_rg.1 0.361 0.415
Are you afraid what the future holds for the
person you care for?
zarit7_rg.1 0.340 0.346
Do you wish you could leave the care of the
person you care for to someone else?
zarit18_rg.1 –0.758
Do you feel angry when you are around the
person you care for?
zarit5_rg.1 –0.713
Do you feel strained when you are around the
person you care for?
zarit9_rg.1 –0.674
Do you feel uncertain about what to do
about the person you care for?
zarit19_rg.1 –0.613
Do you feel that you will be unable to take care
of the person you care for much longer?
zarit16_rg.1 –0.602
Do you feel embarrassed over the behaviour of
the person you care for?
zarit4_rg.1 –0.584
Overall, how burdened do you feel in caring for
your relative?
zarit22_rg.1 –0.576
Do you feel uncomfortable about having friends
over because of the person you care for?
zarit13_rg.1 0.369 –0.391





Time 1.233 2 24754846 0.291
Group 0.646 1 561897 0.422
Interaction 0.466 2 89862616 0.628
Component 1: negative appraisal
Time 1.552 2 1562062 0.212
Group 0.504 1 483265 0.478
Interaction 0.816 2 6865985 0.442
Component 2: adequacy as a care partner
Time 0.582 2 407414 0.559
Group 0.111 1 92008 0.739
Interaction 0.849 2 195724 0.428
Component 3: burden and strain
Time 2.027 2 608124 0.132
Group 1.237 1 1260074 0.266
Interaction 0.838 2 1370133 0.433
df, degrees of freedom.
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TABLE 42 The ZBI mean and component scores for co-resident caregivers, by time point and trial arm
Time point Trial arm Mean SE 95% CI
Total score
Baseline Control 25.0 2.84 19.4 to 30.5
ATT intervention 25.1 2.92 19.4 to 30.8
Week 12 Control 25.5 2.91 19.8 to 31.2
ATT intervention 26.3 2.98 20.5 to 32.2
Week 24 Control 25.2 2.93 19.4 to 30.9
ATT intervention 27.1 2.98 21.2 to 32.9
Component 1: negative appraisal
Baseline Control 11.6 1.34 9.0 to 14.2
ATT intervention 11.6 1.38 8.9 to 14.3
Week 12 Control 12.3 1.38 9.6 to 15.0
ATT intervention 11.8 1.41 9.0 to 14.5
Week 24 Control 11.9 1.40 9.2 to 14.7
ATT intervention 12.8 1.41 10.0 to 15.5
Component 2: adequacy as a care partner
Baseline Control 3.5 0.53 2.4 to 4.5
ATT intervention 3.5 0.54 2.5 to 4.6
Week 12 Control 3.2 0.54 2.1 to 4.2
ATT intervention 3.8 0.55 2.7 to 4.8
Week 24 Control 3.3 0.55 2.2 to 4.4
ATT intervention 3.4 0.55 2.4 to 4.5
ZBI Component 3: Burden and strain
Baseline Control 6.1 1.08 4.0 to 8.2
ATT intervention 6.3 1.10 4.1 to 8.4
Week 12 Control 6.3 1.11 4.2 to 8.5
ATT intervention 7.2 1.13 5.0 to 9.4
Week 24 Control 6.0 1.12 3.8 to 8.2
ATT intervention 7.0 1.13 4.8 to 9.2





Time 1.388 2 25730363 0.250
Group 2.290 1 6245543 0.130
Interaction 0.489 2 15591551 0.613
CES-D-10
Time 0.246 2 503980 0.782
Group 0.016 1 370269 0.899
Interaction 0.159 2 916269 0.853
df, degrees of freedom.
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TABLE 44 The Anxiety and Depression mean scores for co-resident caregivers, by time point and trial arm
Time point Trial arm Mean SE 95% CI
STAI-6
Baseline Control 37.5 2.51 32.6 to 42.5
ATT intervention 39.2 2.55 34.2 to 44.2
Week 12 Control 38.7 2.61 33.6 to 43.9
ATT intervention 40.0 2.64 34.8 to 45.2
Week 24 Control 38.4 2.65 33.2 to 43.6
ATT intervention 41.9 2.64 36.7 to 47.1
CES-D-10
Baseline Control 8.8 1.05 6.7 to 10.9
ATT intervention 8.3 1.07 6.2 to 10.4
Week 12 Control 8.7 1.08 6.6 to 10.8
ATT intervention 8.1 1.10 6.0 to 10.3
Week 24 Control 8.6 1.09 6.5 to 10.8
ATT intervention 8.5 1.10 6.4 to 10.7





Time 0.372 2 74615089 0.690
Group 0.007 1 404895 0.931
Interaction 0.150 2 119338508 0.861
Component 1: negative appraisal
Time 0.816 2 7177464.9 0.442
Group 0.019 1 1066716 0.890
Interaction 1.038 2 20626935 0.354
Component 2: adequacy as a care partner
Time 0.755 2 456838.93 0.470
Group 0.251 1 136990.12 0.617
Interaction 0.767 2 236804.1 0.465
Component 3: burden and strain
Time 1.491 2 523331.74 0.225
Group 0.237 1 1210269 0.626
Interaction 0.672 2 2791857 0.511
df, degrees of freedom.
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TABLE 46 The ZBI mean and component scores for spousal caregivers, by time point and trial arm
Time point Trial arm Mean SE 95% CI
Total score
Baseline Control 31.7 1.69 28.4 to 35.1
Intervention 31.3 1.76 27.8 to 34.7
Week 12 Control 32.5 1.76 29.0 to 35.9
Intervention 31.8 1.82 28.2 to 35.4
Week 24 Control 32.0 1.79 28.5 to 35.5
Intervention 32.2 1.83 28.6 to 35.8
Component 1: negative appraisal
Baseline Control 15.5 0.801 13.9 to 17.1
Intervention 15.5 0.832 13.9 to 17.1
Week 12 Control 16.3 0.843 14.6 to 17.9
Intervention 15.3 0.871 13.6 to 17.0
Week 24 Control 15.9 0.864 14.2 to 17.6
Intervention 16.1 0.877 14.3 to 17.8
Component 2: adequacy as a care partner
Baseline Control 3.5 0.29 2.9 to 4.1
Intervention 3.6 0.30 3.0 to 4.2
Week 12 Control 3.4 0.31 2.8 to 4.0
Intervention 3.7 0.32 3.1 to 4.3
Week 24 Control 3.6 0.32 2.9 to 4.2
Intervention 3.4 0.32 2.7 to 4.0
Component 3: burden and strain
Baseline Control 7.9 0.62 6.7 to 9.1
Intervention 7.6 0.64 6.4 to 8.9
Week 12 Control 8.1 0.65 6.8 to 9.3
Intervention 8.4 0.67 7.1 to 9.7
Week 24 Control 7.7 0.66 6.4 to 9.0
Intervention 8.1 0.67 6.8 to 9.4





Time 1.668 2 941283.6 0.189
Group 0.977 1 1667711 0.323
Interaction 1.564 2 1978748 0.209
STAI-6
Time 2.583 2 52141891 0.076
Group 3.061 1 6614194 0.080
Interaction 0.986 2 13038219 0.373
df, degrees of freedom.
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TABLE 48 The Anxiety and Depression mean scores for spousal caregivers, by time point and trial arm
Time point Trial arm Mean SE 95% CI
CES-D-10
Baseline Control 11.1 0.63 9.9 to 12.4
Intervention 10.9 0.65 9.6 to 12.2
Week 12 Control 10.9 0.67 9.6 to 12.3
Intervention 10.6 0.69 9.2 to 11.9
Week 24 Control 10.7 0.69 9.3 to 12.0
Intervention 11.6 0.69 10.2 to 12.9
STAI-6
Baseline Control 41.1 1.45 38.3 to 43.9
Intervention 42.4 1.49 39.4 to 45.3
Week 12 Control 41.8 1.57 38.7 to 44.8
Intervention 42.7 1.60 39.6 to 45.9
Week 24 Control 41.7 1.63 38.6 to 44.9
Intervention 45.5 1.63 42.3 to 48.7
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